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Chapter 1: Introduction and outline of the thesis
Viral hepatitis infeCtion
Viral hepatitis, a group of diseases caused by infection of preferentially hepato-
tropic viruses, is the leading cause of liver inflammation worldwide. There are an 
estimated 400 million people affected by viral hepatitis infection, with 6–10 million 
new cases of infections reported annually.1 Hepatitis B virus (HBV) and hepatitis 
C virus (HCV) are the two most prominent forms of viral hepatitis, with 240 million 
and 130–150 million individuals chronically infected respectively.2,3 acute HBV 
infection is spontaneously resolved in over 90 % of infected adults, but if not 
resolved results in a chronic persistent infection, particularly in neonates that 
contract the infection through vertical transmission.4 this is in stark contrast to 
acute HCV infection, where only 15–25 % of adults infected spontaneously clear 
the virus without treatment and the majority progress to chronicity.5,6
Prolonged infection with HBV and HCV results in a state of chronic liver in-
flammation, and consequently a significantly increased risk of developing liver 
cirrhosis and/or hepatocellular carcinoma. every year, an estimated 686,000 
and 700,000 people die due to complications related to HBV and HCV infection 
respectively.7 Despite significant advances in prevention and treatment, including 
a prophylactic HBV vaccine and highly effective direct-acting antivirals (DAAs) 
against both HBV and HCV, these two diseases still pose a massive disease 
burden globally, with HCV-related end-stage liver disease still being one of the 
leading causes of liver transplantation in the United states.8
hepatitis b Virus
HBV is a member of the Hepadnaviridae family of viruses, with a partially double-
stranded dna genome held in a relaxed circular formation (rC-dna) by overlap-
ping 5’ ends of the two dna strands. the genome is approximately 3200 base 
pairs in length and encodes a total of 7 proteins; the pre-core protein (hepatitis 
B envelope antigen, HBeag), core protein (HBcag), 3 surface proteins (HBsag), 
X protein (HBxag), and a dna polymerase. Collectively, these proteins comprise 
the 42 nm viral particle that consists of a protein nucleocapsid core, composed 
of HBcag, which surrounds the viral genome and polymerase, as well as a lipid 
envelope embedded with surface proteins (HBsag). HBxag, a non-structural 
protein, is required for the efficient transcription of covalently closed circular DNA 
(cccdna), a plasmid-like episome that functions as a template for viral rnas, 
and consequently new virions. The non-particulate HBeAg, generally located 
between the nucleocapsid core and lipoprotein envelope, is secreted and ac-
cumulates in the serum as a soluble antigen. replication of HBV can be divided 
into 3 mains phases; (I) the release of the rC-dna-containing nucleocapsid into 
the cytoplasm and transport of rC-dna to the nucleus for repair and formation of 
cccdna, (II) transcription of cccdna to form viral rnas, (III) and encapsidation of 
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these rnas, together with the dna polymerase, for reverse transcription of new 
RC-DNA and consequently formation of infectious virions.9,10
The 8 major genotypes of HBV, denominated A-H, show diff erent geographical 
distribution, with a/d being the predominant genotypes found in europe and B/C 
in asia. Contrary to HCV infection, chronic HBV infections are characterized by 
disease episodes with diff erentiating serum levels of HBV DNA, alanine transfer-
ase (alt), a marker of liver damage, and HBV HBeag. Using these parameters, 
diff erent clinical phases have been discerned to describe the dynamics of the 
natural history of chronic HBV infection, and determine the indication for antiviral 
treatment on the basis of rate of viral replication and alt elevation. Chronic 
HBV patients have been categorized into 4 clinical phases: the HBeag-positive 
immune tolerant (It) and immune active (Ia) phases, as well as the HBeag-
negative inactive carrier (IC) and hepatitis (eneG) phases (figure 1). Currently, 
the european association for the study of liver disease (easl) recommends 2 
mains strategies for the treatment of chronic HBV infection; treatment for a fi nite 
period with PEGylated interferon-α (IFN-α) or a nucleot(s)ide analogue (NA), 
such as entecavir and tenofovir, or long-term treatment with na(s). the main 
advantage of IFN-α treatment is the potential for long-term systemic control of 
HBV infection off  therapy with an opportunity to obtain a sustained virological 
response (sVr), while nas have been shown to be highly potent inhibitors of 
HBV replication, have a high barrier to resistance, and induce few off -target ef-
fects but demonstrate low levels of SVR off  treatment.11
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figure 1. natural course of disease for acute and chronic viral hepatitis infections.
schematic presentation of viral load (HBV dna and HCV rna) as well as alanine transferase (alt) levels, 
a marker of liver damage, in the serum of acute or chronically infected HBV and HCV patients. typical time 
courses for acute viral hepatitis infections range from weeks to months until resolution, while progression 
of chronic hepatitis infection occurs over signifi cantly longer periods (years). HBV clinical phases: immune 
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hepatitis C Virus
HCV is a member of the flavivirus family of viruses, with a small positive-stranded 
RNA genome. The viral particle is approximately 50–55 nm in size and consists of 
an icosahedral protein core encased by a lipoprotein envelope. the viral proteins 
comprising these structures, and other non-particulate proteins, are encoded 
by the 9600 base pair genome and can be classified into 3 major groups; core 
protein, envelope glycoproteins (e1 and e2), and non-structural proteins (ns2, 
ns3, ns4a/B, ns5a/B, and p7). the structural proteins e1 and e2 are found as 
dimers anchored to and radiating from the viral envelope, while HCV core proteins 
compose the nucleopcasid surrounding the viral genome. HCV replication begins 
after the binding and internalization of the virus by a hepatocyte via endocytosis. 
HCV rna is released into the cytoplasm, and the viral rna is translated into one 
large polyprotein at the endoplasmic reticulum. the ns3 protein, together with 
NS2 or NS4A, form the NS2–3 cysteine protease and NS3 serine protease/NS4A 
cofactor complexes that are responsible for the cleavage of functional proteins 
from the HCV polyprotein. once the functional proteins have been cleaved, 
rna replication can be facilitated by the rna-dependent polymerase ns5B and 
the viral components are assembled into an infectious HCV virion that is later 
released from the hepatocyte. the ns5a protein has no enzymatic activity, but is 
essential for proper viral rna replication and modulates cell-signaling pathways. 
although the exact roles of membrane proteins ns4B and p7 remain more am-
biguous, they have also been demonstrated to be important in viral replication 
and formation of infectious virions respectively.12,13
HCV has 6 major genotypes (designated 1–6) and more than 50 different sub-
genotypes. The absence of an HCV proofreading exonuclease and subsequently 
high nucleotide error rate during rna replication likely explains the large geno-
typic variation. recent advances in daas have completely shifted the landscape 
of chronic HCV therapy from 24–48 week PEGylated IFN-α/ribavirin centered 
treatment strategies (54–56 % SVR in patients)14,15 to shorter 8–12 week, more 
tolerable, and highly efficacious DAA regimens (94–99 % SVR in treatment na-
ïve and experienced patients).16–18 daas, such as sofosbuvir, daclatasvir, and 
ledipasvir, directly inhibit different HCV functional proteins (e.g. sofosbuvir NS5B 
and daclatasvir/lepidasvir NS5A) with limited off-target effects and have therefore 
become the recommended treatment strategy by the easl.19
innate immUne response in Viral hepatitis
Infection with a virus triggers a series of diverse immune responses in the host 
in attempt to interrupt and eradicate virus while minimizing damage to the host 
itself. In viral infections, such as HBV and HCV, the cumulative effectiveness of 
these host immune responses is the determining factor in successfully clearing 
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the virus or developing a chronic persistent infection. traditionally the mammalian 
immune system and response has been divided into two major categories, the 
innate and adaptive immune systems. the innate immune response is evolu-
tionarily conserved among multi-cellular organisms and represents the first line 
defense and immediate response against infections, while the adaptive immune 
system provides a more versatile means of specific of defense against pathogens 
and protects the host against subsequent reinfection with the same pathogen.
Cells of the innate immune system recognize common antigens called 
pathogen-associated molecular patterns (PaMPs) via pattern recognition recep-
tors (Prrs) such as toll-like receptors (tlrs).20,21 the recognition of antigens 
initiates the innate immune response, leading to the upregulation of major 
histocompatibility complex (MHC) classes I and II as well as their respective 
co-stimulatory molecules, in addition to the secretion of inflammatory cytokines 
that more efficiently prime and subsequently initiate the adaptive response.20,22 
during HCV infection, cytosolic viral rna is sensed by retinoic acid-inducible 
gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), 
as well as double-stranded rna (dsrna) by tlr3 in endosomes, leading to 
Ifn-mediated responses and the eventual production of various types of Ifns 
that suppress HCV replication.23,24 In contrast, HBV infection seems to lack an 
induction of Ifn-responses and HBV is only limitedly recognized by the innate 
immune system.25,26 these contrasting inductions of the innate immune response 
can partially be attributed to a difference in viral kinetics; HCV is characterized by 
a rapid increase in serum rna levels immediately after infection, while increases 
in HBV dna levels are delayed, with the exponential phase of HBV replication 
only occurring weeks after infection.
interferons
as previously referenced, Ifns are one of the key components of the innate im-
mune response to viral infections. Ifns, described to have anti-viral, anti-prolifer-
ative, and immunomodulatory effects, are divided into three majors classes; type 
I, II, and III IFNs, each with unique complimentary receptor complexes through 
which they signal. type I Ifns, the most prominent and well-studied class, is 
comprised of 13 partially homogenous IFN-α subtypes, IFN-β, as well as the 
more poorly defined IFN-δ, IFN-ε, IFN-ζ, IFN-κ, IFN-τ, and IFN-ω.27 IFN-α/β pro-
duction has been described for a large range of cells in the body, but specific im-
mune cells, such as plasmacytoid dendritic cells (pdCs), have been shown to be 
especially potent producers of type I Ifns.28,29 type II Ifns are composed of only 
one cytokine, IFN-γ, and signal through its own unique IFN-γ receptor, a tetramer 
of IFN-γR1 and IFN-γR2 complexes, expressed on a broad range of cell types.30 
IFN-γ is primarily produced by natural killer (NK) and T cells. Lastly, type III IFNs, 
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tion in recent years, especially after the discovery of polymorphisms within the 
IFN-λ gene locus that are associated with spontaneous as well as IFN-α/ribavirin 
therapy-induced clearance of HCV infection.31–35 emerging evidence points to 
pDCs and a specific subset of BDCA3-expressing myeloid DCs (mDCs) as the 
primary immune cells capable of producing type III Ifns, while hepatocytes have 
also been shown to express and produce IFN-λ messenger RNA (mRNA) and 
protein upon HCV infection.36–38
type i and iii interferon signaling
Unlike type II Ifns, types I and III Ifns are potent inducers of an antiviral re-
sponses in infected and still uninfected cells to block viral replication and spread 
of infection. The similar antiviral effects of type I and III IFNs can partially be 
explained by comparable Janus kinase (JaK)/signal transducer and activator of 
transcription (STAT) signaling cascades triggered upon IFN-α and IFN-λ receptor 
engagement (figure 2). for both types of Ifns, engagement of their respec-
tive receptors results in activation of receptor-associated tyrosine kinases JaK1 
figure 2. Type I and III IFNs are distinguished by their unique complimentary receptor com-
plexes through which they signal.
IFN-α and other type 1 IFNs, engage through the IFN-α receptor complex, composed of IFN-αR1 and 
IFN-αR2, while IFN-λ signals through the IFN-λR1 and IL-10R2 complex. Despite triggering distinct recep-
tor complexes, the downstream signaling of both IFN-α and IFN-λ is regulated through JAK/STAT signal 
transduction, ultimately resulting in the induction of Ifn-stimulated response elements (Isre) and initiation 
of IsG transcription.
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and tyrosine kinase 2 (tYK2), leading to the recruitment of signaling molecules 
stat1 and stat2. this is followed by the phosphorylation of stat1 and stat2 
and recruitment of Ifn regulatory factor 9 (Irf9). together with the dimerized 
stat1 and stat2, Irf9 forms Ifn-stimulated gene factor 3 (IsGf3) complexes 
that bind promoter sequences in DNA ultimately resulting in the initiation of gene 
transcription.39–41
All members of the IFN-λ family use a specific transmembrane receptor het-
erodimer, the IFN-λR1 and IL-10R2 complex, which structurally differs from the 
IFN-α receptor complex, a heterodimer of the IFN-αR1 and IFN-αR2 subunits. 
In contrast to the ubiquitously expressed IFN-α receptor, the distribution of the 
IFN-λ receptor is more limited. Murine models have shown that epithelial cells 
express the receptor complex and respond to IFN-λ stimulation by eliciting an 
antiviral response.42 Outside non-hematopoietic cells, specifically epithelial cells 
and hepatocytes, expression of the IFN-λR1 chain in humans has only been well 
described on pDCs, fibroblasts, and macrophages.43–45 Many of the Ifn-stimu-
lated genes (IsGs) (e.g. myxovirus resistance 1 (MX1) and 2’-5’-oligoadenylate 
synthetase (oas)) transcribed after engagement of type I and III Ifn receptors 
are similar and function to induce an antiviral state within the cell. However, 
specific differences have been described for the signaling of IFN-α and IFN-λ. 
One example of this is the direct interaction between IFN-αR2 and IFN-induced 
protein ubiquitin specific peptidase 18 (Usp18) that inhibits further response to 
IFN-α, thereby creating a negative feedback loop.46,47 this negative feedback 
loop is reflected in the shorter duration of immune response by IFN-α stimulation 
when compared to the more prolonged response observed by IFN-λ in epithelial 
cells and hepatocytes.48–50
to avoid detection by the innate immune system, both HBV and HCV have 
developed several strategies to interfere with the induction of Ifns.51 the HBV 
polymerase is able to block tlr3 and rIG-I induction of Irf activation, inhibit 
stimulator of IFN genes (STING)-stimulated IRF3 activation, and inhibit IFN-α-
induced nuclear translocation of stat1.52–54 In addition, HBxag has been shown to 
downregulate the expression of mitochondrial antiviral signaling protein (MaVs), 
a downstream mediator of protein kinase r (PKr)-induced IsG expression.55 In 
HCV infection, ns3-ns4a serine proteases cleave MaVs and toll/Il-1 receptor 
domain-containing adaptor inducing IFN-β (TRIF), a downstream mediator of the 
tlr3-induced signal transduction.56,57
Effects of Type I and III Interferons on Immune cells
type I Ifns have been shown to be strong modulators of multiple immune cell 
populations, including antigen presenting cells (aPCs), such as dCs, monocytes, 
and macrophages (and their downstream promotion of t cell responses), as well 
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receptor prevalence and their respective signaling kinetics, the effects of IFN-λ 
on immune cells still remain controversial with limited evidence for many of these 
populations.
IFN-α has been previously demonstrated to have an activating effect on APCs, 
and enhances the expression of MHC and co-stimulatory molecules, such as 
Cd80 and Cd86, on the surface of dCs; this transiently increases the ability of 
dCs to stimulate t cells.58–60 aPCs are also potent producers of interleukin 12 
(Il-12), a crucial factor for driving t helper 1 (th1) responses during viral infec-
tions and an important factor in inducing IFN-γ production of T cells and NK cells. 
Although IFN-α has been shown to enhance bioactive IL-12 (IL-12p70) produc-
tion in combination with tlr activation,61 inhibitory effects have been described 
for the production of Il-12 subunit p40 (Il-12p40) by aPCs.62,63 this is in contrast 
to the effects of IFN-λ described on specific APCs. The stimulation of monocyte-
derived macrophages with IFN-λ, in combination with activation via specific 
tlrs, resulted in an enhancement of macrophage Il-12p40 production whereas 
IFN-α inhibited TLR-induced IL-12p40 production.43 Il-12p70 was, however, not 
produced by these stimulated macrophages without the addition of stimulatory 
signals, such as CD40 ligation or IFN-γ, required for the production of bioactive 
Il-12.64–66 APCs that produce IFN-λ, such as pDCs, have also been demonstrated 
to be stimulated and modulated by type III Ifns in an autocrine loop.37,45
B cells play an important role in the resolution of viral infections through the 
production of neutralizing antibodies. IFN-α exposure of B cells strongly promotes 
humoral immunity via enhanced survival, reduced apoptosis, and enhancement of 
activation, proliferation, class switching, and immunoglobulin (Ig) production.67–69 
These effects are best observed when B cells are additionally stimulated via the B 
cell receptors (BCR), CD40, or TLRs, with IFN-α being able to enhance TLR7 sen-
sitivity of B cells by selectively upregulating tlr7 expression.70,71 IFN-α-induced 
enhancement has been shown to be beneficial for generation of neutralizing 
antibodies, especially during viral infection.72 In contrast, excessive production of 
Igs against dna complexes in patients with systemic lupus erythematosus (sle) 
is in part the result of an undesired IFN-α effect on B cells.73 However, unlike 
IFN-α, the effects of IFN-λ on B cells have not been investigated in detail. Various 
studies have suggested that B cells express the IFN-λ receptor,74 however, the 
responsiveness of B cells to IFN-λ is not well-described. Multiple myeloma B cells 
have been shown to proliferate in response to IFN-λ1,75 and other studies have 
suggested a type I and II Ifn independent mechanism of tlr7 upregulation in 
B cells.76
nK cells play an important role in the innate immune response to viral infec-
tion, specifically in their ability to recognize and respond to virus-infected cells 
by excretion of cytotoxic factors and cytokines (e.g. IFN-γ) that act as a first 
response to control the infection and activate the subsequent adaptive immune 
responses. The engagement of specific surface receptors on NK cells by soluble 
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factors, such as Il-12 and Il-18, results in cellular activation and the triggering of 
effector activities.77,78 IFN-α has also been described as a potent promotor of the 
function and survival of NK cells, specifically in the setting of NK cell interaction 
with Ifn-producing activated pdCs leading to enhanced activation and cytolytic 
activity, and thereby promoting antiviral immunity.79–81 additionally, during both 
influenza and vaccinia virus infections, the direct activation of NK cells by IFN-α 
is required for the expression of cytolytic mediators and production of IFN-γ.82,83 
Indirect effects of IFN-α on NK cells have also been described, mediated through 
dCs in an Il-15-dependent manner, in tlr-stimulated mice and during MCMV 
infection.84,85 In contrast to the well-defined effects of type I IFNs on NK cells, 
reports about the effects of type III IFNs have been scarce and controversial. 
Adoptive transfer experiments in mice with IFN-λR1-deficient NK cells do suggest 
that a direct IFN-λ engagement is necessary for optimal production of IFN-γ and 
anti-tumor activity.86 However, only a single study in humans described IFN-λ 
as being able to partially inhibit NK-cell-derived IFN-γ production upon IL-12/15 
stimulation.87,88 However, an effect of IFN-λ on NK cells could not be reproduced 
in an ensuing response to this study and was later disproved by the original study 
authors.89,90
NK cELLs IN VIRaL INFEcTIoNs
NK cells represent one of the first lines of defense of the innate immune response 
to viral infections. activated nK cells respond to stress signals of virus-infected 
cells via two types of mechanisms; direct mechanisms, including the release and 
expression of cytotoxic mediators, such as granzymes, perforins, and tumor ne-
crosis factor (tnf)-related apoptosis-induced ligand (traIl), that result in lysis of 
the infected cells, and indirect mechanisms that involve the release of cytokines, 
such as IFN-γ and TNF, and result in the triggering of antiviral responses that 
inhibit viral replication. these stress-induced signals include surface markers, 
such as altered MHC expression and ligands to regulatory receptors, as well as 
soluble factors, of which IL-12, IL-15, IL-18, and IFN-α/β are well described and 
known promotors of NK-cell effector activity.77,78,91
nK cell activity is strictly governed by a balance of activating and inhibitory 
receptors on the cell surface. Some of the major classifications of these regula-
tory receptors include C-type lectin-like receptors (nKG2a, nKG2C, nKG2d), 
natural cytotoxicity receptors (nKp30, nKp44 and nKp46), and killer cell 
immunoglobulin-like receptor (KIrs). during viral infection the balance shifts from 
inhibition to activation after a critical threshold of activation signals exceeds those 
of inhibition.91 additionally, the intensity of expression of surface glycoprotein 
Cd56 can be used to divide nK cells into two subgroups; the less developmen-
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developmentally mature Cd56dim subset that predominantly mediates cytotoxic 
activity. Differentiation of NK cells from CD56bright to Cd56dim cells has also been 
described and shown to contribute to functional and phenotypic heterogeneity 
observed during the life span of NK cells. Many details of this differentiation pro-
cess remain undefined, but the dynamics and outcome are likely affected by viral 
infections. During the differentiation process, NK cells diminish CD56 expression 
as well as lose expression of NKG2A, and subsequently acquire KIR and CD57 
expression, ultimately resulting in a more terminally differentiated phenotype, that 
display reduced IFN-γ producing and proliferative capacities.92,93
In recent years the classic division of labor between the innate and adaptive 
immune systems has been challenged, with reports describing developmental 
and functional qualities for NK cells that are commonly associated with adap-
tive immune cells. Of these features, the ability of NK cells to acquire functional 
immunological memory and undergo continuous differentiation resulting in the 
formation of specific NK cell repertoires has been highlighted in viral infection 
settings.94,95 In humans, a long-lived memory-like nK cell population have been 
described at higher frequencies in cytomegalovirus (CMV)-seropositive individu-
als than seronegative individuals.96,97 this specialized population of nK cells was 
found to express high levels of the of C-type lectin nKG2C, in combination with 
maturation marker Cd57. a memory phenotype for nK cells has also been sug-
gested in Mycobacterium tuberculosis and hantavirus infection,98,99 and associa-
tions of nK cell maturation and memory markers have been observed in chronic 
viral hepatitis patients, but only when also CMV-seropositive.97
aims and oUtline of this thesis
the therapeutic use of Ifns in both HBV and HCV infection has diminished since 
the introduction of highly effective DAAs. However, IFNs are still potent immuno-
modulators that, in combination with nK cells, represent two pillars of the innate 
immune system in the response to pathogens and the resolution of infections. 
therefore, the primary aim of the work presented in this thesis was to understand 
the function, and dysfunction, of these specific aspects of the innate immune 
system in the resolution or persistence of viral hepatitis infection.
The association of polymorphisms within the IFN-λ gene locus and spontaneous 
as well as therapy-induced clearance of HCV infection is still poorly understood, 
but suggests an important role for IFN-λ in the triggering of an effective antiviral 
response. Therefore, the first logical step to determine the importance of IFN-λ 
in viral hepatitis was to investigate the endogenous levels in the serum of chroni-
cally infected patients and how these associated with patient IFN-λ polymorphism 
genotypes as well as disease state/outcome (Chapter 2).
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In addition to the role of endogenously produced IFN-λ in the setting of chronic 
viral hepatitis, much of the underlying basic biology of IFN-λ still remains unex-
plained. the antiviral aspects of this class of cytokines have been well estab-
lished, with many similarities described to type I Ifns. However, this then raises 
the question what is the evolutionary benefit of having two classes of IFNs if their 
immunological role is truly redundant? therefore, further understanding is still 
needed about the few distinctions described for type III IFNs, specifically the IFN-λ 
receptor and its expression on immune cells as well as the associated responses 
after triggering. With studies reporting the expression of the IFN-λ receptor on 
B cells but limited information available on the actual effects of IFN-λ,74–76 we 
decided to investigate in detail the role of IFN-λ on the regulation and modulation 
of human B cell function and how this compared to that of IFN-α (Chapter 3).
nK cells represent another compartment of lymphocytes with poorly described 
response to type III IFNs, and conflicting results have been reported for both 
the expression of the IFN-λ receptor as well as the direct effects of IFN-λ on 
human nK cells.87–90 Monocyte-derived macrophages, on the other hand, have 
been both described to express the IFN-λ receptor as well produce enhanced 
levels of IL-12p40 upon engagement of this receptor, specifically in combination 
with activation via tlrs.43 this is of particular interest in hepatitis infection as 
TLR-activated liver-resident macrophages (Kupffer cells) have been shown to 
exert effector function in NK cells, mediated through cytokine induced activation 
and production of IFN-γ.100 therefore, to better understand the biological role 
of IFN-λ, we investigated the effects of IFN-λ on NK cells in both a direct and 
indirect capacity through its modulation of tlr-activated macrophages (Chapter 
4). Similarly, other studies have investigated the effects of IFN-λ in modulating 
the function of TLR-activated fibroblasts, specifically IL-6 and IL-8 production, 
in the setting of rheumatoid arthritis (RA) synovial inflammation. Our comments 
on these studies and the importance of IFN-λ in the context of inflammatory 
diseases, such as ra, can be found in Chapter 5.
as previously discussed, chronic HBV infection is characterized by disease 
episodes with differentiating viral loads and/or markers of liver damage (e.g. ALT). 
a previous systems biology study of the peripheral blood transcriptomes in the 
distinct chronic HBV clinical phases reported an upregulation of cytotoxicity/nK 
cell activity-related genes clustered in the Ia and eneG phases, suggesting a link 
between nK cell activity and the elevated alt observed in these phases.101 We 
therefore chose to investigate the role of differential NK cell functionalities in con-
tributing to the distinct features observed during the HBV clinical phases, including 
the fluctuations in liver damage markers and HBV replication (Chapter 6).
The high rates of spontaneous clearance (50 %-80 %) observed in patients that 
have previously resolved an acute HCV infection strongly suggest that immuno-
logical memory, and consequently immunity, acquired during the primary infection 
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described developmental and functional qualities for NK cells that are commonly 
associated with immunological memory, including the continuous differentiation 
and formation of specific NK cell repertoires in viral infection settings.94–97,99 With 
limited information available on the development and persistence of memory-like 
nK cells during and after HCV infection, we chose to characterize and compare 
the nK cell compartments of individuals who either resolved an acute HCV infec-
tion and individuals that developed a chronic infection (Chapter 7).
a summary of the work presented in this thesis, as well as the importance and 
implications of these studies as a whole are discussed in Chapter 8.
20
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part i: systemic levels and immunological regulation of type III Ifns in viral hepatitis infection
abstraCt
Besides type I interferons, type III interferons, including IFN-λ1 (IL-29), possess 
potent antiviral activity. In patients infected with the hepatitis C virus (HCV), it has 
been demonstrated that viral clearance is associated with genetic variation near 
the IFN-λ3 (IL-28B) gene. The rapid influx of research being conducted on this 
family of cytokines has led to several inconsistencies and controversies, includ-
ing the possible correlation of serum cytokine levels with disease in chronic viral 
hepatitis patients. In a detailed study, well-characterized cohorts of patients with 
HBV and HCV were evaluated with 3 different immunoassays, and no differences 
in the levels of serum IFN-λ were observed between patient groups, disease 










Chapter 2: Endogenous IFN-λ in Viral Hepatitis Patients
introdUCtion
Hepatitis C virus (HCV) and hepatitis B virus (HBV) infection are two of the lead-
ing causes of chronic liver disease and inflammation worldwide. More than 500 
million people are persistently infected with HBV and/or HCV and are at a serious 
risk of developing chronic liver disease, cirrhosis, and hepatocellular carcinoma 
(lavanchy 2008).
Endogenous interferons (IFN), specifically IFN-α, play a pivotal role in host 
defense against viral infection, and has also been one of the cornerstones for the 
treatment of chronic HCV and HBV infection over the past 20 years. recently a 
distinct class of IFNs, the family of IFN-λ, has become the topic of intense inves-
tigation in the field of viral hepatitis originating with the observation that single 
nucleotide polymorphisms (SNPs) near the gene encoding for IFN-λ3 displayed 
an exceptionally strong association with spontaneous as well as therapy-induced 
clearance of HCV (Ge and others 2009; suppiah and others 2009; tanaka and 
others 2009; Thomas and others 2009). IFN-λ1 (also known as interleukin-29 
or IL-29), IFN-λ2 (IL-28A), and IFN-λ3 (IL-28B) are known to possess potent 
antiviral activity via mechanisms similar to those of IFN-α despite triggering a 
unique IFN-λ receptor pair (Doyle and others 2006; Dumoutier and others 2004; 
Zhou and others 2007). The IFN-α receptor is composed of 2 unique receptor 
chains, IFN-αR1 and IFN-αR2, whereas the IFN-λ receptor is comprised of IFN-λ 
receptor 1 (IFN-λR1, also known as IL-28RA) and IL-10 receptor 2 (IL-10R2). 
IFN-αR1, IFN-αR2, and IL-10R2 are ubiquitously expressed, while the expres-
sion of IFN-λR1 appears to be limited to plasmacytoid DC, B cells, epithelial 
cells, hepatocytes, and macrophages (dumoutier and others 2004; liu and oth-
ers 2011). The more restricted expression of IFN-λR1 could potentially make 
IFN-λ a more specific antiviral therapeutic, and explain the reduced incidence of 
side-effects reported during antiviral therapy of pegylated-IFN-λ1 as compared 
to pegylated-IFN-α treatment (Muir and others 2010). Current clinical trials are 
further examining benefits of using pegylated-IFN-λ1 as an alternative to conven-
tional IFN-α based treatment of chronic HCV infection.
The association of the IFN-λ3 gene polymorphisms with spontaneous clear-
ance of acute HCV infection suggests an important role for IFN-λ in triggering 
an effective antiviral response in infected individuals. The first logical step to 
determine the importance of endogenous IFN-λ in chronic HCV is to investigate 
the levels in the blood of chronically infected HCV patients. However, the rapid 
influx of research being conducted on this family of cytokines have led to several 
inconsistencies and controversies. this includes incongruities in the levels of 
IFN-λ measured in the sera of HCV patients and healthy individuals as well as 
cell populations that express IFN-λR1 (Dring and others 2011; Kramer and others 
2011). These conflicting results show that IFN-λ levels in the serum of healthy 
controls are higher than those of chronically infected HCV patients (langhans 
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and others 2011), and conversely that HCV patient IFN-λ serum levels are el-
evated compared to those of healthy individuals (diegelmann and others 2010; 
dolganiuc and others 2012). to resolve these discrepancies and understand the 
role of IFN-λ in viral clearance we performed a detailed cross-sectional analysis 
of IFN-λ sera levels in a large cohort of HCV infected, HBV infected, and healthy 
individuals. Furthermore, to confirm and validate our findings, serum IFN-λ con-
centrations were determined by 3 different immunoassays.
materials and methods
patients
sera were collected from the blood of 124 chronically infected HCV patients, 
22 resolved HCV patients, 93 chronically infected HBV patients, 20 acutely in-
fected HBV patients, and 25 chronically infected HBV patients currently receiving 







































































































































































Chapter 2: Endogenous IFN-λ in Viral Hepatitis Patients
nucleot(s)ide analog therapy, who visited the outpatient clinic. the characteristics 
of the enrolled subjects are listed in table 1. as presented in table 1, 77 out of the 
124 chronic HCV patients were selected from our bio-bank on the basis of their 
alt values, being either lower than 40 IU/l or higher than 160 IU/l. after collection, 
the sera were immediately aliquoted and stored at -80°C. Serum HCV-RNA levels 
were determined by quantitative PCR (Cobas® Ampliprep/ Cobas® TaqMan® 
HCV test (limit of detection < 15 IU/ml, roche diagnostics, the netherlands), and 
serum HBV dna levels were determined by standard clinical diagnostics of the 
erasmus MC, rotterdam. In addition, sera from blood of 20 healthy individuals 
were included in the study. the institutional ethical review board of the erasmus 
MC, rotterdam approved the clinical protocols, and written informed consent was 
obtained from all individuals prior to their inclusion. the study was conducted 
according to the principles expressed in the declaration of Helsinki.
il-28b genotype determination
the Il-28B rs12979860 gene polymorphisms were determined using competitive 
allele-specific PCR (KASP; KBioscience Hoddesdon, UK).
Immunoassay for detection of IFN-λ1 and IFN-λ2/3 in serum
IFN-λ concentrations in the sera of individuals were determined using sandwich 
ELISA specific for IFN-λ1 (Human IFN lambda 1 ELISA Ready-Set-Go, eBiosci-
ence) with a detection limit of 8 pg/ml and a validation range between 8 and 
1000 pg/ml. these results were then validated using elIsa reagents from other 
commercial/non-commercial sources (Verikine-dIY™ Human Interferon lambda 
ELISA, PBL Interferon Source, and Human IFN-λ1 ELISA, Bristol-Myers Squibb 
(Murine Anti-IFN-λ1 Capture Antibody E10137, Murine Anti- IFN-λ1 Biotinylated 
Bio-E7900). Due to the fact that IFN-λ2 and IFN-λ3 are 96 % homologous, a single 
IFN-λ2/3 sandwich ELISA (Verikine-DIY™ Human Interferon Lambda 2/3 ELISA, 
PBl Interferon source) was used to measure the combined cytokine levels (detec-
tion limit of 125 pg/ml and a validation range between 125 and 8000 pg/ml).
statistiCal analysis
data is expressed as mean values ± standard error of the mean (seM) unless in-
dicated otherwise. data was analyzed with Prism 5.0 software (GraphPad) using 
the Mann-Whitney U test to compare variables between 2 independent groups 
and the Spearman rank correlation coefficient test for nonparametric correlations. 
In all analyses, a 2-tailed P value of less than 0.05 (confidence interval of 95 %) 
was considered statistically significant.
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results & discussion
To examine the role of endogenous IFN-λ in chronically infected HBV and HCV 
patients, we performed a cross-sectional analysis of IFN-λ1 and IFN-λ2/3 serum 
levels in 124 chronically infected HCV patients, 22 HCV resolved HCV patients, 
93 chronically infected HBV patients, 25 chronically infected HBV patients cur-
rently receiving nucleot(s)ide analog therapy, 20 acutely infected HBV patients, 
and 20 healthy individuals (table 1).
No significant differences were identified when comparing the serum IFN-λ1 
levels of healthy individuals to those of chronically infected HCV (p = 0.169) 
and HCV patients with therapy-induced sVr (p = 0.115) or between the patient 
groups themselves (p = 0.357) (fig. 1a). Next, we stratified the HCV patients on 
the basis of IFN-λ3 (IL-28B) genotype as well as various clinical parameters, 
after which we performed further cross-sectional analysis to determine if any of 
these factors were associated with IFN-λ1 levels in serum. Of the total chronic 
HCV patient group, 47 were genotyped for the IFN-λ3 SNP at loci rs12979860, 
with a C allele frequency of 45.7 %. We observed no difference in IFN-λ1 levels 
between patients homozygous for the C allele, heterozygous patients, and those 
homozygous for the t allele (fig. 1B). serum alt (fig. 1C, 1d), HCV viremia, and 
degree of liver fibrosis were all found to not significantly correlate with IFN-λ1 lev-
els in the sera of HCV infected individuals (data not shown). Serum IFN-λ1 levels 
of patients with varying alt levels were further compared by selecting patients 
within 2 clinically relevant groups; those with normal ALTs (“Low ALT” ≤ 40IU/l) 
and those with extremely elevated alt levels (“High alt” > 160IU/l; 4x the norm) 
(p = 0.137). The ALT levels of these patients were checked to confirm they had 
remained consistent for at least 6 months prior to the date of blood collection. We 
found it necessary to ensure that the reagents used would not bias any results, 
and validated all measurements using a secondary and tertiary elIsa kit from 
different commercial/non-commercial sources. Although it is notable that some 
of the individual measurements did vary between the immunoassay kits, the 
overall results remained unaffected and validated that there are no differences 
in endogenous IFN-λ1 serum levels of chronic HCV patients as compared to 
healthy individuals. Additionally, the levels of serum IFN-λ2/3 were measured for 
patients chronically infected with HCV and healthy individuals and no differences 
between individual groups or correlations with clinical parameters were observed 
(fig. 1e-f).
furthermore, we examined whether patients chronically infected with HBV 
demonstrated enhanced levels of IFN-λ1 in serum. As shown in fig. 2a, no 
differences were observed when comparing chronic HBV patients with healthy 
individuals or chronic HCV patients. Serum IFN-λ1 levels of chronically infected 
HBV patients receiving nucleot(s)ide analog therapy (n = 25), and acutely infected 
HBV patients (n = 20) were also measured, and showed no significant differences 
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(fig. 2a-B). the chronic HBV patients were further divided in 3 clinical groups; 
immune-active, immune-tolerant, and inactive carriers but again no differences in 
IFN-λ1 serum levels were observed (fig. 2C). all measurements were validated 
using additional elIsa kits, and the results remained consistent across reagent 
kits used, showing no significant differences or correlations between any clinical 
groups.
figure 1. IFN-λ1 and IFN-λ2/3 serum levels of HCV patients do not differ from those of 
healthy individuals, and do not correlate with various genotypic and clinical factors.
(A) Levels of IFN-λ1 were measured from the sera of various healthy and HCV patient populations. (B) 
IFN-λ1 serum levels of chronic HCV patients were stratified according to their rs12979860 (IL-28B) geno-
type. (C) IFN-λ1 serum levels of chronic HCV patients were plotted against their corresponding ALTs. (D) A 
second group of patients was selected with either clinically normal ALTs (“Low ALT” ≤ 40IU/l) or those with 
extremely (4x the norm) elevated ALT levels (“High ALT” > 160 IU/l). (E) IFN-λ2/3 levels were measured 
from sera of healthy and HCV patient populations. (F) IFN-λ2/3 serum levels of chronic HCV patients were 
stratified according to their rs12979860 (IL-28B) genotype.
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We investigated the role of endogenous IFN-λ levels in the blood of viral hepa-
titis patients and observed that contrary to previous findings, no significant pat-
terns emerged when comparing the serum IFN-λ1 or IFN-λ2/3 levels of healthy 
controls and patients with various genotypic and clinical factors (diegelmann and 
others 2010; dolganiuc and others 2012; langhans and others 2011). It has also 
been previously suggested that decreased IFN-λ levels of chronic HCV patients 
may partially explain disease progression to chronicity and associations between 
IFN-λ3 SNPs with spontaneous and therapy induced viral clearance (Langhans 
and others 2011). Although our findings are similar in respect to IFN-λ2/3, 
we did not detect a decrease in IFN-λ1 levels in the blood of chronic HCV or 
HBV patients and no correlation between serum IFN-λ levels and rs12979860 
genotypes, suggesting that no such link exists. although there is a clear link 
between rs12979860 and various other IFN-λ3 SNPs with HCV self-clearance 
and probability of patient response to therapy, this is not explained by differences 
in endogenous IFN-λ levels. Outside of these differences observed in chronic 
HCV patients our results, regarding the levels and range of IFN-λ1 detected in 
healthy individuals and therapy or spontaneously resolved patients, resemble 
figure 2. Endogenous IFN-λ1 levels do not differ in serum of acute and various chronic HBV 
patient groups.
(A) IFN-λ1 levels measured from the sera of healthy, chronic HCV, and chronic HBV patient populations. (B) 
IFN-λ1 serum levels of healthy controls, chronic HBV patients, chronic HBV patients receiving nucleot(s)
ide analog therapy, and acute HBV patients. (C) IFN-λ1 serum levels of immune-active, immune-tolerant, 
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those described previously described (langhans and others 2011). to try and 
avoid biases created by patient cohort selection or reagents used, we validated 
our original findings using patients with extremes for various clinical criteria (ALT 
and viral load) to rule out the influence of these factors and used secondary 
and tertiary immunoassays from different distributers to validate our results. Ad-
ditionally, when comparing the IFN-λ1 levels in the serum of healthy individuals, 
chronic HCV, and resolved HCV patients we observed no differences, suggesting 
that quantity of endogenous IFN-λ1 in blood is not significantly affected during 
viral hepatitis or the resolution of it. With respect to IFN-λ2 and IFN-λ3, it is no-
table that these cytokines are virtually identical, with a 96 % amino acid homology 
(Sheppard and others 2003) and current reagents have difficulty measuring these 
individual cytokines accurately due to cross-reactivity.
Our data, which was obtained from a large cohort of well-defined patients and 
validated by multiple, distinct immunoassays, demonstrate that serum IFN-λ 
levels are not affected by infection with HCV or HBV, and not associated with 
specific disease stages or parameters. This study is also the first to in detail 
describe the IFN-λ serum levels of various groups of HBV infected patients. Our 
findings, however, do not exclude the possibility that local production of IFN in 
the liver is affected, or that the novel member the type III interferon family, IFN-λ4 
(Prokunina-Olsson and others 2013) demonstrates differential expression in 
disease. Lastly, endogenous IFN-λ could have little effect on viral clearance, and 
that difference in sensitivity or response of cells determines the disease or treat-
ment outcome. Either way, continued research on the IFN-λ family of cytokines is 
necessary to fully understand its immunological activity, and its possible benefits 
or disadvantages as a therapeutic.
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abstraCt
Over the last decade, increased emphasis has been placed on finding alterna-
tives to interferon (IFN)-α-based therapies. One such alternative, IFN-λ, has 
shown therapeutic promise in a variety of diseases, but research of this family 
of cytokines has primary been focused on their antiviral activities. the goal of 
this study was to investigate the role of IFN-λ in the regulation and modulation 
of B cell function. We show that similar to IFN-α, IFN-λ1 is able to augment 
tlr-mediated B cell activation, partially attributed to an upregulation of tlr7 
expression, and that both naïve and memory B cells express the limiting type III 
IFN receptor complex, IFN-λR1. Furthermore, this IFN-λ-enhanced B cell activa-
tion resulted in increased cytokine and immunoglobulin production during tlr7 
challenge, most prominently after the addition of helper t cell signals. Ultimately, 
these elevated cytokine and immunoglobulin levels could be partially attributed to 
the increase in proliferation of tlr7-challenged B cells by both type I and type III 
IFNs. These findings demonstrate the ability of IFN-λ to boost humoral immunity, 
an important attribute to consider for further studies on immunity to pathogens, 
vaccine development, and ongoing advancement of therapeutic strategies aimed 
at replacing IFN-α-based treated with IFN-λ.
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the antiviral activities of type III interferons (Ifn) to a wide variety of viruses 
have been extensively studied in recent years. Potent antiviral effects have 
been described in hepatitis C virus (HCV), human immunodeficiency virus (HIV), 
influenza, and a myriad of other infections [1–3]. The family of type III IFNs, also 
known as IFN-λ, consists of 4 members, IFN-λ1, IFN-λ2, IFN-λ3 and IFN-λ4, 
that all bind to the same receptor heterodimer, consequently activating the signal 
transducers and activators of transcription 1 (stat1) and stat2, and inducing 
expression of Ifn-stimulated genes (IsGs). type III Ifns resemble the type I 
IFNs, IFN-α and IFN-β, in many ways; exhibiting overlapping antiviral activities 
and nearly identical activation of signaling downstream of their respective recep-
tors [4–6]. This is not necessarily expected as type I IFNs and type III IFNs signal 
via distinct receptor complexes. The heterodimeric IFN-α receptor is ubiquitously 
expressed across divergent cell populations, whereas expression of the IFN-λ 
receptor appears to be more restricted and expression of the complete receptor 
has primarily been described on cells of epithelial origin, specifically epithelial 
cells, hepatocytes, and fibroblasts [6–8].
The expression of the IFN-λ receptor on many immune cells and their respon-
siveness to type III IFN is still largely unclear. Expression of the IFN-λ receptor on 
plasmacytoid dendritic cells (DC) has already been established [9], and we, as 
well as others, have demonstrated that monocyte-derived macrophages, but not 
monocytes, express the limiting IFN-λ receptor dimer, IFN-λR1, and are conse-
quently responsive to stimulation by IFN-λ [10–12]. Interestingly, we showed that 
the effect of IFN-λ was distinct from that of IFN-α, with opposing effects of these 
types of Ifns observed on tlr-induced Il-12p40 production. Moreover, although 
IFN-α had a potent, direct effect on natural killer (NK) cells, IFN-λ was able to 
indirectly affect NK cells via macrophage-derived IL-12, due to the absence of a 
complete IFN-λ receptor complex on NK cells.
type I Ifns have been shown to be strong modulators of multiple immune 
cell populations, including B cells. IFN-α exposure of B cells strongly promotes 
humoral immunity via enhanced survival, reduced apoptosis, and enhancement 
of activation, proliferation, and immunoglobulin production [13–15]. These effects 
are best observed when B cells are additionally stimulated via the B cell receptor 
(BCR), CD40, or toll-like receptors (TLRs) [16, 17]. IFN-α-induced enhancement 
has been shown to be beneficial for generation of neutralizing antibodies, espe-
cially during viral infection [18]. In contrast, excessive production of antibodies 
against dna complexes in patients with systemic lupus erythematosus (sle) is 
also, at least in part, the result of an undesired IFN-α effect on B cells [19].
However, unlike IFN-α, little information is available on the effects of IFN-λ on B 
cells. Various studies have demonstrated that B cells express the IFN-λ receptor 
[20], but the responsiveness of B cells has not been studied in detail. Multiple 
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myeloma B cells have been shown to proliferate in response to IFN-λ1 [21], and 
other studies have suggested a type I and II Ifn independent mechanism of 
TLR7 up-regulation in B cells [22]. Therefore, to gain further insight into the effect 
of IFN-λ on the B cell compartment, we investigated in detail the role of IFN-λ on 
the regulation and modulation of human B cell function in comparison to IFN-α.
materials and methods
b cell isolation and culture
Human peripheral blood mononuclear cells (PBMC) were isolated from buffy 
coats (Sanquin Blood Supply, Rotterdam, The Netherlands) using density gradi-
ent centrifugation (Ficoll-Paque, GE Healthcare, Uppsala, Sweden). Monocytes 
and B cells were then purified from the PBMC fraction using magnetic labeled 
Cd14 or Cd19 micro-beads (Miltenyi Biotec, Bergisch Gladbach, Germany), 
respectively according to the protocol provided by the manufacturer. the purity 
of monocytes and B cells isolated and used in this study always exceeded 95 %.
B cells were cultured in rPMI1640 medium (lonza, Verviers sprl, Belgium) 
with the supplementation of 10 % heat-inactivated fetal calf serum (FCS, Sigma-
aldrich, st. louis, Mo, Usa), penicillin and streptomycin (Gibco, Carlsbad, Ca, 
USA), L-glutamate (Lonza), and 1M HEPES Buffer (Lonza).
Cfse labeling and proliferation assay
Isolated Cd19+ B cells were labeled using 0.1 μM CFSE (Vybrant® Cfda se Cell 
tracer Kit, Invitrogen, Carlsbad, Ca, Usa) according to the protocol provided 
by the manufacturer. labeled B cell were then cultured for 5 days in rPMI1640 
medium (10 % FCS; Lonza) with 10 ng/ml IFN-α2b (Intron A, Merck, Whitehouse 
Station, NJ, USA) or 100 ng/ml IFN-λ1 (Bristol-Myers Squibb, Wallingford, 
Ct, Usa) alone or in combination with tlr2 agonist Pam3CsK4 (100 ng/ml; 
InvivoGen, san diego, Ca, Usa), tlr7/8 agonist r848 (100 ng/ml; enzo life 
Sciences, Farmingdale, NY, USA), or TLR9 agonist CpG-B (5 μg/ml; ODN 2006, 
InvivoGen). all cultures were performed with or without mimicked t cell help pro-
vided by soluble Cd40 ligand (sCd40l, 100 ng/ml; r&d systems, Minneapolis, 
Mn, Usa) and f(ab’)2 fragments of anti-IgM (αIgM, 5 μg/ml; Jackson ImmunoRe-
search, Suffolk, UK). Proliferation was measured by flow cytometry (FACS Canto 
II, Bd, san diego, Ca, Usa) and analyzed using flowJo (tree star Incorporated, 
ashland, or, Usa).
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stimulation of B cells and surface marker analysis
0.5x106 PBMC from healthy donors were stimulated with 10 ng/ml IFN-α2b (Intron 
A, Merck) or 100 ng/ml IFN-λ1 (Bristol-Myers Squibb) alone or in combination 
with r848 (100 ng/ml; enzo life sciences) for 3, 6, and 24 hours. Cellular activa-
tion and surface marker expression was measured on Cd3-/Cd19+/Cd27+/- B 
cells (anti-Cd3-Pe (UCHt1, Biolegend, san diego, Ca, Usa), anti-Cd19-aPC-
efluor780 (HIB19, eBioscience, san diego, Ca, Usa), and anti-Cd27-fItC 
(L128, BD Biosciences) using flow cytometric analysis with anti-CD25-APC 
(2a3, Bd Biosciences), anti-Cd40-Pe-Cy5.5 (5C3, eBioscience), anti-Cd69-
Pe-Cy7 (tP1.55.3, eBioscience), anti-Cd80-fItC (B9.12.1, Beckman Coulter, 
Breda, CA, USA), anti-CD86-Pacific Blue (IT2.2, Biolegend), anti-HLA-ABC-FITC 
(W6/32, Biolegend), and anti-Hla-dr-PerCP-Cy5.5 (ln3, eBioscience) using 
flow cytometry (FACS Canto II, BD Biosciences) and analyzed using FlowJo 
(Tree Star Incorporated). Titration for concentrations of IFN-λ1 and IFN-α and the 
subsequent effect on CD69 expression are depicted in supplementary figure 2a.
for cytokine and immunoglobulin production in supernatant, 0.5x106 isolated 
Cd19+ B cells were stimulated with TLR agonists and IFN-α2b or IFN-λ1 as 
described above for 3, 5, and 7 days. all cultures were performed with or without 
mimicked t cell help, sCd40l (100 ng/ml; r&d systems) and f(ab’)2 fragments 
of anti-IgM (5 μg/ml; Jackson ImmunoResearch).
Immunoassay for detection of cytokines and immunoglobulins in 
supernatants
the concentrations of various cytokines were measured in the supernatants of 
stimulated Cd19+ B cells by the use of sandwich ELISA specific for IL-6 and IL-10 
(ready-set-Go Kits, eBioscience) with a sensitivity for both assays of 2 pg/ml. 
Immunoglobulins were measured in the supernatants of stimulated B cells using 
sandwich ELISA kits specific for IgG and IgM (Bethyl Laboratories, Montgomery, 
tX, Usa) with a sensitivity of 7.8 ng/ml and 15.6 ng/ml, respectively.
gene expression quantification
total rna was isolated from HeK293 r19, hepatocytes isolated from healthy 
donors livers, as well as flow cytometric sorted total CD20+ B cells, Cd14+ 
monocytes, Cd20+/Cd27- naïve B cells, Cd20+/Cd27+ memory B cells, and 
Ifn-stimulated isolated Cd19+ B cells using the rneasy kit (Qiagen, Hilden, 
Germany) and cdna was prepared using the Primescript cdna synthesis kit 
(takara, shiga, Japan) from 500 ng rna. all real-time PCr reactions were 
performed using a MyIQ5 detection system (Bio-rad, Hercules, Ca, Usa) and 
relative mrna expression levels were calculated using the housekeeping gene 
GaPdH. the following primer/probe sets (applied Biosystems, Carlsbad, Ca, 
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Usa) were used for the housekeeping gene and genes of interest: GaPdH 
(Hs00266705_g1), IFN-λR1 (Hs00417120_m1), IFN-αR1 (Hs01066115_m1) 
IFN-αR2 (Hs01022060_m1), Mx1 (Hs00895608_m1), OAS1 (Hs00973637_m1), 
and tlr7 (Hs00152971_m1).
statistical analysis
data is expressed as the mean value ± standard error of the mean (seM) un-
less indicated otherwise. data was analyzed with Prism 5.0 software (GraphPad 
software Incorporated, san diego, Ca, Usa) using the Mann-Whitney U test to 
compare variables between independent groups and the spearman rank correla-
tion coefficient test for nonparametric correlations. In all analyses, a 2-tailed P 
value of less than 0.05 (confidence interval of 95 %) was considered statistically 
significant.
resUlts
Both naïve and memory B cells express IFN-λR1 mRNa, and IFN-λ1 
stimulation in combination with tlr7/8 ligation is able to activate b cells
Type I IFN stimulation has been shown to affect specific B cell TLR expression 
and responsiveness after challenge with their respective agonists [16, 23]. Since 
little is known about the immune effects of type III IFN, we chose to explore to 
what extent type III Ifn are able to regulate B cell activation, alone or in combina-
tion with tlr stimulation, as well as how these compare to type I Ifn. to do so, 
we stimulated human B cells for 3, 6, and 24 hours with either IFN-α, IFN-λ1, or 
IFN-α/IFN-λ1 alone or in combination with the TLR7/8 ligand R848 and performed 
flowcytometric analysis for an array of activation markers. Of the activation mark-
ers tested, only CD69 was found to be significantly upregulated by IFN-λ1 as well 
as IFN-α, but only in combination with R848 triggering (figure 1a-B). this was 
true for both the frequency of CD69-expressing B cells as well as for the mean 
fluorescent intensity (MFI) of CD69 expression levels on B cells (supplementary 
figure 1a-B). IFN-α, however, was able to already induce significantly increased 
CD69 expression at 3 hours, while significant effects of IFN-λ1 were only ob-
served after 6 hours. IFN-α alone was also able to significantly induce CD69 
expression, something not observed for IFN-λ1 stimulation. However, CD25 
expression (figure 1a), Cd40, Cd80, Cd86, Hla-aBC, and Hla-dr (data not 
shown) were all unaffected by IFN-λ1 stimulation, with or without the addition of 
tlr challenge. similar results were observed when analyzing Cd27- naïve and 
Cd27+ B cells independently (supplementary figure 2B), suggesting that both 
naïve and memory B cell populations are responsive to IFN-λ1 stimulation.
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figure 1. Both naïve and memory B cells express IFN-λR1 mRNA, and IFN-λ1 stimulation in 
combination with tlr7/8 ligation is able to activate B cells
(A) PBMCs (n = 6) were stimulated 3, 6, or 24 hours with IFN-λ or IFN-α, with or without the combination of 
TLR7/8 agonist R848, and flow cytometric analysis was performed to determine the expression of the acti-
vation markers Cd69 and Cd25 on Cd3-/Cd19+ B cells. (B) Individual (n = 12) results for Cd69 expression 
on B cells after 24 hours IFN/R848 stimulation. (C) Representative gene expression of IFN-λR1, IFN-αR1, 
and IFN-αR2 mRNA by sorted primary resting monocytes, total B cells, CD27- naïve B cells, and Cd27+ 
memory B cells. The relative mRNA expression was measured by qPCR, using primary hepatocytes and 
HEK293 cells stably transfected to express IFN-λR1 (HEK293R19) as positive controls. Expression levels 
are shown as the ΔΔCT relative to the housekeeping gene GAPDH. Data are shown as mean ± SEM and 
are representative of 4 (a-B) independent experiments.*P < 0.05, **P < 0.01, and ***P < 0.001 as com-
pared to the control condition (Mann-Whitney U test).
48
part i: systemic levels and immunological regulation of type III Ifns in viral hepatitis infection
To determine if type I and type III IFNs are able to act on equivalent B cell popu-
lations, naïve and memory B cells were sorted based on their Cd27 expression, 
and qPCR analysis was performed for the expression of their respective recep-
tors. A HEK293 cell line (HEK293 R19) stably transfected to express IFN-λR1 
mrna as well as primary human hepatocytes, known to express the receptor 
and respond to IFN-λ [6], were included as comparative positive controls, while 
the primary human monocytes were included as negative controls. Both IFN-λR1 
and IFN-αR1/2 mRNA expression were found in naïve CD27- and memory Cd27+ 
B cells, using total sorted B cells as a comparative control and sorted Cd14+ 
monocytes as negative control for IFN-λR1 expression (figure 1C). Collectively 
this data shows that similar to type I Ifn, type III Ifn are able to induce B cell 
activation, in combination tlr7/8 challenge, and that both naïve and memory B 
cells could be perspective targets.
IFN-λ1 stimulation induces Isg and TLR7 expression in primary human B cells
The ability of IFN-α to enhance TLR7 sensitivity of B cells by selectively up-
regulating TLR7 expression has been previously described [16]. To determine if 
IFN-λ1 resembles type I IFNs in this ability, and to confirm the ability of B cells to 
respond to type III IFNs, isolated B cells were stimulated with either IFN-α, IFN-λ, 
or a combination of IFN-α/IFN-λ1, and qPCR was performed for the expression 
of ISGs Mx1 and OAS1, TLR7, and IFN-λR1. Both IFN-λ1 and IFN-α were able to 
significantly upregulate MX1 and OAS1 mRNA expression (figure 2a), confirming 
B cell responsiveness to both type I and III IFNs. IFN-λ1 and IFN-α were also both 
able to significantly upregulate TLR7 expression (figure 2B), a potential explana-
tion for the enhanced activation observed in response to tlr7/8 stimulation dur-
ing co-culture with IFN-λ1. IFN-λR1 expression, however, was only slightly, but 
significantly, upregulated by IFN-α stimulation, similar to the regulation by IFN-α 
on IFN-λR1 expression described in hepatocytes [24]. The combined stimulation 
of IFN-α and IFN-λ1 had similar effects as compared to the individual cytokines 
with only a minimal synergistic effect.
IFN-λ1 enhances TLR7/8-induced immunoglobulin production and TLR9-
induced cytokine production of B cells
With the confirmed expression of the IFN-λ receptor on both naïve and memory 
B cells and observed increased activation after tlr7/8 stimulation, the next step 
was to determine to what extent IFN-λ1 was able to modulate B cell function. This 
was done by stimulating isolated B cells with either IFN-α or IFN-λ1 in combina-
tion with r848, and assessing immunoglobulin and cytokine production at days 3, 
5, or 7 using immunosorbent assays. As expected, both IFN-λ1 and IFN-α were 
able to enhance tlr7/8-mediated IgG and IgM production in isolated B cells, 
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and increased consistently over the culture period, with highest augmentation 
observed at day 7 (figure 3a). The effect of IFN-λ1 or IFN-α on stimulation in 
the presence of TLR2 (Pam3CSK4) and TLR9 (CpG) differed from the cultures 
containing r848; Pam3CsK4 was unable to induce IgG or IgM production, and 
CpG-mediated immunoglobulin production was unaltered by the addition of either 
type I or III Ifn (figure 3a).
Concurrently to the immunoglobulin analysis, isolated B cells were also evalu-
ated for their cytokine production upon Ifn and tlr stimulation. after culturing 
for 3 days, IFN-λ1 showed a strong trend toward enhancement of R848-mediated 
IL-6 (p = 0.055), whereas no effect on IL-10 levels was observed (figure 3B). 
In contrast, both R848 and CpG-mediated IL-6 production were significantly 
increased by IFN-α at day 3. At day 7, IL-6 and IL-10 levels were significantly 
altered by IFN-α in R848 co-stimulations, and only IL-6 was enhanced by both 
IFN-α and IFN-λ in combination with CpG. These results implicate a role for both 
IFN-α and IFN-λ in the modulation of TLR-triggered cytokine and immunoglobulin 
production of B cells.
figure 2. IFN-λ1 stimulation induces ISG and TLR7 expression in primary human B cells
(A) Purified B cells (n = 6) were stimulated with either IFN-α, IFN-λ, or a combination of IFN-α/IFN-λ1 for 3 
hours, and qPCR was performed for the expression of ISGs MX1 and OAS1, (B) TLR7, and (C) IFN-λR1. 
Expression levels are shown as the ΔΔCT relative to the housekeeping gene GAPDH. Data are shown as 
mean ± seM and are representative of 2 independent experiments.*P < 0.05 and **P < 0.01, as compared 
to the control condition (Mann-Whitney U test).
50
part i: systemic levels and immunological regulation of type III Ifns in viral hepatitis infection
figure 3. IFN-λ1 enhances TLR7/8-induced immunoglobulin production and TLR9-induced 
cytokine production by B cells
(A) Purified B cells (n = 5) were stimulated with R848 in combination with either IFN-α or IFN-λ, and super-
natants were harvested at days 3, 5, and 7 for elIsa analysis of IgG and IgM. Identical cultures were per-
formed using medium, Pam3CsK, and CpG-B and results are shown for day 7 of stimulation. (B) Il-6 and 
Il-10 levels were determined by elIsa of the aforementioned B cell cultures using medium, Pam3CsK, 
R848 or CpG-B stimulation supplemented with either IFN-α or IFN-λ after 3 and 7 days. Data are shown as 
mean ± seM and are representative of 3 independent experiments.*P < 0.05 and **P < 0.01 as compared 
to the control condition (Mann-Whitney U test).
51









bCr and Cd40 ligation are able to further increase ifn/tlr-mediated 
cytokine production of human B cells
after observing that type III Ifn was able to promote tlr-mediated B cell anti-
body and cytokine production, we were interested to study if this modulation could 
be further affected by additional B cell signals. TLR and antigen receptors have 
been well-established integrators of B cell responses, including but not limited 
to the production of Il-6 and Il-10 as well as a broad range of immunoglobulin 
subclasses.[25] We therefore collected supernatants after 3 and 7 days of TLR 
stimulated B cells cultured in the presence of IFN-α or IFN-λ1, this time with simu-
lated t cell help in the form of Cd40 ligation and triggering of the B cell receptor 
via IgM. The addition of sCD40L and anti-IgM (αIgM) significantly enhanced the 
levels of IL-6 and IL-10 in supernatants of B cells stimulated with IFN-λ1 at day 
3 and 7 alongside of TLR7/8 and TLR9 challenge (except for IL-10 day 7 IFN-λ1/
r848, p = 0.055) (figure 4). IFN-α had a similar effect with significant or strong 
trends for increased tlr7/8 and tlr9-mediated Il-6 and Il-10 production by 
B cells exposed to mimicked t cell help at both day 3 and 7. the importance 
of additional t cell help for robust cytokine production can be explained by the 
predominance of naïve B cells in the peripheral blood compartment, and the previ-
ously established requirement of additional signals for naïve B cell activation.[17]
figure 4. BCr and Cd40 ligation further increase Ifn/tlr-mediated cytokine production by 
human B cells
(A, B) Purified B cells (n = 5) were stimulated with an array of TLR agonists, Pam3CSK, R848 or CpG-
B, in combination with mimicked T cell help, using sCD40L and αIgM. The cultures were supplemented 
with either IFN-α or IFN-λ and supernatants were harvested at day 3 and day 7 for ELISA analysis of 
Il-6 and Il-10 production. data are shown as mean ± seM and are representative of 3 independent 
experiments.*P < 0.05 and **P < 0.01 as compared to the control condition (Mann-Whitney U test).
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similar to type I IFN, type III IFN enhance TLR and cd40/BcR-mediated B 
cell proliferation
the increased cytokine and immunoglobulin production observed by type I and 
III Ifn stimulation led us to examine the possibility that these Ifn-induced ef-
fects may be the result of enhanced B cell proliferation. to do so, we stimulated 
Cfse-labeled B cells with Pam3CsK4, r848, or CpG alone or in combination 
with IFN-α or IFN-λ for 5 days (figure 5a). only tlr9 (CpG) challenge alone was 
able to induce B cell proliferation without the addition of either Ifn. the addition 
of type I as well as type III Ifns enhanced r848-induced B cell proliferation, but 
did not further increase CpG-induced responses. as expected, the additional B 
cell triggering using Cd40-ligand and BCr ligation augmented the proliferative 
responses. The frequency of proliferated B cells upon CD40 and BCR stimula-
tion (figure 5a, B) was increased upon additional r848 and CpG stimulation. 
figure 5. similar to type I Ifn, type III Ifn enhances tlr and BCr-mediated B cell proliferation
(a) Cfse-labeled human B cells were cultured in the presence of Pam3CsK4, r848, or CpG-B in com-
bination with IFN-α or IFN-λ1 for a total of 5 days. sCD40L and αIgM were added to a fraction of the cul-
tures, and the results were analyzed using flow cytometry. Shown are histograms of a representative for 
B cell proliferation (B) and collective results of multiple donors (n = 4). (C) accompanying IgG production 
measured in the supernatant of B cells after 7 days of stimulation (n = 5). data are shown as mean ± seM 
and are representative of 3 independent experiments.*P < 0.05 and **P < 0.01 as compared to the control 
condition (Mann-Whitney U test).
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However, r848-induced, but not CpG-induced, proliferative responses were 
significantly increased by IFN-α as well as IFN-λ1. The higher levels of B cell 
proliferation upon stimulation of R848 and IFN-α or IFN-λ1 in combination with 
CD40/BCR ligation were mirrored by a significant increase of IgG production in 
supernatants of these cells (figure 5C). Collectively, these results confirm a role 
of both IFN-α and IFN-λ1 in the enhancement of TLR7/8-mediated B cell prolif-
eration and IgG production. TLR9 stimulation, although being the most effective 
inducer of proliferation alone, was independent and unaffected by the addition of 
either type of Ifns.
disCUssion
The focus of this study was to examine the ability of IFN-λ to modulate the activity 
and function of human B cells, both alone and in combination with specific TLR 
activation. We demonstrate that similar to IFN-α, IFN-λ1 is able to augment TLR-
mediated B cell activation, but only in combination with tlr7/8 or tlr9 ligation. 
In contrast to IFN-α, IFN-λ1 stimulation alone was unable to activate B cells, 
indicated by the lack of induction of Cd69 expression. Both naïve and memory B 
cells expressed the limiting type III IFN receptor component, IFN-λR1, as well the 
complete IFN-αR1/2 complex. IFN-λ1 stimulation alone was however sufficient to 
induce IsGs Mx1 and oas1 as well as tlr7 expression in B cells. We further 
show that this IFN-λ-enhanced B cell activation resulted in increased cytokine 
and immunoglobulin production during both tlr7/8 and tlr9 challenge, most 
prominently after the addition of helper t cell signals. Ultimately, these elevated 
cytokine and immunoglobulin levels could be partially attributed to the increase in 
proliferation of tlr7/8-challenged B cells by both type I and type III Ifns.
Previous studies have investigated and established the effects of type I IFNs on 
B cells [13–15] and its ability to enhance TLR7 sensitivity of B cells by selectively 
up-regulating TLR7 expression [16]. However, the effects of type III IFNs on B cell 
tlr response and function still remain relatively unexplored, with descriptions 
of non-type I and II IFN enhancement of TLR7 prospectively attributed to IFN-λ 
[22]. Our study is the first to definitely demonstrate that this ability to enhance 
tlr-induced responses in B cells, partially attributed to an upregulation of tlr7 
expression, is in fact also a characteristic of IFN-λ. The upregulation of ISGs and 
TLR7 observed after the combined stimulation of IFN-α and IFN-λ1 resembled 
that of either Ifn independently, most likely due to the overlapping signaling 
cascades described for type I and III IFNs [26, 27]. However, although stimulation 
with either Ifn alone was able to induce Mx1 and oas1 expression, one aspect 
where IFN-λ differed from IFN-α, was in its inability to independently (without the 
addition of tlr challenge) activate B cells, assessed by Cd69 expression. this 
immediate action of IFN-α has been shown to be integral in the early activation of 
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B cells during influenza infection, mediating activation, transcriptional response, 
and the antibody responses [18]. IFN-λ, however, has previously been described 
to be kinetically distinct and has a more delayed effect on specific cellular popula-
tions than that of IFN-α [28, 29]. These divergences in kinetics and its requirement 
of additional signals to activate B cells suggest that IFN-λ could represent a more 
postponed and specific means of B cell activation compared to that of IFN-α.
type I Ifns have been shown to act on all populations of B cells, but this is 
not the case for tlr expression and response in B cells. Higher levels of tlr7 
and tlr9 expression and increased responses of their respective ligands have 
been reported on memory B cells as compared to naïve B cells [30, 31]. We dem-
onstrate that, similar to IFN-αR1/2, IFN-λR1 is expressed at comparable levels 
on both Cd27- naïve B cell and Cd27+ memory B cell subsets and upregulate 
CD69 expression upon TLR7/8 challenge in combination with IFN-λ1 stimulation, 
indicating that type I and III IFNs are similar in their targeting of B cells at different 
activation stages. this suggests that the necessity of an additional tlr signal 
for the induction of B cell activation by IFN-λ compared to IFN-α is not the result 
of targeting differing subsets, and that expression of the IFN-λ receptor is not 
associated with B cell memory phenotype, as described for tlr expression.
DCs have been described as potent producers of both IFN-α and IFN-λ, with 
IFN-α production primarily attributed to plasmacytoid DCs and IFN-λ production 
to BdCa3+ myeloid DCs [32–36]. As previously discussed, DC-derived IFN-α has 
been shown to increase B cell responsiveness to tlr7 stimulation, and more 
recent studies have suggested similar roles for IFN-λ in the up-regulation of B cell 
TLR7 expression as well as in their capacity to produce immunoglobulins [22, 37]. 
In our study, we now conclusively establish that IFN-λ, in combination with TLR7 
challenge, was able indeed to induce B cell activation and subsequently increase 
immunoglobulin production, as well as cytokine production, which were partially 
attributed to enhanced B cell proliferation. Interestingly, we also observed an 
increase in IL-6 and IL-10 production by B cells stimulated with IFN-λ in combina-
tion with CpG, but in contrast to R848 stimulation, had no effect on proliferation 
or immunoglobulin production. this implies an additional mechanism, apart from 
the effect of IFN-λ on B cell proliferation, for the enhancement of TLR-induced 
cytokine production by B cells. although initially observed in combination with 
tlr9 challenge, this does not have to be limited to tlr9 stimulation, as this 
effect may act in conjunction with the effects of B cell proliferation. IL-6 and IL-10 
production have been shown to be a drivers of B cell proliferation and/or im-
munoglobulin production, and key factors in the observed hyperactivity of B cells 
in sle patients, leading to immune complexes and tissue and organ damage 
[38–40]. The promotion of the immune response by IFN-λ resembles our previous 
observations in macrophages, where IFN-λ was able to promote IL-12p40 and 
TNF production upon TLR4 and TLR7/8 stimulation [10, 11]. Although, IFN-λ1 
was specifically used in this study with the goal of understanding this specific 
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cytokine’s therapeutic potential, our previous studies have shown the IFN-λ2–3 
had nearly identical effects to IFN-λ1 on monocyte-derived macrophages, due to 
their comparable receptor affinities.
The continued investigation of IFN-λ and its immunomodulatory capacities, 
independent of direct antiviral activities, is integral in understanding this class of 
cytokines and the role it plays in antiviral immunity. In this study, we were able to 
demonstrate the effects of IFN-λ on B cells, specifically in combination with TLR 
ligation, an important attribute for future studies to consider when determining 
the role of IFN-λ in the controlling of infections, but also for the exploration of the 
therapeutic potential of IFN-λ in treatment of chronic hepatitis B infection, as well 
in ongoing efforts to advance vaccine efficacies.
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supplementary figure 1. IFN-λ1 stimulation in combination with TLR7/8 ligation is able to 
activate B cells
(A) PBMCs (n = 6) were stimulated 3, 6, or 24 hours with IFN-λ or IFN-α, with or without the combination 
of TLR7/8 agonist R848, and flow cytometric analysis was performed to determine the expression of the 
activation markers Cd69 on Cd3-/Cd19+ B cells. (B) Individual (n = 6) results for Cd69 MfI on B cells after 
24 hours Ifn/r848 stimulation. data are shown as mean ± seM and are representative of 3 independent 
experiments. *P < 0.05 as compared to the control condition (Mann-Whitney U test).
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supplementary figure 2. IFN-λ1 stimulation in combination with TLR7/8 ligation is able to 
activate both naïve and memory B cells
(A) PBMCs (n = 6) were stimulated 24 hours with IFN-λ or IFN-α at varying concentrations, with or without 
the combination of TLR7/8 agonist R848, and flow cytometric analysis was performed to determine the 
expression of the activation markers Cd69 on Cd3-/Cd19+ B cells. (B) PBMCs (n = 6) were stimulated 
3, 6, or 24 hours with IFN-λ or IFN-α, with or without the combination of TLR7/8 agonist R848, and flow 
cytometric analysis was performed to determine the expression of the activation markers Cd69 on Cd3-/
Cd19+/Cd27-/+ naïve and memory B cells. data are shown as mean ± seM and are representative of 3 
independent experiments. *P < 0.05 as compared to the control condition (Mann-Whitney U test).
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abstraCt
With increasing interest in alternative options to interferon-alpha (IFN-α)-based 
treatments, IFN-λ has shown therapeutic promise in a variety of diseases. Al-
though the antiviral activity of IFN-λ has been extensively studied, there is limited 
knowledge regarding the immunological functions of IFN-λ and how these differ 
from those of other classes of IFNs. In this study, we investigated the effects of 
IFN-λ on primary human natural killer (NK) cells, both in a direct and indirect 
capacity. We demonstrate that in contrast to IFN-α, IFN-λ is unable to directly 
stimulate NK cells, due to the absence of IFN-λ receptor chain 1 (IFN-λR1) on 
NK cells. However, IFN-λ, in combination with TLR4 challenge, is able to induce 
the production of select members of the Il-12 family of cytokines in monocyte-
derived macrophages. We further show that through macrophage-mediated Il-12 
production, IFN-λ is able to indirectly affect NK cells and ultimately induce IFN-γ 
production.
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natural killer (nK) cells play an important role in the innate immune response, 
specifically in their ability to recognize and respond to stressed cells, including 
virus-infected, transformed, and damaged cells. activated nK cells respond 
to these stress signals by excretion of cytotoxic factors, including perforin and 
granzymes, as well as cytokines, such as interferon-γ (IFN-γ) and tumor necrosis 
factor (TNF), that act as a first response to control the source of distress as well 
as to activate subsequent adaptive immune responses[1, 2]. NK cells express an 
array of activating receptors, such as C-type lectin-like receptors (e.g. nKG2d) 
and natural cytotoxicity receptors (nCrs), and inhibiting receptors, C-type lectin-
like receptors (e.g. nKG2a) and killer cell immunoglobulin-like receptor (KIrs). It 
is currently believed that nK-cell activation or inhibition is governed by a balance 
of signaling by these receptors, and results after a critical threshold of activation 
signals exceeds inhibition[3].
nK-cell activation ensues after interacting with infected or distressed cells, 
shifting the balance of inhibitory and activating stimuli delivered via specific 
surface molecules. these include stress-induced surface markers, including al-
tered MHC expression, as well as soluble factors, of which Il-12 and Il-18 are 
well-described and known triggers of NK-cell effector activity[1, 2, 4]. Various cell 
types, such as dendritic cells (dCs) and macrophages, are able to modulate the 
function of nK cells by changing the cytokine micro-environment and interacting 
with reciprocal surface molecules[5–8]. These interactions have been shown to 
play an important role in anti-tumor and anti-inflammatory responses in a myriad 
of diseases. In line with this, the activity of nK cells can be promoted by expo-
sure to interferon-α (IFN-α), e.g. during interaction with IFN-producing activated 
plasmacytoid DCs leading to enhanced activation and cytolytic activity[9–11], and 
thereby promoting antiviral immunity.
In recent years, the type III family of IFNs, comprised of IFN-λ1, IFN-λ2, IFN-λ3, 
and IFN-λ4, has received increased attention, especially after the discovery of 
polymorphisms within its gene locus that were associated with spontaneous as 
well as therapy-induced clearance of hepatitis C virus (HCV)[12–15]. All mem-
bers of the IFN-λ family use a specific receptor heterodimer, the IFN-λR1 and 
IL-10R2 complex, which structurally differs from the IFN-α receptor complex, but 
they trigger common JAK/STAT signaling cascades, albeit with different kinetics. 
for both types of Ifn, phosphorylation of stat1 and stat2 has been described, 
which form complexes that bind promoter sequences in DNA ultimately result-
ing in the initiation of gene transcription[16, 17]. In contrast to the ubiquitously 
expressed IFN-α receptor, the distribution of the IFN-λ receptor is more limited. 
Murine models have shown that epithelial cells express the receptor complex and 
responded to IFN-λ stimulation by eliciting an antiviral response[18]. Outside of 
non-hematopoietic cells, specifically epithelial cells and hepatocytes, expression 
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of the IFN-λR1 chain in humans has been well-described on plasmacytoid DCs, 
fibroblasts[19, 20], and recently on macrophages[21].
We have previously demonstrated that monocyte-derived macrophages ex-
pressed a functional IFN-λ receptor complex, and that triggering of this receptor 
in combination with activation via specific toll-like receptors (TLRs) resulted in 
an enhancement of macrophage IL-12p40 production[21]. This was in contrast 
to IFN-α, which inhibited TLR-induced IL-12p40 production in monocyte-derived 
macrophages. Il-12p70 was, however, not detected in the supernatants of these 
stimulated macrophages, due to the absence of additional stimulatory signals, such 
as CD40 ligation or IFN-γ, required for the production of bioactive IL-12[22–24]. At 
present, it is unclear how triggering of similar signaling pathways by IFN-α and IFN-λ 
results in divergent biological activities. Besides macrophages, further functional 
differences have been described between IFN-α and IFN-λ in their modulation of 
hepatocytes, where IFN-λ has been shown to activate a more restricted subset of 
cells as well as induce sustained interferon-stimulated gene responses[25, 26].
To further define a role for IFN-λ in antiviral immune responses, the goal of 
this study was to determine whether IFN-λ could exert any immunomodulatory 
effects on NK cells, and if so, how that response compared to the action of type 
I IFNs. A previous study had described IFN-λ as being able to partially inhibit NK 
cell-derived IFN-γ production upon IL-12/15 stimulation[27, 28], but an effect of 
IFN-λ on NK cells could not be reproduced in an ensuing response to the original 
article[29]. To better understand the biological role of IFN-λ, we investigated the 
effects of IFN-λ on NK cells in both a direct and indirect capacity through its 
modulation of tlr-activated macrophages.
resUlts
In contrast to IFN-αR1/2, IFN-λR1 is only expressed after monocyte to 
macrophage differentiation
The direct effects of IFN-α on NK cells have been well-described[10, 11], but the 
ability of IFN-λ to act on NK cells has received little attention. To address this issue, 
our first approach was to determine if human NK cells express a functional IFN-λ 
receptor. This was achieved by comparing the mRNA expression of IFN-α and 
IFN-λ receptors on primary NK cells and NK92 cells by quantitative PCR (qPCR). 
A HEK293 cell line stably transfected to express IFN-λ receptor mRNA as well 
as primary human hepatocytes, known to express the receptor and respond to 
IFN-λ[25, 26], were included as comparative positive controls, while the monocytic 
tHP-1 cell line as well as primary human monocytes were included as negative 
controls. Although both IFN-αR1 and IFN-αR2 chains were ubiquitously expressed 
across all primary cells and cell lines (figure 1a), IFN-λR1 mRNA expression 
was not detected in either primary nK or nK92 cells (figure 1B). Monocytes 
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were also devoid of IFN-λR1 expression; however, differentiation of monocytes to 
macrophages by culture with granulocyte macrophage colony-stimulating factor 
(GM-CSF) resulted in an induction and continuous upregulation of IFN-λR1 over a 
6 day period (figure 1C). IFN-αR1 and IFN-αR2, both already highly expressed on 
monocytes, remained relatively unaltered across the differentiation process.
IFN-α, but not IFN-λ1, is able to directly stimulate and enhance effector 
function in NK cells
to further investigate nK cell responsiveness to type III Ifns, isolated primary 
NK cells were incubated with either IFN-α or IFN-λ1 overnight and analyzed for 
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figure 1. IFN-αR1/2 are ubiquitously expressed across both primary NK and monocytes and 
NK92/THP-1 cell lines, whereas IFN-λR1 is only expressed after monocyte to macrophage 
differentiation
(A and B) Expression of IFN-αR1, IFN-αR2, and IFN-λR1 genes in THP-1 and NK92 cell lines, and expres-
sion of IFN-λR1 genes in primary human monocytes and NK cells (n = 3 samples). The relative mRNA 
expression was measured by qPCR, using primary hepatocytes and HEK293 cells stably transfected to 
express IFN-λR1 (HEK293R19) as positive controls. (C) mRNA expression of IFN-αR1, IFN-αR2, and IFN-
λR1 measured in monocytes (n = 6) at day 0, 2, 4, and 6 of culture with GM-CSF to induce macrophage 
differentiation was measured by qPCR. All expression levels are shown as the ΔΔCT relative to the house-
keeping gene GaPdH. (a-C) data are representative of 2 independent experiments, and (C) are shown 
as mean ± seM (n = 6 samples).
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including Cd69, a marker of lymphoid cell activation, and C-type lectin trans-
membrane receptors nKG2a and nKG2d. the percentage of Cd69 expressing 
NK cells was increased by almost sevenfold in IFN-α cultures (76.3 %) compared 
to those exposed to medium alone (11.3 %) or IFN-λ1 (13.5 %) (figure 2a), while 
expression of inhibitory receptor nKG2a and the activating receptor nKG2d re-
mained unaffected in all conditions (figure 2a and data not shown). the cytolytic 
capacity of Ifn-stimulated nK cells was assessed by measuring the degranula-
tion marker Cd107a after coculture with the target cell line K562, and by mrna 
expression of protease granzyme B (GZMB). NK cells exposed to IFN-α during 
the 5 hour coculture period with K562 cells expressed higher levels of Cd107a 
(32.2 %) while coculture with IFN-λ1 (21.1 %) showed no difference from the 
medium condition (19.8 %) (figure 2B). Stimulation with IFN-α, in combination 































































































figure 2. IFN-α, but not IFN-λ1, directly stimulates and enhances effector function in NK cells
(A) Surface marker and intracellular flow cytometric analysis of CD69 (n = 5 samples) and NGK2A (n = 4) 
in isolated primary NK cells, stimulated overnight with IFN-α or IFN-λ1. (B) The cytolytic capacity of IFN 
stimulated NK cells was assessed by flow cytometry analysis of degranulation marker CD107a after 5 
hours of coculture with target cell line K562 (n = 4). (C) mRNA expression of protease granzyme B (GZMB) 
(n = 4) in NK cells, stimulated with IFN-α or IFN-λ1 in combination with IL-18, measured by qPCR. Expres-
sion is shown as the ΔΔCT relative to housekeeping gene GAPDH. (D) Intracellular flow cytometry analysis 
of IFN-γ (n = 4) in isolated primary NK cells, stimulated overnight with IFN-α or IFN-λ1 in combination with 
Il-18. data are shown as mean ± seM and are representative of 2 independent experiments. *P < 0.05. 
**P < 0.01; Mann-Whitney U test.
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whereas IFN-λ1 again remained ineffective (figure 2C). lastly, isolated primary 
NK cells were incubated with either IFN-α or IFN-λ1, in addition to IL-18, overnight 
and analyzed by intracellular flow cytometry for production of IFN-γ (figure 2d) 
and TNF (data not shown). In contrast to IFN-α, IFN-λ1 was unable to directly 
increase the frequency of primary NK cells producing IFN-γ, but not TNF, upon 
IL-18 stimulation. This highlights a direct action of IFN-α on NK cells, resulting 
in activation, cytotoxicity, and cytokine production, that does not exist for IFN-λs, 
most likely due to the absence of IFN-λ receptor expression.
TLR-mediated IL-12 family expression is differentially modulated by IFN-λ1 
and IFN-α in macrophages
the interactions between nK cells and other innate immune cells have been 
well-documented in various diseases, with implications for anti-tumor and anti-
inflammatory responses[5–8]. Although we determined that IFN-λ1 is unable to 
directly affect NK cells, an indirect effect was still feasible, exerted through 
cross-talk between macrophages and nK cells in a cytokine-dependent manner. 
First, monocyte derived-macrophages, primed with IFN-α or IFN-λ1, were further 
challenged with tlr4 agonist lPs for an additional 4 hours for gene expression 
analysis or 24 hours for immunoassay analysis of proinflammatory cytokines. To 
determine to what extent IFN-λ1 stimulation regulates macrophage IL-12 related 
cytokine production, qPCR for various subunits of the IL-12 family were performed. 
as shown in figure 3a, increased expression of Il12B (encoding Il-12p40), Il23a 
(IL-23p19), and EBI3 were observed in IFN-λ1/LPS-stimulated macrophages com-
pared to the IFN-α/LPS conditions. IL27A (IL-27p28) mRNA was upregulated by 
incubation of both IFN-α/LPS and IFN-λ1/LPS, whereas IL12A (IL-12p35) mRNA 
expression was undetectable in all conditions (data not shown).
to determine if the mrna levels measured correlated with protein produc-
tion, cytokine levels of Il-12 family members were measured by elIsa in the 
supernatants of stimulated macrophages. Increased levels of Il-12p40 and Il-23 
were detected in the supernatants of IFN-λ1/LPS-stimulated cells, in contrast to 
IFN-α/LPS stimulation (figure 3B and C). Il-12p70 and Il-27 were not detected 
in any condition. these undetectable levels of Il-12p70 can be explained by the 
lack IL-12p35 mRNA expression previously seen by qPCR. Bioactive IL-12 was 
produced by supplementation of IFN-γ to the TLR challenge of macrophages 
after the initial priming with IFN-λ1, but not after IFN-α pretreatment (figure 3d). 
Inter-culture variability was observed in levels of macrophage Il-12p40 produc-
tion, but the trend of increased production after IFN-λ1 preincubation was seen in 
all cultures, while IFN-α response was more heterogeneous (figure 3C).
further multiplex analysis of macrophage-associated cytokines and chemo-
kines showed significantly elevated levels of TNF, GM-CSF, and IP-10 in the 
supernatants of macrophages stimulated with IFN-λ1 compared to control and 
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IFN-α conditions (Supporting Information figure 1). Overall, differences can be 
observed between IFN-α and IFN-λ1 in their modulation of TLR-induced cytokine 
production by macrophages, with a specific emphasis on multiple members of 
the Il-12 family.
IFN-λ1-mediated IL-12 production by macrophages induces IFN-γ 
production by NK and NK92 cells
To test the effects of IFN-λ on cross-talk between macrophages and NK/NK92 
cells, supernatants from macrophages incubated with IFN-α or IFN-λ1 in com-
bination with LPS and IFN-γ were used to stimulate primary NK cells and NK92 





























































































































































IL12B IL23A IL27A EBI3A.
figure 3. TLR-mediated IL-12 family cytokine expression is differentially modulated by 
IFN-λ1 and IFN-α in macrophages
(a) levels of gene expression (n = 3 samples) and (B) protein (n = 13) of the Il-12 family members (Il-
12p40, IL-12p70, IL-23, and IL-27) in macrophages stimulated with IFN-α or IFN-λ1 for 5 hours and then 
further challenged with LPS. mRNA expression levels were measured by qPCR after an additional 4 hours 
of tlr challenge, and protein levels by elIsa after an additional 24 hours. all gene expression is shown as 
the ΔΔCT relative to housekeeping gene GAPDH. (C) Individual results for IL-12p40 of IFN/LPS-stimulated 
macrophages (n = 13). (d) Bioactive Il-12p70 levels were measured by elIsa in the supernatants of mac-
rophages preincubated of IFN-α or IFN-λ1 for 5 hours, followed by an additional 24 hours of stimulation 
with LPS and IFN-γ (n = 8). (A, B, and D) Data are shown as mean + SEM and (A-D) are representative of 
3 independent experiments, and *P < 0.05. **P < 0.01; Mann-Whitney U test.
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then determined by intracellular FACS analysis of IFN-γ and TNF production 
in the respective conditions. Supernatants from IFN-λ1/LPS-stimulated macro-
phages were able to increase the percentage of IFN-γ-producing cells, but not 
tnf-producing cells (data not shown) when compared with 3 nK cell donors 
treated with supernatants from medium/lPs- stimulated macrophages (figure 4a 
and B). the same was true for nK92 cell cultures, where a 2.5-fold increase in 
IFN-γ positive cells was observed compared to NK92 cell cultures treated with 
supernatants from both medium/LPS and IFN-α/LPS stimulated macrophages 








































































figure 4. IFN-λ1 mediated IL-12 production of macrophages is able to induce eff ector func-
tion in nK and nK92 cells
Supernatant from macrophages treated with IFN-α or IFN-λ1 in combination with LPS and IFN-γ were 
used for overnight stimulation of (a and B) isolated primary nK cells from three healthy donors and (C and 
d) nK92 cells. all supernatants were supplemented with Il-18 during overnight stimulation. (a) Intracel-
lular IFN-γ levels were measured using fl ow cytometry. Plots are representative of 5 and 8 independent 
experiments respectively. (B and C) data are shown as mean ± seM ((B) n = 5 or (C) n = 8 samples) and 
arerepresentative of 2 independent experiments. (d) Individual results for supernatants of multiple donors 
for macrophage-mediated IFN-γ production in NK92 cells. Data shown are representative of 2 independent 
experiments. *P < 0.05. **P < 0.01; Mann-Whitney U test.
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seen with the IFN-α pretreated supernatants, but this can partially be attributed to 
the direct action of IFN-α on NK and NK92 cells.
IFN-γ production in NK92 cells is IL-12 dependent in IFN-λ1/LPs-stimulated 
macrophages
To determine the mechanism of action for induction of NK92 effector function by 
Ifn-stimulated macrophages, various blocking and neutralization assays were 
performed. Neutralization of IL-12p40 in IFN-λ1/LPS-stimulated macrophages 
abrogated IL-12-mediated IFN-γ production in NK92 cells while neutralization of 
IL-12p40 in IFN-α/LPS-stimulated macrophages partially abrogated IL-12-medi-










































































figure 5. Macrophage-mediated IFN-γ production in NK92 cells is IL-12-dependent in IFN-λ1/
LPS but not in IFN-α/LPS-stimulated macrophages
nK92 cells were cultured with the supernatants of Ifn and lPs-stimulated macrophages in the pres-
ence of neutralizing/blocking antibodies for IL-12p40 and IFN-αR1/2 (n = 8 samples). All supernatants were 
supplemented with IL-18 during overnight stimulation. (A) Intracellular IFN-γ and TNF was measured us-
ing flow cytometry. Plots are representative of 2 independent experiments. (B) The percentage of IFN-y+ 
cells in NK92 cells was measured by flow cytometry. Data are shown as mean ± SEM (n = 8 samples) 
and are representative of 2 independent experiments. (C) Individual results for Il-12p40 neutralization in 
supernatants from all 8 samples for macrophage-mediated IFN-γ production in NK92 cells. Data shown are 
representative of 2 independent experiments. *P < 0.05. **P < 0.01; Mann-Whitney U test.
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IFN-α receptor in macrophages stimulated with IFN-α/LPS showed a strong, but 
not significant, trend in reduction in IFN-γ production in NK92 cells, however no 
effect was observed after stimulation with IFN-λ1/LPS. Due to the heterodimeric 
nature of the IL-12 family, we were unable to exclude an effect of IL-23 on IFN-γ 
production of nK cells, and therefore performed identical assays using Il-23p19 
neutralizing antibodies. again Il-12p40 neutralization resulted in an almost com-
plete diminishment of IFN-γ producing NK92 cells, while IL-23p19 neutralization 
had no effect (Supporting Information figure 2). These results confirm the direct 
action of IFN-α on NK cell effector function, and demonstrate that IFN-λ1 acts 
indirectly on nK cells through macrophage-derived Il-12p40 production.
disCUssion
The focus of this study was to investigate the ability of IFN-λ1 to modulate the 
activity of nK cells in both a direct and an indirect capacity. We demonstrate that 
unlike IFN-α, IFN-λ1 is unable to directly activate and promote effector function in 
nK cells, presumably due to the lack of cellular expression of the complete type 
III IFN receptor complex. However, IFN-λ1 priming, in combination with TLR4 
activation, is able to induce select members of the Il-12 family of cytokines in 
monocyte-derived macrophages. We further show that IFN-λ1, in combination 
with IFN-γ, is able to indirectly affect NK cells through macrophage-mediated 
IL-12 production, ultimately inducing IFN-γ production.
As a first step, we demonstrate that NK cells do not express the IFN-λR1 chain, 
and that consequently IFN-λ1 is unable to directly act on this cell population. This 
is in contrast to previous reports suggesting that type III Ifns have an inhibitory 
effect on IFN-γ production upon IL-12/IL-15 stimulation[27, 28]. Our study not 
only investigated the effects of type I and III IFNs on cytokine production, but also 
on NK cell activation and cytotoxicity. We showed that IFN-α is able to activate 
as well as promote cytolytic action and IFN-γ production by NK cells, whereas 
IFN-λ1 was unable to alter any of these parameters. These findings are cor-
roborated in a response to Dring et al. that questioned their original findings, also 
reporting the absence of IFN-λR1 receptor expression in primary NK cells and the 
inability of IFN-λ to induce IFN-γ production or degranulation in any capacity[29, 
30]. Combined, these results convincingly show that IFN-λ lacks the ability to 
directly activate and affect multiple facets of NK cell effector function.
We do, however, propose for the first time an indirect link between IFN-λ1 and 
nK cells, mediated through the stimulation of macrophages. this interaction was 
unique to IFN-λ1, due to differences in immunomodulatory properties between 
IFN-α and IFN-λ1, specifically in their regulation of various subunits of the IL-
12 family of cytokines (Il12B, Il23a, and eBI3) in macrophages. In contrast to 
IFN-λ1, which promoted the production of specific IL-12-related cytokines (IL-12 
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and IL-23), IFN-α actually reduced macrophage-facilitated IL-12 production. 
Through the blocking of IFN-αR1/2 on NK cells and neutralizing IL-12 in super-
natants from Ifn-primed macrophages, we were able to show that enhancement 
of NK-cell derived IFN-γ production by IFN-α was mainly mediated by a direct 
interaction with NK cells, and partially affected by IL-12 neutralization. IFN-λ1, on 
the other hand, was dependent on Il-12, with almost complete abrogation of Ifn-
γ-producing NK cells after IL-12 neutralization. Despite having different modes 
of action, both the direct effects of IFN-α and indirect effects of IFN-λ1 were 
found to be independent of cell-to-cell contact since soluble factors in Ifn/tlr-
challenged macrophage supernatants, supplemented with IL-18, were sufficient 
to induce IFN-γ production in NK cells. It is of note, that IFN-γ stimulation of mac-
rophages was needed for the production of bioactive Il-12, potentially leading to 
a positive feedback loop between NK cells and macrophages of IFN-γ and IL-12 
production. Previous publications have also described a role for Il-12-related 
cytokines in macrophage-NK cell interactions. Specifically, macrophage-derived 
expression of IL-23 and IL-27 induced the production of IFN-γ and GM-CSF in NK 
cells[31–33]. Although the production of IL-27 was monitored in IFN-λ-stimulated 
macrophages, the effects on NK cell function was not explored in this study.
In contrast to the ubiquitous expression of the IFN-αR1/2 subunits across vari-
ous cell populations, resting monocytes do not express IFN-λR1 until after the 
initiation of macrophage differentiation via culture with GM-CSF, resulting in an 
induction and constant upregulation of receptor expression. the expression of 
the IFN-α receptor on NK cells and the ability of IFN-α to directly activate these 
cells, promoting degranulation, cytotoxicity, and IFN-γ production, are distinct 
from the effects of IFN-λ. These features of IFN-α activation make it an important 
mediator in the induction of an immediate immune response upon challenge in 
the peripheral as well as the tissue compartments. In contrast, the restricted 
expression of IFN-λR1 prevented a direct action of IFN-λ on both NK cells and 
monocytes, with only responses observed on differentiated macrophages. This 
suggests that IFN-λ might play a more prominent role in tissue-specific responses 
as compared to the periphery, in line with other studies describing that IFN-λ1 has 
a more delayed and prolonged effect through activation of specific tissue-resident 
cells, specifically epithelial cells and hepatocytes[25, 26]. TLR-dependent cross-
talk between nK cells and macrophages has already been described in tissue-
specific interactions in the liver. TLR-activated liver-resident macrophages have 
been shown to exert effector function in NK cells, specifically by inducing their ac-
tivation and IFN-γ production[34]. The ability of IFN-λ1 to modulate TLR-induced 
cross-talk between macrophages and nK cells could have implications in the 
enhancement of IFN-γ production by liver NK cells, a critical factor in the inhibi-
tion of HCV replication and in the response to HBV infection[35–37]. The delayed 
activation of NK cells by IFN-λ, mediated through macrophage IL-12 production, 
could explain the observed differences in biological functions between the type I 
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and type III IFNs in inflammatory responses, but also by differences in kinetics or 
sustainability of the response. It should be noted that a similar kinetic on innate 
immune response activation by type III Ifns has been previously described for 
DCs and hepatocytes[26, 30, 38].
Collectively, this study provides the first example of an indirect regulatory effect 
unique to IFN-λ1, mediated through macrophage cytokine production and inde-
pendent of cell-to-cell contact. This is distinct from IFN-α, which directly activates 
nK cells, and can inhibit macrophage Il-12 production. further studies of both 
the antiviral and immunoregulatory effects of IFN-λ1 are warranted to understand 
the basic biology of type III Ifns and their activities as therapeutic agents.
materials and methods
Cell culture and isolation
Human peripheral blood mononuclear cells (PBMCs) were isolated from buffy 
coats (Sanquin Blood Supply) using density gradient centrifugation (Ficoll-
Paque, GE Healthcare). Monocytes and NK cells were then purified from the 
PBMC fraction using magnetic labeled Cd14 micro-beads (Miltenyi Biotec) and 
human nK Cell Isolation Kit (Miltenyi Biotec) according to the protocol provided 
by the manufacturer. the purity of monocytes and nK cells isolated and used in 
this study always exceeded 95 %.
Macrophages were generated from the aforementioned purified monocytes 
by culturing with 20 ng/ml GM-CSF (Leukine® (sargramostim)) in 6-well plates 
(Costar) at a density of 0.75 x 106 cells/ml in rPMI1640 medium (lonza) 
supplemented with 10 % fetal calf serum (Sigma), penicillin/streptomycin (Gibco), 
l-glutamine (lonza), and HePes (lonza). the medium was partially refreshed 
at days 2 and 5, and the monocyte-derived macrophages were harvested at day 
6 for use in various assays.
HEK293 cells that were stably transfected to express the IFN-λ receptor 
(HEK293 R19) were cultured using RPMI1640 medium supplemented with 10 % 
fetal calf serum. tHP-1, nK92, and K562 cell lines were cultured using the rec-
ommended conditions by the atCC.
stimulation of monocyte-derived macrophages
Monocyte-derived macrophages were cultured in X-Vivo medium (lonza) with 
10 ng/ml IFN-α-2b (Intron A, Merck) or 100 ng/ml IFN-λ1 (Bristol-Myers Squibb) 
for 5 hours and then further challenged with the tlr4 agonist lipopolysaccharide 
(100 ng/ml; lPs-sM Ultrapure, InvivoGen) for an additional 6 or 24 hours at 
a cell density of 1 x 106 cells/ml. Cells were harvested at 4 hours for mrna 
analysis, and supernatants were harvested at 24 hours for immunosorbent and 
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further assays. In a fraction of the assays, 10 ng/ml IFN-γ (Miltenyi Biotec) was 
supplemented along with the lPs addition for the production of bioactive Il-12 
for later stimulation of nK cells.
stimulation and intracellular cytokine analysis of NK/NK92 cells
Isolated primary nK cells and nK92 cells were stimulated with 10 ng/ml Ifn-
α-2b (Intron A, Merck) or 100 ng/ml IFN-λ1 (Bristol-Myers Squibb) alone or in 
combination with 100 ng/ml IL-18 (R&D Systems) for 5 hours for quantitative PCR 
or overnight for surface marker expression and intracellular cytokine production. 
Cellular activation and surface marker expression was measured using flowcyto-
metric analysis with anti-CD69-Pacific Blue (FN50, Biolegend), anti-NKG2A-PE 
(Z119, Beckman Coulter), and anti-NKG2D-PerCP (ID11, BD Pharmingen).
the aforementioned supernatants of monocyte-derived macrophages were 
diluted in a 1:1 ratio with RPMI1640 containing 10 % FCS and used to stimulate 
primary nK cells and nK92 cells for 24 hours with the supplementation of Il-18 
(100 ng/ml). Antibodies against IFN-αR1/2 (MRHAR-2, Millipore), IL-12p40 (C8.6, 
eBioscience) and Il-23p19 (HnU2319, eBioscience) were added for blocking 
and neutralizing purposes, respectively.
For analysis of cytokine production in NK cells, 10 μg/ml brefeldin A (Sigma) 
was added after 18 hours and cells were incubated for an additional 3 hours. 
Samples were then fixed with 2 % formaldehyde, and permeabilized for intra-
cellular staining with anti-IFN-γ-PE-Cy7 (eBioscience) and anti-TNF-PE (BD 
Pharmingen). Cytokine-producing cells were detected by flow cytometry (FACS 
Canto II, Bd) and analyzed using flowJo (tree star Incorporated).
NK cell cd107a degranulation
Isolated NK cells (0.1 x 106 cells/200 μl) were seeded with K562 cells in a 96 
well plate in a 1:1 effector to target ratio. IFN-α-2b (10 ng/ml; Intron A, Merck) or 
recombinant IFN-λ1 (100 ng/ml; Bristol-Myers Squibb) as well as anti-CD107a-
Pe (H4a3, Bd Pharmingen) were added to the culture and after 90 minutes, 
Golgistop (Bd) was added, followed by incubation for an additional 3.5 hours. 
Degranulated cells were detected by flow cytometry (FACS Canto II, BD) and 
analyzed using flowJo (tree star Incorporated).
Immunoassay for detection of cytokines in supernatants
the concentrations of various cytokines were measured in the supernatants of 
stimulated macrophages by the use of sandwich ELISAs specific for IL-12p40 
(clones C8.6 and C8.3, Biolegend), Il-12p70, Il-23, Il-27, and tnf (ready-set-
Go Kits, eBioscience) with a sensitivity of 30 pg/ml, 4 pg/ml, 15 pg/ml, 64 pg/
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ml, and 4 pg/ml, respectively. Simplex bead sets for IL-1α, IL-1β, IL-1RA, IL-6, 
IL-12p40, IL-18, IFN-β, GM-CSF, TNF, and IP-10 (eBioscience) were used to 
measure the concentrations of cytokines and chemokines in supernatants with 
sensitivity ranges of 1–630 pg/ml, 3–3 000 pg/ml, 38–150000 pg/ml, 10–5000 pg/
ml, 5–1350 pg/ml, 11–12700 pg/ml, 11–2500 pg/ml, 14–3 600 pg/ml, 4–3000 pg/
ml, and 3–650 pg/ml respectively.
Gene expression quantification of IFN-αR1/2, IFN-λR1, GZMB, and IL-12 
family subunits
total rna was isolated from HeK293 r19, tHP-1, and nK92 cell lines as well as 
from primary human hepatocytes (isolated from healthy donors livers), primary 
nK cells, monocytes, and monocyte-derived macrophages using the rneasy 
kit (Qiagen) and cdna was prepared using the Primescript cdna synthesis kit 
(takara) from 500 ng rna. all real-time PCr reactions were performed using a 
MyIQ5 detection system (Bio-rad) and relative mrna expression levels were 
calculated using the housekeeping gene GaPdH. the following primer/probe 
sets (Applied Biosystems) or forward/reverse SYBR Green primer sequences 
were used for the genes of interest:
GAPDH (Hs00266705_g1), IFN-αR1 (Hs01066115_m1),  
IFN-αR2 (Hs01022060_m1), IFN-λR1 (Hs00417120_m1),  
GZMB (Hs01554355_m1)
Il-12p35: fw: 5’-CCaCtCCaGaCCCaGGaatG-3’,  
 rv: 5’-GaCGGCCCtCaGCaGGt-3’
Il-12p40: fw: 5’-aCGGaCaaGaCCtCaGCCaC-3’,  
 rv: 5’-GGGCCCGCaCGCtaa-3’
Il-23p19: fw: 5’-GaGCCttCtCtGCtCCCtGat-3’,  
 rv: 5’-aGttGGCtGaGGCCCaGtaG-3’
Il-27p28: fw: 5’-GCGGaatCtCaCCtGCCa-3’,  
 rv: 5’-GGaaaCatCaGGGaGCtGCtC-3’
eBI-3: fw: 5’-CCGaGCCaGGtCCtaCGtCC-3’,  
 rv: 5’-CCaGtCaCtCaGttCCCCGt-3’
statistiCal analysis
data is expressed as the mean value ± standard error of the mean (seM) unless 
indicated otherwise. data was analyzed with Prism 5.0 software (GraphPad) us-
ing the Mann-Whitney U test to compare variables between independent groups 
and the Spearman rank correlation coefficient test for nonparametric correlations. 
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In all analyses, a 2-tailed P value of less than 0.05 (confidence interval of 95 %) 
was considered statistically significant.
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Supplementary Figure 1.





















































































































Multiplex cytokine analysis of macrophage-associated cytokines and chemokines in IFN/TLR-stimulated macrophages
Multiplex analysis was performed on the supernatants of macrophages pre-incubated with IFNα or IFNλ1 for 5 hours and then
further challenged using LPS, with (n=8) or without (n=13) IFNγ, for an additional 24 hours. Specific macrophage-associated
cytokines and chemokines IFNβ, IL-1α, IL-1β, IL-1RA, IL-6, IL-18, GM-CSF, TNF, and IP-10 were selected as targets for analysis.
supplementary figure 1. Multiplex cytokine analysis of macrophage-associated cytokines 
and chemokines in Ifn/tlr-stimulated macrophages
Multiplex analysis was performed on the supernatants of macrophages pre-incubated with IFNα or IFNλ1 
for 5 hours and then further challenged using LPS, with (n = 8) or without (n = 13) IFNγ, for an additional 24 
hours. Specifi c macrophage-associated cytokines and chemokines IFNβ, IL-1α, IL-1β, IL-1RA, IL-6, IL-18, 























Supplementary Figure 2. IFNγ production by NK92 triggered by supernatant from IFNλ1/LPS-stimulated macrophages is
IL-23 independent
NK92 cells were cultured with the supernatants of IFN and LPS stimulated macrophages in the presence of neutralizing antibodies
against IL-12p40 and IL-23p19 (n=3). All supernatants were supplemented with IL-18 during overnight stimulation, and
intracellular IFNγ was measured using flow cytometry. (A) Representative histogram of macrophage-mediated IFNγ production by
NK92 cells, cultured with supernatants of IFNλ1/LPS-stimulated macrophage (solid black line), in addition to IL-12p40
neutralization (filled light-grey line) or IL-23p19 neutralization (dashed black line). B) Collective results obtained from 3
independent donors.
supplementary figure 2. IFNγ production by NK92 triggered by supernatant from IFNλ1/
lPs-stimulated macrophages is Il- 3 independ nt
nK92 cells were cultured with the supernata ts of I n and lPs sti ulated macrophages in he presence 
of neutralizing antibodies agai st Il-12p40 and Il-23p19 (n = 3). all supernatants were supplemented with 
IL-18 during overnight stimulation, and intracellular IFNγ was measured using fl ow cytometry. (A) Repre-
sentative histogram of macrophage-mediated IFNγ production by NK92 cells, cultured with supernatants 
of IFNλ1/LPS-stimulated macrophage (solid black line), in addition to IL-12p40 neutralization (fi lled light-
grey line) or Il-23p19 neutralization (dashed black line). B) Collective results obtained from 3 independent 
donors.
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FACS gating strategy for CD69 and NKG2A expression on isolated human NK cells
.supplementary figure 3. faCs gating strategy for Cd69 and nKG2a expression on iso-
lated human nK cells
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abstraCt
Unraveling the mechanisms underlying the inflammatory response in rheumatoid 
arthritis is crucial in order to better understand the disease and to develop novel 
therapeutic approaches. Although the effect of type I IFNs on fibroblasts and 
in the context of rheumatoid arthritis has been described for some time, little is 
known on the effects of the type III interferons, also known as IFN-lambda. In 
this issue, Xu and collegues demonstrate that one of the members of the Ifn-
lambda family, IFNλ1 enhances TLR expression and consequently promotes the 
production of pro-inflammatory cytokines known to be involved in initiating and 
maintaining the inflammatory responses in rheumatoid arthritis.
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Interferons (Ifns), known for their anti-viral, anti-proliferative, and immunomodu-
latory effects, are one of the immune system’s first lines of defense against bacte-
rial and viral infections. three classes of Ifns have been described, designated 
type I, II, and III and are distinguished by their unique complimentary receptor 
complexes through which they signal (figure 1). type I Ifns, which are com-
prised of 13 IFNα subtypes as well as IFNβ, IFNω, and various others, engage 
through the IFNα receptor complex, composed of IFNαR1 and IFNαR2 chains. 
type I Ifns have been well described and are used as a therapeutic for a myriad 
of diseases, including viral infections, auto-immune diseases, and even various 
forms of cancer. More recently, type III IFNs, also known as the IFNλs, have 
become of particular interest in the immunological field, with recent publications 
focusing on rheumatoid arthritis (RA) [1, 2]. IFNλ, comprised of IFNλ1, IFNλ2, 
IFNλ3, and IFNλ4, engage through the IFNλR1 and IL-10R2 complex. Despite 
triggering distinct receptor complexes, the downstream signaling of both type I 
and type III Ifns is regulated through JaK/stat signal transduction, ultimately 
resulting in the induction of Ifn-stimulated response elements (Isre) and initia-





figure 1: IFNα, and other type 1 IFNs, engage through the IFNα receptor complex, com-
posed of IFNαR1 and IFNαR2, while the IFNλs signal through the IFNλR1 and IL-10R2 com-
plex. Despite triggering distinct receptor complexes, the downstream signaling of both IFNα 
and IFNλ is regulated through JAK/ STAT signal transduction, ultimately resulting in the induc-
tion of Ifn-stimulated response elements (Isre) and initiation of gene transcription. opposed 
to the ubiquitously expressed IFNα receptor, the IFNλ receptor appears to be more limited in 
its expression.
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expressed, the IFNλ receptor is more limitedly expressed potentially making it a 
more specific activator of immune responses.
When first described, it was suggested that IFNλ primarily acts on cells of 
epithelial origin [3], making it an activator of the innate immune response. He-
patocytes, also shown to be responsive to IFNλ stimulation [4], only became of 
particular interest after the discovery of single nucleotide polymorphisms (snPs) 
located near the gene encoding for IFNλ3 that were associated with spontane-
ous as well as therapy-induced clearance of the hepatitis C virus [5], but also 
demonstrating that IFNλ’s activity was not restricted to epithelial cells. The article 
by Xu et al. in this issue of Arthritis Research & Therapy describes the effects of 
IFNλ on fibroblasts and its context in RA [1]. Previously, the same research group 
demonstrated that IFNλ1 was expressed at higher levels in peripheral blood 
mononuclear cells (PBMC), serum, synovial fluid, and synovium in RA patients 
as compared to healthy individuals [2]. They now continue by showing that IFNλ1 
is able to enhance TLR expression and consequently TLR-induced IL-6 and IL-8 
production in the RA synovial fibroblasts (RA-FLS), contributing to RA synovial 
inflammation. Importantly, these effects are not only described in cell fibroblast 
cell lines, but also in primary fibroblasts (see supplementary figures). IFNλ and 
its modulation of tlr activation has also been described in monocyte-derived 
macrophages, where IFNλ incubation resulted in enhanced IL-12p40 and TNF 
production [6]. Outside of macrophages, B cells [7], and plasmacytoid dendritic 
cells [8] limited literature has described IFNλ and its effects on immune cells. 
Monocytes and natural kills cells, first reported to be IFNλ-responsive cellular 
subsets, have since been described as unresponsive [6, 9]. Due to an initial 
focus on anti-viral activity, IFNλ’s immunological role and activity on immune cell 
populations still remains incomplete. However, increasing evidence suggests 
IFNλ also plays a larger role in immunoregulation.
Xu et al. convincingly show that IFNλ may have a detrimental effect for RA 
patients by enhancing to fibroblast-mediated pro-inflammatory cytokines, which 
may ultimately contribute to synovial inflammation. Similar effects have been 
described for IFNα in RA-FLS [10], and a large portion of literature has focused 
on the similarities between type I and III Ifns. the distinctions between these 2 
classes of cytokines however remain almost completely undefined. Thus far, only 
differences between type I and III IFN have been reported in the regulation of 
pro-inflammatory cytokine production by macrophages [6], making it imperative 
to further investigate the unique qualities of IFNλ. The introduction of fibroblasts 
as an IFNλ-responsive population is an important finding, and may stimulate re-
search on the underlying causes of inflammation in RA. Synovial-macrophages, 
another central population in ra research, have yet to be investigated for their 
response to IFNλ. This, in combination with the data presented by Xu et al. on 
ra-fls, could give a more complete understanding of the immunological role of 
IFNλ in RA.
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abstraCt:
Background: Chronic HBV infection can be divided into 4 distinct clinical phases: 
immune tolerant, immune active, inactive carrier, and HBeag-negative hepatitis. 
Using a systems biology approach, we recently identified innate immune re-
sponse components, specifically NK cells as a distinctive factor of specific HBV 
clinical phases. to expand on this study and identify the underlying immunologi-
cal mechanisms, we performed a comprehensive profiling of NK cells in chronic 
HBV infection.
methods: Peripheral blood from untreated chronic HBV patients was used to 
analyze phenotypic markers, as well as cytokine production and cytoxicity of nK 
cells.
results: the overall composition, phenotype, and cytolytic activity of the nK cells 
remained constant across all clinical phases, with the exception of a few specific 
markers (KIrs, nKp46). Cd56bright NK cells of chronic HBV patients differed in 
their ability to produce IFN-γ between the clinical phases pre- and post-HBeAg 
seroconversion.
Conclusion: this depicts a shift in nK cell characteristics between the immune 
active, under heavy viral or immune pressure, and inactive carrier phases, that 
coincides with HBeag seroconversion. although these changes in nK cells do not 
appear to be completely responsible for differences in liver damage characteristic 
of specific clinical phases, they could provide a step toward understanding im-
mune dysregulation in chronic HBV infection.
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Infection with the hepatitis B virus (HBV) leads to non-cytopathic infections of 
the hosts’ hepatocytes. Control of viral replication and subsequent liver injury 
are believed to be the consequence of the activity of the host immune response 
to infection. Contrary to infections with the hepatitis C virus (HCV), chronic HBV 
infections are characterized by episodes with differentiating serum levels of HBV 
dna, alanine transferase (alt), a marker of liver damage, and HBV envelope 
antigen (HBeAg). Using these parameters, different clinical phases have been 
discerned to describe the dynamics of the natural history of chronic HBV infection 
over a period of many years, and determine the indication for antiviral treatment 
on the basis of rate of viral replication and alt elevation. Chronic HBV patients 
have been categorized into 4 clinical phases: the HBeag-positive immune toler-
ant (It) and immune active (Ia) phases, as well as the HBeag-negative inactive 
carrier (IC) and hepatitis (eneG) phases (european association for the study 
of the, 2012). the nomenclature to describe the natural course of HBV infection 
has led to confusion on the underlying mechanisms, as the It phase accurately 
describes the situation where high levels of HBV dna are observed without el-
evated alt levels in serum, but erroneously suggests that the immune response 
is more tolerant to the presence of virus than in other phases. this, however, is 
not the case, since normal HBV-specific T cell responses are observed and no 
distinctive HBV-specific or global T cell activity could be identified in any of the 
clinical phases (Bertoletti and Hong, 2014; Park et al., 2016).
over the last decade the importance of natural killer (nK) cells has been ex-
tensively described in chronic viral hepatitis (rehermann, 2013). Various studies, 
including our own, have shown that chronic HBV patients and healthy individuals 
have similar total numbers of Cd56+Cd3- nK cells in peripheral blood (tjwa et al., 
2011; tjwa et al., 2014), whereas the ability of nK cells from patients to produce 
interferon (IFN)-γ is impaired (Boni et al., 2015; Lunemann et al., 2014; Oliviero 
et al., 2009; Peppa et al., 2010; tjwa et al., 2011). However, a myriad of studies 
have reported conflicting results, observing no difference or even higher levels 
of IFN-γ production by NK cells in HBV patients compared to healthy individuals 
(Conroy et al., 2015; Li et al., 2014; Sun et al., 2012; Zhang et al., 2011). Part of 
the variation in outcome of these studies may be attributed to the large variety 
in stimuli (e.g. interleukin (IL)-2, IL-12, IL-15, IL-18, IFNα, PMA, and ionomycin) 
used alone or in combination to trigger IFN-γ production by NK cells. Also, the 
clinical and virological characteristics of the chronic HBV patients examined 
are likely to influence the features of the NK cell compartment, as many of the 
patient cohorts in these studies are an unsegregated mixture of all clinical phases 
(lunemann et al., 2014; oliviero et al., 2009; Peppa et al., 2010; tjwa et al., 
2011), whereas others examined either HBeag-positive or HBeag-negative 
patient groups (Boni et al., 2015; Conroy et al., 2015). this may be of particular 
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relevance, as in vitro studies have demonstrated that exposure of nK cells to 
HBeAg affected IL-18 receptor signaling, and consequently reduced the capacity 
to produce IFN-γ (Jegaskanda et al., 2014). In addition, HBV infection may alter 
the activation potential of nK cells by modulating the balance of activating and 
inhibitory receptors on the cell surface. during viral challenge the balance shifts 
from inhibition to activation after a critical threshold of activation signals exceeds 
those of inhibition (lanier, 2005; Vivier et al., 2011). We previously showed that 
chronic HBV patients express elevated levels of the inhibitory receptor nKG2a 
and downregulated expression of activating receptors Cd16 and nKp30 (tjwa et 
al., 2011), although in general reports of the phenotype of NK cells differ between 
studies with vast degree of conflicting results (Mondelli et al., 2010).
We recently performed a systems biology study of peripheral blood transcrip-
tomes in chronic HBV infection to better identify the mechanisms that govern 
the distinct clinical phases. Besides enhanced activity of Ifn-stimulated genes 
(IsG) in the It phase and B cell-function related genes in the Ia phase, we also 
observed that upregulation of cytotoxicity/nK cell activity-related genes clustered 
in the Ia and eneG phase, i.e. the clinical phases with elevated alt levels (Van-
wolleghem et al., 2015). In the current study, we hypothesized that differential 
nK cell functionalities contribute to the distinct features observed during the HBV 
clinical phases, including the fluctuations in liver damage markers and HBV rep-
lication. numerical, phenotypical, and functional analysis of immune parameters, 
of nK cells obtained from the 4 clinical phases was conducted to obtain an in 
depth profiling of NK cells throughout the course of natural history of chronic HBV 
infection.
materials and methods
patient selection and characteristics
Prospectively collected peripheral blood mononuclear cell (PBMC) samples from 
40 31 untreated chronic HBV patients attending the outpatient hepatology clinic 
of the erasmus MC (rotterdam, the netherlands) were selected, if there were 
no concomitant HIV, HCV, or HdV infections or oncological/rheumatological 
diseases. In addition, patients were excluded if they were pregnant, had signifi-
cant steatosis on liver ultrasound, other liver pathology on liver biopsy, or had 
received antiviral treatment within the previous year. Liver fibrosis, as determined 
by histology or transient elastometry, was restricted to a maximum f2 Metavir 
score or maximum elasticity of 7.0 kPa. Based on serum HBV dna, alt levels, 
and HBeag presence at the time of sampling, patients were categorized into 
4 clinical HBV phases according to international guidelines (european associa-
tion for the study of the, 2012). Immune tolerant (It) patients had detectable 
serum HBeag and repetitive normal alt values (< 40 U/l) for at least 1 year. 
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the HBeag-positive immune active (Ia) and HBeag-negative (eneG) patients 
had repetitive or intermittent abnormal serum alt (> 40 U/l) values, and HBV 
dna levels > 2,000 IU/ml. Inactive carrier (IC) patients were HBeag-negative 
and had both repetitive normal alt values (< 40 IU/l) and HBV dna levels below 
20,000 IU/ ml for at least 1 year. serum alt was measured on an automated 
analyzer, qualitative serum HBsAg and HBeAg levels were measured on an 
architect abbott analyzer, and serum HBV-dna levels were measured using the 
COBAS AmpliPrep-COBAS Taq-Man HBVv2test (CAP-CTM; Roche Molecular 
systems) (Chen et al., 2012; feld et al., 2007; Papatheodoridis et al., 2012). 
Patient characteristics are presented in table 1. PBMC were isolated from ve-
nous blood by ficoll separation (Ficoll-PaquetM plus, amersham), and stored at 
-150°C until used for the various assays. Written informed consent was obtained 
from all participants. the study protocol was approved by the institutional ethics 
committee and conducted in accordance with the guidelines of the declaration 
of Helsinki.
Expression of cell surface and intracellular molecules by flow cytometry
To determine the frequency and phenotype of peripheral blood NK cells, multi-
color flow cytometry was performed on PBMC with anti-CD3-Alexa-Fluor700 
(oKt-3, Beckman), anti-Cd56-aPC-efluor780 (CMssB, Beckman), anti-
Cd57-aPC (HCd57, Biolegend), anti-KIr2d-Biotin (nKVfs1, Miltenyi biotech), 
anti-KIr3dl1/dl2-Biotin (5133, Miltenyi biotech), streptavidin-efluor450 (eBio-
science), anti-NKG2A-PE (Z199, Beckman), anti-NKG2C-Alexa-488 (134591, 
R&D), anti-NKG2D-PerCP-Cy5.5 (1D11; BD), anti-NKp30-PE (Z25, Beckman), 
anti-NKp44-Biotin (P44–8, Biolegend), anti-NKp46-PE-Cy5 (BAB281, Beckman), 
anti-CD69-PacificBlue (FN50; Biolegend) and Live/Dead Aqua (Life Technolo-
gies). for intracellular expression of cytotoxic markers, PBMC (0.5x106 cells/200 
μl) were fixed with 2 % formaldehyde, and permeabilized for intracellular staining 
with anti-granzyme B-Pe (GB11, eBioscience), anti-perforin-PerCP-efluor710 
(G9, eBioscience), and anti-traIl-alexa488 (75402, r&d). Cells were again 
assessed by flow cytometry (FACS Canto II, BD) and analyzed using FlowJo ver-
sion 10.1 (tree star Inc). representative faCs plots for surface and intracellular 
molecules assessed that are not shown in the primary text/figures can be found 
in supplementary figure 1.
stimulation and intracellular cytokine analysis of NK cells
PBMC were stimulated with Il-12 (0.25 ng/ml) and Il-18 (10 ng/ml) overnight 
for surface marker expression and intracellular cytokine production. after 18 
hours, brefeldin A (10 μg/ml, Sigma) was added to the cultures and the cells 
were incubated for an additional 3 hours. Cellular activation and surface markers 
table 1: HBV patient characteristics








sex (m/F) 3/4 4/2 5/3 9/1
age (years) 29.7 36.8 38.0 40.9
(24–47) (18–89) (30–08) (29–97) 
ethnicity:
asian 7 5 5 4 
african 0 0 3 3 
other 0 1 0 3 
alt 23.3 131.3 28.9 56.3
(14–49) (64–429) (8–89) (29–93) 
hbV dna (iU/ml) 5.7x108 3.8x108 1.5x103 1.3x106
(1.6x108–8.1x109) (3.4x107–7.1x109) (2.0x101–1.6x103) (9.4x101–1.3x107) 
hbsag (iU/ml) 52930 36628 6152 5439
(150–03730) (6495–52570) (1–17970) (543–33466) 
hbeag Positive Positive negative negative
hbV genotype:
a 0 1 0 3 
b/C 5 5 4 2 
d 0 0 0 2 
e 0 0 1 0 
Unknown 2 0 3 3 
ibrosis:
f0-f1 6 2 8 8 
f1-f2 1 4 0 2 
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were measured using anti-CD3-PacificBlue (OKT3, eBioscience), anti-CD56-
PE (MY31, BD), and anti-CD69-APC (L78, BD), followed by fixation with 2 % 
formaldehyde, and permeabilization for intracellular staining with anti-IFN-γ-FITC 
(25723.11, Bd). activated and cytokine-producing nK cells were assessed by 
flow cytometry (FACS Canto II, BD) and analyzed using FlowJo version 10.1 
(tree star Inc).
statistical analysis
data are expressed as the mean value ± seM, unless indicated otherwise. the 
data were analyzed with Prism, version 5.0, software (GraphPad software) using 
the Mann-Whitney U test to compare the variables between independent groups 
and the Spearman rank correlation coefficient test for nonparametric correlations. 
In all analyses, a 2-tailed P < 0.05 (95 % confidence interval) was considered 
statistically significant.
resUlts
baseline characteristics of hbV patient cohort
In order to study differential immune compartments in HBV clinical phases, we 
carefully selected a cohort of untreated chronically HBV-infected patients, without 
any other co-morbidities, attending our outpatient clinic. to rule out the impact of 
advanced liver fibrosis on any identified immune parameters, patients with more 
than an F2 fibrosis score were excluded (table 1). typical for the natural history 
of chronic HBV infections, patients in the It phase were the youngest group, 
followed chronologically by Ia, IC, and ultimately eneG patients. In addition, 
more females were represented in the asymptomatic It and Ia groups, given that 
they are more likely to be referred after routine HBsag testing during pregnancy 
(table 1). Although different ethnicities were observed in our tertiary hospital, 
most of the patients are of Asian ancestry. This is reflected by the fraction of pa-
tients infected with HBV genotypes B or C, excluding the eneG group (table 1). 
Owing to the stringent definition criteria, differences in ALT and HBV-DNA levels 
were observed between the clinical phases, and undetectable or unreactive 
HBeag were measured in all IC and eneG patients (figure 1a). furthermore, 
similar to previous reports (Jaroszewicz et al., 2010), quantitative HBsAg levels 
were lowest in IC patients and with a subtle increase seen again in patients in the 
eneG phase (figure 1B).
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The frequencies of circulating NK cells and cytolytic molecule-expressing 
NK cells do not differ between the HBV clinical phases
to understand the role nK cells play in the natural course of chronic HBV infec-
tion, we assessed the phenotype and function of NK cells in the 4 specific clinical 
phases by flow cytometry. As shown in figure 2a, we observed no significant dif-
ferences in the percentage of total Cd56+Cd3- nK cells, or the ratio of Cd56bright 
and Cd56dim subsets in the peripheral blood between any of the clinical groups.
next, we performed intracellular analysis of the cytolytic mediators perforin, 
granzyme B, and tnf-related apoptosis-inducing ligand (traIl) (figure 2B). no 
differences were observed in the expression of any of these cytotoxic markers in 
nK cells, with all expression levels remaining stable across the 4 clinical phases. 
In line with these findings, also K562-induced degranulation of NK cells did not 
differ (data not shown). Collectively, these results show no discerning factors in 
the total NK cell and NK cell subset frequencies, as well as expression of cytolytic 
mediators of NK cells in the different chronic HBV clinical phases.























B. HBeAg (log IU/ml) HBsAg (log IU/ml)
HBV DNA (log IU/ml) ALT (IU/ml)A.
figure 1. Baseline characteristics of chronic HBV patients separated into the four clinical 
phases based on HBV dna, alt, HBeag, and HBsag levels.
(a) serum samples of 31 chronic HBV patients were assessed for their HBV dna, alt, (B) HBeag, and 
HBsag levels.
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The frequencies of IFN-γ+/cd56bright expressing NK cells differ in Ic 
patients when compared to the preceding clinical phases
To explore if the functionality of NK cells is correlated to a specific HBV clinical 
phase, we investigated the activation and cytokine-producing capacity of nK 
cells upon stimulation with Il-12 and Il-18 in the aforementioned chronic HBV 
patient cohort. as shown in figure 3a and 3B, the percentages of Cd69 and 
IFN-γ expressing total NK cells after stimulation were consistent across all 4 
groups. However, when analyzing NK cell subsets a significant (1.3 fold) increase 
in the frequencies of IFN-γ-producing CD56bright, but not Cd56dim nK cells was 
observed in patients in the IC phases relative to those in the preceding It and Ia 
clinical phases (figure 3C). Differential capacities for particular effector functions 
have long been described for the Cd56bright and the Cd56dim nK cell subsets, with 
Cd56bright being able to produce higher levels of cytokine under certain conditions 
(Campbell et al., 2001; Cooper et al., 2001; Jacobs et al., 2001). This differential 
IFN-γ production observed in the CD56bright populations of It and Ia patients could 
therefore attribute to the distinct elevated viral load levels or expression of ad-
ditional viral antigens (HBeag) observed in these phases.



































%CD56+CD3- Lymphocytes %CD56bright NK Cells %CD56dim NK Cells
%Perforin+ NK Cells %Granzyme B+ NK Cells %TRAIL+ NK CellsB.
A.
figure 2. The frequency of circulating NK cells and cytolytic molecule-expressing NK cells do 
not differ between the clinical phases.
(a) representative dot-plot showing the gating strategy for Cd56+Cd3- nK cells in peripheral blood (B) the 
collective frequencies of CD56+Cd3- NK cells within the lymphocyte population of patients in the four differ-
ent clinical phases, and the frequencies of CD56bright and Cd56dim nK cells within the total nK cell popula-
tion in PBMC of patients in the different clinical phases. (C) Intracellular perforin, intracellular granzyme B, 
and traIl expression were measured within the total nK cell compartment of the aforementioned groups. 
IT (n = 7), IA (n = 6), IC (n = 8), and ENEG (n = 10), all samples were evaluated by flow cytometry and data 
are shown as mean ± seM. * denotes p < 0.05 and ** p < 0.01 (Mann-Whitney U test).
99









NK cells of chronic HBV patients in the HBeag-positive phases are 
characterized by reduced KIR and increased NKp46 expression as 
compared to the eneg phase
nK cell activity is tightly regulated by a balance of activating and inhibitory recep-
tors, and during viral infection the balance shifts from inhibition, the steady-state 
condition, toward activation (lanier, 2005; Vivier et al., 2011). C-type lectin-like 
inhibitory receptor (Cd94-nKG2a) and killer-cell immunoglobulin-like receptors 
(KIrs) comprise two of the main classes of inhibiting nK cell receptors, while 
nCr (e.g. nKp30, nKp46) and C-type lectin-like receptors (e.g. nKG2d) are two 
primary classes of activating nK receptors (lanier, 2005). We therefore chose 
to investigate the expression of these receptors on nK cells in the setting of 
the natural history of HBV infection. although the expression of activating nCr 
nKp30 remained stable across all 4 clinical phases, nK cells of eneG patients 











































figure 3. The frequency of IFN-γ+/Cd56bright expressing NK cells differs in IC patients when 
compared to the preceding clinical phases.
(A) Representative dot-plots for the CD69 expression and (B) intracellular IFN-γ expression of NK cells, for 
PBMC either left unstimulated or in the presence of Il-12/Il-18 overnight, of chronic HBV patients in the 
It, Ia, IC and eneG clinical phases. Collective results of multiple patients in each group shown in far right 
panels. (C) The frequency of IFN-γ-expressing NK cells was further divided into CD56bright and Cd56dim nK 
subsets. IT (n = 7), IA (n = 6), IC (n = 8), and ENEG (n = 10), all samples were evaluated by flow cytometry 
and data are shown as mean ± seM. * denotes p < 0.05 and ** p < 0.01 (Mann-Whitney U test).
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also express significantly lowers levels of activating NCR NKp46 than the IT 
group (figure 4a). No differences were observed in the expression of inhibi-
tory nKG2a, as well as activating nKG2d, C-type lectin receptors on nK cells 
between any of the It, Ia, IC, and eneG phases (figure 4C). the expression of 
KIRs, however, was significantly reduced (1.25 fold) on NK cells from patients 
in the HBeag-positive It and Ia clinical phases relative to patients with eneG 
hepatitis (figure 4C).
Concurrently to investigating the activation and inhibitory potential of the nK 
cells in the varying HBV clinical phases, we chose to investigate the develop-
mental phenotype of these cells using the specific differentiation-associated 
markers Cd16, Cd57, and nKG2C (Beziat et al., 2010; Bjorkstrom et al., 2010; 
Luetke-Eversloh et al., 2013). During analysis of these differentiation-associated 
receptors, only significant differences were observed when comparing CD57 in 
the two HBeAg-positive phases, with a significant reduction of CD57 expression 
seen in HBV patients in the Ia clinical phase relative to the It phase (figure 4B). 
additional analysis for all phenotypic markers was also performed on both the 
Cd56bright and Cd56dim nK cell subsets (supplementary figures 2–3). An increase 
in expression of activation receptor expression observed in Cd56bright nK cells of 
IC patients, specifically NKp30 and NKG2D expression in respect to the earlier 
























































%NKG2C+ NK Cells%NKG2A+ NK Cells %KIR+ NK Cells
%NKp30+ NK Cells %NKp46+ NK Cells %CD16+ NK Cells %CD57+ NK Cells
%NKG2D+ NK Cells
A.
figure 4. nK cells of chronic HBV patients in the HBeag-positive phases are characterized 
by reduced KIr and increased nKp46 expression as compared to the eneG phase.
Flow cytometric analysis was performed on the PBMC of chronic HBV patients in different clinical phases 
to determine the expression of (a) nCrs and activating receptors nKp30 and nKp46, (B) maturation-
associated markers Cd16 and Cd57, (C) as well as a panel of KIrs and c-type lectin activating and inhibi-
tory receptors nKG2a, nKG2C, and nKG2d on total nK cells. It (n = 7), Ia (n = 6), IC (n = 8), and eneG 
(n = 10), all samples were evaluated by flow cytometry and data are shown as mean ± SEM. * denotes 
p < 0.05 and ** p < 0.01 (Mann-Whitney U test).
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HBeag-postive It and Ia phases (It only for nKG2d). Collectively these results 
suggest an increased inhibitory potential and reduced activation potential in the 
nK cells of eneG patients compared to both HBeag-positive phases, and a 
reduction of differentiated CD57+ nK cells during the transition from the It phase 
to the Ia phase.
disCUssion
Previous modular transcriptome analysis of the whole blood of HBV patients 
identified NK cell/cytotoxicity activities as a distinctive marker in the elevated 
alt phases, Ia and eneG, when compared to the It phase (Vanwolleghem et 
al., 2015). to build on this study and to obtain a more detailed insight into the 
heterogeneity among chronic HBV patients, we examined, in the detail, nK cells 
throughout the course of the natural history of chronic HBV infection, specifically 
their potential causal role in the fluctuations of liver damage markers and HBV 
replication observed in these clinical phases. We demonstrate that (1) the overall 
composition, phenotype, and cytolytic activity of the nK peripheral cell compart-
ment remains relatively constant across all clinical phases, with the exception of 
a few specific markers (e.g. KIRs, NKp46, and CD57), (2) CD56bright nK cells of 
chronic HBV patients differ in their ability to produce IFN-γ between the clinical 
phases pre- and post-HBeag seroconversion.
the Ia and eneG clinical phases are characterized by elevated levels of alt 
and liver damage. We hypothesized that this could partially be attributed to in-
creased direct cytolytic activity and killing of infected hepatocytes by nK cells, but 
were surprised to find no measurable differences in the expression of cytotoxic 
mediators perforin, granzyme, and traIl across any clinical phases. In line with 
this, overall similarities were observed by flow cytometry in expression of NK cell 
activation (nKG2d, nKp30) and inhibitory receptors (nKG2a) when comparing the 
inflammatory (IA/ENEG) and non-inflammatory (IT/IC) phases. Furthermore, the 
lack of differences observed in the total percentage of NK cells in the lymphocyte 
compartment, as well as subset composition (Cd56bright/dim), suggests no increase 
in the proportion of nK cells or a phenotypic skewing toward the more cytolytic 
Cd56dim subset. However, the significant changes observed in the proportion of 
nK cells expressing nKp46 and KIrs suggest an altered activation potential of 
NK cell compartments during specific clinical phases, markedly the ENEG phase. 
nK cells from patients in the terminal phase of the natural history of HBV infection, 
eneG, expressed decreased levels of activating nCr nKp46 and enhanced levels 
of inhibitory, and markers of NK cell differentiation, KIRs, potentially resulting a de-
creased potential for activation for nK cells during this phase. additionally, nKp46 
has been shown to trigger nK cell activation and cytotoxicity upon ligation, but is 
expressed on mature nK cells irrespective of their activation in humans (Kruse et 
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al., 2014). Thus, the functional consequences of these observations are complex 
in nature, and could not be determined in the present study, since the characteristic 
nK cell parameters (granzyme, perforin, degranulation and traIl expression) 
were stable during the natural history of chronic HBV.
although the nK cell compartment composition and expression of cytolytic 
mediators did not differ between clinical phases, one key distinction was the 
ability of Cd56bright NK cells to produce IFN-γ upon cytokine stimulation. IFN-γ 
has been shown to be a trigger for the process of non-cytolytic HBV clearance 
and recruitment of inflammatory immune cells in both the innate and adaptive im-
mune response to HBV infection (Bertoletti and ferrari, 2016; Maini and Gehring, 
2016). We demonstrate a differential capacity to produce IFN-γ in NK cells of 
chronic HBV patients pre- and post-HBeAg seroconversion, specifically between 
the IT/IA and IC phases. This differential production of IFN-γ observed could 
be the result of enhanced immune pressure due to high viral and antigen load 
present during the HBeag-positive clinical phases, relieved after seroconversion 
and the subsequent viral suppression. However, we cannot say if this is a direct 
result of the high levels of viral particles and antigens present, or an indirect effect 
due to the coinciding immune activity in these phases.
Collectively, by conducting a detailed analysis of the phenotype and function of 
NK cells using clinically well-defined patient cohorts, we were able to character-
ize distinctive nK cell compartmental alterations during the progression of the 
chronic HBV natural history. our data, obtained using peripheral blood, provide 
no evidence for higher nK cell activities during the Ia and eneG phase, thereby 
limiting the likelihood that nK cells are responsible for observed liver damage 
during these specific phases as reflected by fluctuating serum ALT levels. How-
ever, our findings show subtle changes indicative of a shift in NK cell phenotype 
and function between the Ia phase under heavy viral or immune pressure, and 
the IC phase, that coincides with the process of HBeag seroconversion. these 
observations shed light on the differences in the NK cell compartment during the 
natural history of chronic HBV, which may help better understand the extensive 
heterogeneity of immune responses observed in chronic HBV patients.
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supplementary figure 1. representative faCs plots for surface and intracellular molecules.
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supplementary figure 2. flow cytometric analysis was performed on the Cd56bright nK 
cells in PBMC of chronic HBV patients in different clinical phases to determine the expression 
of (a) nCrs and activating receptors nKp30 and nKp46, (B) maturation-associated markers 
Cd16 and Cd57, (C) as well as a panel of KIrs and c-type lectin activating and inhibitory 
receptors nKG2a, nKG2C, and nKG2d on total nK cells. It (n = 7), Ia (n = 6), IC (n = 8), and 
ENEG (n = 10), all samples were evaluated by flow cytometry and data are shown as mean ± 
seM. * denotes p < 0.05 and ** p < 0.01 (Mann-Whitney U test).
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C.
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supplementary figure 3. flow cytometric analysis was performed on the Cd56bright nK 
cells inPBMC of chronic HBV patients in different clinical phases to determine the expression 
of (a) nCrs and activating receptors nKp30 and nKp46, (B) maturation-associated markers 
Cd16 and Cd57, (C) as well as a panel of KIrs and c-type lectin activating and inhibitory 
receptors nKG2a, nKG2C, and nKG2d on total nK cells. It (n = 7), Ia (n = 6), IC (n = 8), and 
ENEG (n = 10), all samples were evaluated by flow cytometry and data are shown as mean ± 
seM. * denotes p < 0.05 and ** p < 0.01 (Mann-Whitney U test).
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abstraCt
Background: natural killer (nK) cells have long been thought of as a purely 
innate immune cell population, but increasing reports have described develop-
mental and functional qualities of NK cells that are commonly associated with 
cells of the adaptive immune system. of these features, the ability of nK cells to 
acquire functional qualities associated with immunological memory and continu-
ous differentiation resulting in the formation of specific NK cell repertoires has 
recently been highlighted in viral infection settings.
methods/results: By making use of a unique cohort of monitored, at risk in-
travenous drug users in this study, we were able to dissect the phenotypic and 
functional parameters associated with NK cell differentiation and NK cell memory 
in patients 3 years after acute HCV infection and either the subsequent self-
clearance or progression to chronicity. We observed increased expression of 
cytolytic mediators and markers Cd56bright and nKp46+ of nK cells in patients with 
chronic, but not self-limited HCV infection. Patients with a self-limited infection 
expressed higher levels of differentiation-associated markers CD57 and KIRs, 
and lower levels of nKG2a.
Conclusions: A more extensively differentiated NK cell phenotype is associated 
with self-clearance in HCV patients, while the nK cells of chronic patients exhib-
ited more naïve and effector NK cell phenotypic and functional characteristics. 
The identification of these distinct NK cell repertoires may shed light on the role 
nK cells play in determining the outcome of acute HCV infections, and the under-
lying immunological defects that lead to chronicity.
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spontaneous clearance of an acute hepatitis C virus (HCV) infection occurs in ap-
proximately 25 % of patients whom contract a primary infection (1). Clearance has 
been associated with strong t cell responses and a rapid induction of neutralizing 
antibodies against the autologous virus (2–5), but in recent years the importance of 
natural killer (NK) cells in this process has received renewed interest (6–9). NK cells 
act by eliminating HCV infection via two type of mechanisms; direct mechanisms, 
including the release of cytotoxic enzymes, such as granzymes and perforins, that 
result in lysis of the infected hepatocytes, and indirect mechanisms that involve the 
release of cytokines, such as interferon (IFN)-γ, by activated NK cells that result in 
triggering of antiviral responses that inhibit viral replication in infected cells.
nK cell activity is strictly governed by a balance of activating and inhibitory re-
ceptors on the cell surface. Some of the major classifications of these regulatory 
receptors include C-type lectin-like receptors (nKG2a, nKG2C, nKG2d), natural 
cytotoxicity receptors (nKp30, nKp44 and nKp46), and killer cell immunoglob-
ulin-like receptor (KIrs) (10, 11). during viral infection the balance shifts from 
inhibition to activation after a critical threshold of activation signals exceeds those 
of inhibition (12). In addition to the regulation of the function of nK cells by these 
cell surface receptors, differentiation from CD56bright to Cd56dim cells has also 
been shown to contribute to functional and phenotypic heterogeneity observed 
during the life span of NK cells. Many details of this differentiation process remain 
undefined, but the dynamics and outcome are likely affected by viral infections. 
During the differentiation process, NK cells lose expression of NKG2A, and 
subsequently acquire KIR and CD57 expression, ultimately resulting in a more 
terminally differentiated phenotype, that display reduced IFN-γ producing and 
proliferative capacities (13, 14).
Besides differentiation of NK cells, in recent years development of NK cells into 
memory-like cells has also been reported in both mice and humans, suggest-
ing more similarities between nK cells and Cd8+ t cells than originally thought 
(15, 16). In humans, a long-lived memory-like nK cell population was described 
at higher frequencies in CMV-seropositive individuals than CMV-seronegative 
individuals (17, 18). these cells were found to express high levels of the of C-
type lectin nKG2C, in combination with maturation marker Cd57 (17). a memory 
phenotype for nK cells has also been suggested in Mycobacterium tuberculosis 
and hantavirus (19, 20), but little information is available in HCV infections. this 
would, however, be highly relevant since in high-risk populations like injecting 
drug users (IDUs), reinfection is frequently observed in patients would have 
previously spontaneously cleared an HCV infection. the clinical observation that 
primary HCV infections are cleared in only a minority of individuals, while spon-
taneous clearance of an HCV reinfection occurs in approximately 80 % of cases 
(21, 22), strongly suggests that immunity acquired during the primary infection 
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may play a role in the protection against HCV reinfection, and that some sort of 
immunological memory to HCV has developed.
With limited information available on the development and persistence of 
memory-like nK cells during and after HCV infection, we chose to characterize 
and compare the nK cell compartments of individuals who either resolved an 
acute HCV infection and individuals that developed a chronic infection. the aim 
of this study was to determine if memory-like nK cells are present following the 
resolution of a primary HCV infection, as well as whether the phenotypic and 
functional parameters associated with the NK cell differentiation process differ 
between the resolved patients and those chronically infected with HCV. By utiliz-
ing the unique cohort of self-clearing IDUs and the characterizing the effector and 
memory nK cell compartments in these individuals, we hope to provide immuno-
logical insight on how and to what extent nK cells might enhance immune-based 
antiviral strategies, such as vaccines and immunomodulators, in HCV infection.
materials and methods
patient selection and characteristics
Isolated peripheral blood mononuclear cells (PBMC) of 32 individuals were 
selected from archived samples collected in the amsterdam Cohort studies 
(aCs), which were in 1984 to investigate the epidemiological, behavioral, and 
psychosocial aspects of HIV/aIds among homosexual men and drug users 
(23–25). In these studies participants were requested to visit the center every 
six months for HIV/HCV-screening, and were evaluated for at-risk behavior and 
various related psychosocial determinants. Blood was collected and stored for 
future studies. HCV rna and antibody tests were performed retrospectively for 
all participants until 2003 and prospectively from october 2007 until 2010 for 
HIV-negative participants (26). the characteristics of the selected patients are 
presented in table 1. all individuals selected were HIV negative/unexposed, and 
at-risk IdUs who were age and ethnically matched individuals who displayed 
similar risk behaviors, and who were reinfection-naïve. the individuals were 
categorized into 3 groups for cross-sectional analysis: 1) at-risk individuals that 
were never exposed to HCV infection and did have serological evidence of HCV 
infection at the time of sampling or at a later time-point (n = 10); 2) at-risk individu-
als that contracted a self-limiting acute HCV infection (viral clearance within first 6 
months of infection) (n = 11); and 3) at-risk individuals that eventually developed 
a chronic infection (viral persistence 6 months post-infection) (n = 11). Using the 
virologic data provided by the bi-yearly visits of participants in the aCs, an ap-
proximate time of infection was determined for the cleared and chronic patients 
(± 6 months) and samples were selected approximately 3 years post-infection. 
additionally, when available, samples were selected from the same self-clearing 
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and chronically infected individuals approximately 1 year post-infection for longi-
tudinal analysis. the study was approved by the local ethics committee, and all 
patients and controls in the study gave informed consent before blood donation.
Expression of cell surface and intracellular molecules by flow cytometry
To determine the frequency and phenotype of peripheral blood NK cells, multi-color 
flow cytometry was performed on PBMC with anti-CD3-Alexa-Fluor700 (OKT-3, 
Beckman), anti-Cd56-aPC-efluor780 (CMssB, Beckman), anti-Cd57-aPC 
(HCd57, Biolegend), anti-KIr2d-Biotin (nKVfs1, Miltenyi biotech), anti-KIr3dl1/
dl2-Biotin (5133, Miltenyi biotech), streptavidin-efluor450 (eBioscience), 
anti-NKG2A-PE (Z199, Beckman), anti-NKG2C-Alexa-488 (134591, R&D), 
anti-NKG2D-PerCP-Cy5.5 (1D11; BD), anti-NKp30-PE (Z25, Beckman), anti-
NKp44-Biotin (P44–8, Biolegend), anti-NKp46-PE-Cy5 (BAB281, Beckman), anti-
CD69-PacificBlue (FN50; Biolegend) and Live/Dead Aqua (Life Technologies). For 
intracellular expression of cytotoxic markers, PBMC (0.5x106 cells/200 μl) were 
fixed with 2 % formaldehyde, and permeabilized for intracellular staining with anti-
granzyme B-Pe (GB11, eBioscience), anti-perforin-PerCP-efluor710 (G9, eBiosci-
ence), and anti-TRAIL-Alexa488 (75402, R&D). Cells were again assessed by flow 
cytometry (faCs Canto II, Bd) and analyzed using flowJo version 10.1 (tree star 
Inc). Quadrants were set on negative expression of markers on Cd3-Cd56- cells. 
approximately 105 viable lymphocytes were collected for each individual sample.
table 1. Participant characteristics at time of sample collection (approximately 3 years post-
acute HCV infection*)
Uninfected Cleared hCV Chronic hCV
numbers 10 11 11
sex M/f 8/2 4/7 4/7
age (yrs) 32.3 (25–59) 30.9 (24–42) 34.7 (24–47)
ethnicity Caucasian 10 8 9
asian - 2 - 
other - 1 2 
time since infection (yrs)* - 2.9 (2.4–4.0) 2.9 (2.0–0.8)
hCV bdna (iU/ml) - < 615 4.9x105
(6.3x103–3.9x106)
anti-hCV negative positive positive
hCV genotype genotype 1 - 1 6
genotype 3 4 4 
genotype 4 1 1 
unknown 5 - 
* estimated as time between first positive HCV bDNA test (with negative test at previous visit) and time of 
sample collection
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stimulation and intracellular cytokine analysis of NK cells
PBMC were stimulated with Il-12 (0.25 ng/ml) and Il-18 (10 ng/ml) overnight 
for surface marker expression and intracellular cytokine production. after 18 
hours, brefeldin A (10 μg/ml, Sigma) was added to the cultures and the cells 
were incubated for an additional 3 hours. Cellular activation and surface markers 
were measured using anti-CD3-PacificBlue (OKT3, eBioscience), anti-CD56-
PE (MY31, BD), and anti-CD69-APC (L78, BD), followed by fixation with 2 % 
formaldehyde, and permeabilization for intracellular staining with anti-IFN-γ-FITC 
(25723.11, BD). Cytokine-producing cells were detected by flow cytometry (FACS 
Canto II, Bd) and analyzed using flowJo version 10.1 (tree star Inc). Quadrants 
were set on negative expression of Cd69 on monocytes and the absence of 
IFN-γ production by B cells.
statistical analysis
data are expressed as the mean value ± seM, unless indicated otherwise. the 
data were analyzed with Prism software, version 5.0 (GraphPad software Inc) 
using the Mann-Whitney U test to compare the variables between independent 
groups and the Spearman rank correlation coefficient test for nonparametric 
correlations. In all analyses, a 2-tailed p < 0.05 (95 % confidence interval) was 
considered statistically significant.
resUlts
NK cells of patients with a chronic, but not self-limited, HcV infection have an 
increased Cd56bright/Cd56dim ratio and expression of granzyme B and TRaIL
Previous studies have implicated a role for nK cells in the innate immune re-
sponse to acute HCV infection (27, 28). to further dissect and understand the 
characteristics of nK cells following self-resolution of acute HCV infection or 
during progression to chronicity, we chose to perform a cross-sectional analysis 
of nK cell phenotype and function in uninfected individuals, patients with a self-
limited HCV infection (cleared), and patients who developed a chronic infection. 
As a first step, using flow cytometric analysis, we evaluated the composition of 
PBMC, and showed that the percentage of total NK cells (defined by CD56+Cd3- 
expression) within the lymphocytes did not differ in the peripheral blood of any 
of the 3 groups (figure 1a). However, an increase in the frequency of CD56bright 
and reduction of Cd56dim expressing nK cells was observed in chronic patients 
as compared to both the uninfected and self-clearing individuals.
Concurrently with the compartmental analysis, the cytotoxic potential of nK 
cells from the uninfected, cleared, and chronic groups was assessed by intracel-
lular analysis of the cytolytic mediators perforin, granzyme B, and tnf-related 
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apoptosis-inducing ligand (traIl) (figure 1B). In contrast to the frequency of 
perforin expressing nK cells, which remained stable across all groups, the fre-
quencies of granzyme B and TRAIL expressing NK cells were significantly higher 
in chronic HCV patients compared to uninfected individuals or patients who had 
cleared the infection. Collectively, these results show an increase in Cd56bright 
expression and cytolytic potential of nK cells from chronic HCV patients, but not 
self-limiting patients, when compared to uninfected individuals.
The frequency of cytokine induced IFN-γ production is unaltered in NK cells 
of self-limited and chronic hCV patients compared to uninfected individuals
Differential capacities for particular effector functions have been described for the 
Cd56bright and the Cd56dim NK cell subsets (29–31). To explore if the observed dif-
figure 1. nK cells of patients with a chronic, but not self-limited, HCV infection have an in-
creased Cd56bright/Cd56dim ratio and expression of granzyme B and traIl
(a) flow cytometric analysis was performed on the PBMC of uninfected, self-clearing, and chronic HCV 
patients to determine the frequency of total CD56+Cd3- NK cells in lymphocytes, and the frequency of 
Cd56bright and Cd56dim of these NK cells. (B) Intracellular flow cytometric analysis of perforin, granzyme B, 
and traIl was performed on the nK cells of the aforementioned patient groups. data are shown as mean 
± seM. * denotes p < 0.05 and **p < 0.01 (Mann-Whitney U test).
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ferences in NK cell composition translated to differential NK cell effector function, 
we investigated the cytokine-producing capacity of these nK cells. PBMC from 
uninfected individuals, self-limited HCV patients, or chronic HCV were cultured in 
the presence of Il-12 and Il-18, and the surface expression of activation marker 
CD69, and intracellular expression of IFN-γ was determined (figure 2a). the 
percentage of Cd69 expressing nK cells after Il-12 plus Il-18 stimulation was 
consistent across all 3 groups (figure 2a-B). Albeit not significant, a trend toward, 
figure 2. Frequency of IL-12/IL-18 induced IFN-γ production is unaltered in NK cells of self-
limited and chronic HCV patients compared to uninfected individuals
(a) PBMC from uninfected, self-clearing, and chronic HCV patients were either left unstimulated (control) 
or stimulated with IL-12/IL-18 overnight, and surface/intracellular flow cytometric analysis was performed 
for the expression of CD69, and IFN-γ. (B) Collective results for multiple donors of CD69 and IFN-γ-positive 
cells after Il-12 and Il-18 stimulation. data are shown as mean ± seM. * denotes p < 0.05 (Mann-Whitney 
U test).
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reduced frequencies of IFN-γ-producing NK cells was observed in patients with 
self-limited HCV relative to chronically infected patients. neither the percentage 
of IFN-γ producing NK cells of self-clearing patients nor chronic HCV patients 
were significantly altered compared to uninfected individuals.
Expression of natural cytotoxicity receptors unaltered on NK cells of self-
clearing hCV patients
nK cell activity is tightly regulated by a balance of activating and inhibitory recep-
tors, and during viral infection, the balance shifts from inhibition, the steady-state 
condition, toward activation (10, 11). nCrs (eg. nKp30, nKp44, nKp46) and 
figure 3. expression of nKp30, nKp44, nKp46 and nKG2d is unaltered on nK cells of self-
clearing HCV patients, whereas the frequency of NKp46+ nK cells is enhanced in patients 
with chronic HCV
flow cytometric analysis was performed on the PBMC of uninfected, self-clearing, and chronic HCV pa-
tients to determine the expression of nKp30, nKp44, and nKp46, as well as nKG2d on total nK cells. data 
are shown as mean ± seM.* denotes p < 0.05 and ** p < 0.01 (Mann-Whitney U test).
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C-type lectin-like receptors (eg. nKG2d) are two of main classes of activating 
nK receptors, and we therefore chose to investigate the expression of these 
receptors on nK cells in a self-limited and chronic HCV setting. flow cytometric 
analysis showed no differential expression of NKp30, NKp44 or NKG2D on NK 
cells between the uninfected, cleared, and chronic groups (figure 3). However, 
the frequency of NKp46-expressing NK cells was significantly higher in chronic 
HCV patients compared to uninfected controls, and showed a trend toward higher 
frequencies as compared to the NK cells of self-limited patients. Collectively, this 
data shows no difference in the expression of particular NCR and other activat-
ing receptors in self-clearing HCV patients compared to uninfected individuals, 
whereas nKp46 expression was elevated in chronic patients.
NK cell memory phenotype is not associated with self-clearance or chronic 
disease in hCV infection
the longstanding dogma of nK cells as a purely innate immune cell population 
has been challenged in recent years, with increasing reports describing qualities 
of nK cells that have commonly been associated with immunological memory 
in response to pathogens (15, 16). We therefore decided to investigate and 
characterize this unique NK cell population in HCV infection, and to determine 
its association with the resolution of acute HCV infections. first, the expression 
of maturation marker Cd57 and the activating Cd94-nKG2C receptor were as-
sessed by flow-cytometry in uninfected individuals, as well as self-cleared and 
chronic HCV patients (figure 4a). CD57 expression, but not NKG2C, was signifi-
cantly greater on nK cells of self-limited HCV patients compared to uninfected 
controls, whereas in chronic patients Cd57 and nKG2C expression remained 
unaltered.
Next, we examined the frequency of CD57+nKG2C++ expressing nK cells, as 
this population has been reported to represent the long-lived nK cell population 
in humans (17, 32, 33). Using flow cytometry, we were able to identify this popula-
tion of NK cells, but did not observe a significant difference in the percentage 
of Cd57+nKG2C++ expressing nK cells between uninfected individuals or either 
HCV patient group (figure 4B). the expression of Cd57+nKG2C++ nK cells 
remained stable from 1 to 3 years post-contraction of acute HCV infection in 
the cleared patients, and in chronic patients (figure 4C), suggesting that this 
population is not diminished after viral clearance or during prolonged chronic 
infection. as a whole, these results show that despite an increased expression of 
CD57 on NK cells of self-limited HCV patients, this did not translate to differential 
frequencies of memory-associated NK cell populations in either self-cleared or 
chronic HCV patients.
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figure 4. nK cell memory-associated phenotype is not associated with self-clearance or 
chronic disease in HCV infection
(A) NK cells in PBMC from uninfected, self-clearing, and chronic HCV patients were analyzed using flow 
cytometry for the expression of the nK cell maturation markers Cd57 and nKG2C. (B) nK cells with a 
memory-associated phenotype were defined based on the expression of CD57+ and nKG2C++. Collective 
results for multiple donors of the frequency of these CD57+nKG2C++ nK cells. (C) Paired time points for 
patients at either 1 year or 3 years post infection. data are shown as mean ± seM. * denotes p < 0.05 and 
** p < 0.01 (Mann-Whitney U test).
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self-limited HcV patient have more highly differentiated NK cell repertoires 
than uninfected and chronically infected individuals
the maturation marker Cd57 expression has not only been linked to memory in 
nK cells, but it has also been implicated, in combination with inhibiting Cd94-
NKG2A receptor and KIRs, as defining markers in the differentiation of CD56dim 
NK cell repertoires (13, 14). To determine the differentiation status among NK 
cell populations and the role it may play in the clearance of HCV infection, we 
assessed the expression and co-expression of nKG2a, Cd57 and KIrs. nK cells 
of self-limited HCV patients expressed significantly reduced levels of NKG2A 
compared to both uninfected and chronically infected individuals (figure 5a). 
this reduction of nKG2a expression was only observed in Cd57- nK cells, but 
not Cd57+ nK cells. KIr expression in the total nK cell compartment of cleared 
patients resembled that of uninfected individuals, whereas chronic patients 
expressed reduced levels of these receptors (figure 5B). KIr expression in self-
limited HCV patients appeared to be mainly attributed to the Cd57+ nK cells 
figure 5. Self-limited HCV patients have more highly differentiated NK cell repertoires than 
uninfected and chronically infected individuals
NK cells in PBMC from uninfected, self-clearing, and chronic HCV patients were analyzed using flow cy-
tometry for the expression of nKG2a and KIrs (KIr2d, KIr3dl1 and KIr3dl2). (a) nKG2a expression 
on total nK cells, and Cd57+ or Cd57- nK cells (B) KIr expression on total nK cells, and Cd57+ or Cd57- 
nK cells. data are shown as mean ± seM. * denotes p < 0.05 and ** p < 0.01 (Mann-Whitney U test).
121









and, similarly to the chronic patients, was significantly reduced on the CD57- nK 
population. nKG2a expression on nK cells was inversely correlated with both 
KIrs and Cd57 expression only on the nK cells of the cleared group, whereas 
KIrs and Cd57 were positively correlated in this subset of patients. Collectively 
this data suggests an enrichment of more highly differentiated NKG2A-Cd57+KIr+ 
cells in patients with a self-limiting HCV infection compared to uninfected and 
chronically infected individuals.
disCUssion
By making use of a unique cohort of monitored, at risk intravenous drug users 
in this study, we were able to dissect the phenotypic and functional parameters 
associated with NK cell differentiation and NK cell memory in patients 3 years 
after acute HCV infection and either the subsequent self-clearance of infection or 
progression to chronicity. Increased frequencies of NK cells expressing CD56bright 
and cytolytic mediators (granzyme B and traIl) were observed in chronically 
infected patients, but not those that cleared the acute infection, suggesting an 
overall more naïve and effector NK cell repertoire during chronic infection. NK 
cells repertoires of patients with a self-limited infection displayed a more highly 
differentiated phenotype, characterized by an increased CD57 and KIR expres-
sion, as well as reduced nKG2a expression, but did not exhibit a memory-like 
phenotype. lastly, cytokine-induced activation, as seen by Cd69, was compa-
rable in all groups, whereas IFN-γ expressing NK cells showed a trend, but non-
significant, decrease in self-limited patients as compared to the chronic group.
A key finding of this study was that, although, we were able to identify the mem-
ory-like nK cell population based on Cd57+nKG2C++ expression in a subset of 
individuals from all groups in this study, no significant differences were observed 
in the total percentages of this specific NK cell repertoire. Additionally, the longi-
tudinal analysis of both chronic and self-resolving patients from 1 to 3 years after 
estimated time of infection demonstrated a stable and unaltered expression and 
composition of this memory-like NK cell compartment. Our findings argue against 
the hypothesis that Cd57+nKG2C++ nK cells observed after resolution of HCV 
infection are genuine memory nK cells induced by HCV exposure. additionally, 
the protective features attributed to expanded expression of these populations 
upon re-exposure previously described in other viral infections, cannot justify the 
increased resistance to reinfection described in acute-resolved HCV patients.
Although we did not observe differences with respect to memory-like character-
istics of nK cells, the phenotype and function of cells observed for acute-resolved 
patients did still drastically differ when compared to that of chronic patients and 
the uninfected group. distinct alterations were observed between self-clearing 
patients and both the chronic and uninfected groups in respect to their expression 
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of maturation and differentiation-associated markers on NK cells. The expression 
of Cd57 and KIrs were positively correlated (supplementary figure 1), and the 
expression of both these receptors was inversely correlated to that of nKG2a, 
suggesting a tight link between the regulation and expression of these receptors 
on the surface of nK cells of acute-resolved patients. this phenotypic alteration 
and regulation of markers resembles those previously described for nK cell dif-
ferentiation [23, 24]. During this differentiation process, NK cells lose expression 
of NKG2A, and subsequently acquire KIRs and CD57, ultimately resulting in a 
more terminally differentiated phenotype that display reduced IFN-γ production 
and proliferative capacity. our data indicates that nK cells of acute self-limited 
HCV patients persist in a more highly differentiated state, even years after the 
clearance of infection, although it is unclear if this is the cause or result of the 
resolution of the acute infection. However, the reduced proliferative and effector 
functionality described for terminally differentiated NK cells, makes it difficult to 
attribute the immunological resistance to reinfection in self-limited HCV patients 
to this nK cell repertoire.
In line with previous studies (34, 35), we observed an altered distribution of 
Cd56bright/dim nK cell subsets in chronic HCV patients, but did not observe an 
overall decrease in the levels of nK cells as described by other studies (34, 
36–38). The NK cells of these chronic patients also expressed significantly lower 
levels of Cd16 (data not shown) and increased levels of nKp46 as compared to 
not only the uninfected group, but also the resolved patients. Increased nKp46 
expression in this group is of particular interest, as it has been shown to be one 
of the principle avenues of nCr-mediated killing and correlated with the cytolytic 
activity of NK cells in HCV patients (39–41). This also supports skewing toward 
cytotoxicity, with increased frequencies of granzyme B and TRAIL expressing 
cells, observed in the chronic patients group. Interestingly, the frequencies of 
perforin expressing NK cells remained constant. This differential regulation of 
perforin versus granzyme B expressing nK cells has been described before 
by others, who showed distinct induction after triggering with Il-2, Il-4, PMa/
ionomycin, and IFNα (42, 43).
Interestingly, however, some of these studies report depressed IFN-γ in chronic 
patients, whereas no differences were observed in the frequency of IFN-γ pro-
ducing nK cells of chronic HCV patients in our study, but instead a trend toward 
reduction in the resolving HCV patients. this could be attributed to the highly dif-
ferentiated phenotype of nK cells in this particular group, previously described to 
be impaired in their cytokine producing and proliferative capacities (13). overall, 
our data, in combination with that previously described in literature, depicts nK 
cells in chronic patients as phenotypically naïve, with increased expression of 
NCRs and cytolytic mediators, reflecting the activation response to a persistent 
viral stimulation.
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Collectively, our findings depict an altered, more extensively differentiated, 
but not memory-like, nK cell compartment in patients after resolving an acute 
infection, as compared to both uninfected individuals and patients with ongoing 
infections. this is in contrast to nK cells of chronic HCV patients that displayed a 
more naïve and effector phenotype with elevated cytotoxic capabilities. Although 
the highly differentiated NK cell repertoire in acute-resolved patients may not de-
scribe the resistance to reinfection observed in self-clearing acute HCV patients, 
the identification of these distinct NK cell repertoires may shed light on the role 
nK cells play in determining the outcome of secondary HCV infections, and the 
underlying immunological defects that lead to chronic infection.
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HBV and HCV infection are the two leading causes of chronic liver inflamma-
tion worldwide, affecting an approximate 370–390 million people.1–3 Currently, 
the viral and immunological mechanisms that underlie either the resolution or 
persistence of viral hepatitis infections are not fully understood. Investigation and 
identification of the integral components in the host immune responses that cu-
mulatively lead to the effective clearance of the virus or development of a chronic 
infection are of the utmost importance. therefore, the overall aim of this thesis 
was to understand the function, and dysfunction, of specific aspects of the innate 
immune system in the resolution or persistence of viral hepatitis infection. the 
two main components of the immune response focused on in this thesis were 
the roles IFNs, specifically type I and III IFNs, and NK cells play in determining 
disease state and outcome.
systemiC leVels and immUnologiCal regUlation of type iii 
ifns in Viral hepatitis infeCtion
Endogenous IFN-λ in viral hepatitis patients
Endogenous IFNs, specifically IFN-α, play a pivotal role in the innate immune 
response to viral infections and for many years represented a cornerstone in the 
treatment of chronic HCV and HBV infection until the recent introduction of daas. 
type III Ifns, however, have only received increased attention since the discovery 
of SNPs within the IFN-λ gene locus that are associated with spontaneous as well 
as IFN-α/ribavirin therapy-induced clearance of HCV infection.4–7 More recent 
publications have attempted to explain these associations, specifically with the 
identification of IFN-λ4 and its association with HCV resolution,8 but the exact 
mechanism still remains unclear. therefore, in Chapter 2 we performed a detailed 
analysis of the endogenous levels of type III Ifns in viral hepatitis patients and 
how these related to patient IFN-λ-polymorphism genotypes as well as disease 
state. We demonstrate that serum IFN-λ levels are not affected by infection 
with either HCV or HBV, and that IFN-λ levels are not associated with specific 
disease stages, outcome, or other parameters (e.g. ALT and IFN-λ3 rs12979860 
genotype). However, this does not exclude endogenous IFN-λ expression from 
being, at least partially, responsible for the associations seen between snPs 
within the IFN-λ gene locus and viral clearance. In this study, we investigated 
the systemic levels of IFN-λ by using serum from viral hepatitis patients, but this 
does not always reflect levels within specific tissues (e.g. intrahepatic levels). 
Studies have shown that IFN-λ3 is one of the predominant IFNs produced by 
hepatocytes during acute HCV infection.9 Differences in the systemic levels of 
IFN-λ may not fully reflect the production of IFN-λ by hepatocytes at the site of 
infection, but instead the production by cells in the peripheral compartment, such 
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as pdCs and BdCa3+ mDCs, known to be producers of IFN-λ during HCV infec-
tion.10,11 these dC populations have been shown to be potent producers of type 
III Ifns, but still represent a relatively small fraction of Ifn-producing cells when 
compared to hepatocytes. additionally, a series of studies have reported impaired 
type I Ifn, but not type III Ifn, signaling in hepatocytes during HCV infection,12,13 
stressing the importance of not only the absolute levels, but also the differences 
in sensitivity of response by hepatocytes and other cell types to Ifns. these 
results, in combination with the differential gene transcript expression, kinetics, 
as well as cytokine production that have been described for IFN-α and IFN-λ in/
by hepatocytes and other tissue resident cells (e.g. macrophages in Chapter 4), 
further stress the potential importance of intrahepatic IFN-λ levels during HCV 
infection.14–17 Collectively, differences in intrahepatic IFN-λ expression and the 
sensitivity of hepatocytes, as well as other liver-resident cells, to this class of 
Ifns could at least partially explain the associations between snPs within the 
IFN-λ gene locus and viral clearance in HCV patients. How this compares to and 
why this may differ in other viral infection settings, such as chronic HBV, is still 
not known. Although some of the same SNPs within the IFN-λ gene locus have 
been associated with IFN-α treatment response in HBeAg-positive chronic HBV 
patients,18,19 these links appears to be much less pronounced. this could have to 
do with differential triggering of immune responses by the two hepatitis viruses, 
partially reflected in the strong ISG response characteristic of HCV infection, but 
almost completely devoid in chronic HBV infection. additionally, cure rates of 
IFN-based therapies are significantly lower in chronic HBV as compared to HCV 
patients, suggesting a higher degree of susceptibility of HCV to the antiviral and 
immunomodulatory effects of IFNs.
immunological regulation of type iii ifns
In addition to the implications of endogenously produced IFN-λ in viral hepatitis 
patients, much of the underlying basic biology of type III Ifns remains unex-
plained. the antiviral aspects of this class of cytokines have been well estab-
lished, with many similarities described to type I Ifns. However, as previously 
stated, this then raises the question; what is the evolutionary benefit of having 
two classes of Ifns if their immunological roles are truly redundant? therefore, 
further investigation is needed to understand the distinctions described for type 
III IFNs, specifically in regards to the IFN-λ receptor and its expression on im-
mune cells as well as the associated responses after triggering. the collective 
aim of Chapters 3, 4, and 5 was to further explore the immunological regulation of 
IFN-λ on specific aspects of the innate immune response to viral infections (e.g. 
pathogen-mediated B cell, macrophages, and nK cells responses), and how this 
compares to that of IFN-α.
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figure 1. IFN-α and IFN-λ diff erentially regulate the innate immune response.
(A) IFN-α and (B) IFN-λ resemble each other in their ability to directly stimulate B cells and augment TLR-
mediated cytokine (Il-6 and Il-10) and Ig production (IgG and IgM), partially attributed to an increase in 
TLR7 response and proliferation. IFN-λ alone is able to induce ISG (MX1 and OAS1) and TLR7 expres-
sion, but additional TLR and helper T cell signals (CD40 and BCR ligation) are required for B cell activation 
and induction of functional responses. Unlike IFN-α, IFN-λ is unable to directly promote eff ector function 
in NK cells (IFN-γ, CD107, and GZMB expression) due to the lack of IFN-λR1 expression. However, IFN-λ 
stimulation, in combination with tlr activation, is able to induce expression of select members of the Il-12 
family of cytokines (Il12B, Il23a, Il27a, and eBI3) in monocyte-derived macrophages. In combination 
with IFN-γ priming, IFN-λ is therefore able to indirectly induce IFN-γ production by NK cells, and potentially 
Cd8 t cells, through macrophage-mediated Il-12 production, ultimately creating an autocrine loop. this 
indirect macrophage-mediated eff ect is unique to type III IFNs, as stimulation with IFN-α reduces the IL-
12p40 and bioactive Il-12 production of macrophages.
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In Chapters 3 and 4, we demonstrate that IFN-λ is able to directly act on B 
cells and monocyte-derived macrophages, but not nK cells and monocytes, 
while IFN-α is able to directly modulate all these cell populations (figure 1a-B). 
Specifically, both type I and III IFNs are able to augment TLR-mediated B cell 
activation, as well as cytokine (Il-6 and Il-10) and Ig production (IgG and IgM), 
partially attributed to an increase in tlr7 response and proliferation. although 
IFN-λ alone is able to induce ISG (MX1 and OAS1) as well as TLR7 expression, 
additional TLR and helper T cell signals, CD40 and BCR ligation, are required 
for B cell activation and induction of functional responses. Unlike IFN-α, IFN-λ 
is unable to directly activate and promote effector function in NK cells (IFN-γ, 
CD107, and GZMB expression), presumably due to the lack of cellular expres-
sion of the IFN-λR1 component of the type III IFN receptor complex. However, 
IFN-λ priming, in combination with TLR activation, is able to induce expression of 
select members of the Il-12 family of cytokines (Il12B, Il23a, Il27a, and eBI3) 
in monocyte-derived macrophages. We further show that IFN-λ, in combination 
with IFN-γ, is able to indirectly affect NK cells through macrophage-mediated 
IL-12 production, ultimately inducing IFN-γ production and potentially creating 
an autocrine loop. This indirect macrophage-mediated effect is unique to type III 
IFNs, as stimulation with IFN-α reduced the IL-12p40 and bioactive IL-12 produc-
tion of macrophages.
Although B cell activity is generally attributed to the antigen-specific adap-
tive immune response, B cells have also been shown to express and respond 
to non-specific antigens via PRRs such as TLR7. Additionally, exposure of B 
cells to type I Ifns strongly promotes humoral immunity via enhanced survival, 
reduced apoptosis, as well as increased B cell activation, proliferation, and Ig 
production.20–22 In Chapter 3, we demonstrate that IFN-λ resembles IFN-α in all 
these aspects, specifically in regards to its upregulation of TLR7 expression and 
enhancement of subsequent responses. The enhancement of B cell responses, 
specifically the increase in antibody production we observe, by both type I and III 
Ifns could play an important part in the resolution of acute hepatitis infections. 
Individuals that spontaneously resolve HBV infection develop antibodies spe-
cific for HBsAg, and these HBsAg-specific antibodies have been shown to have 
virus-neutralizing activity and control HBV infection, even with the persistence of 
cccdna.23 although the importance of neutralizing antibodies in the resolution 
of HCV infection is somewhat less evident, recent studies have described a role 
for HCV-specific antibodies in the control of infection.24 In these studies, acute 
HCV resolution was associated with the early presence of neutralizing antibod-
ies, whereas delayed development of neutralizing antibodies was observed in 
patients that eventually developed a chronic infection.25,26 However, neutralizing 
antibodies specific for HCV E1 and E2 envelope proteins have been shown be 
susceptible to escape mutations.27 this further stresses the importance of an 
immediate induction of antibody responses by B cells in the control and resolution 
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of acute HCV infection, before the development of escape mutations, potentially 
driven by a combination of innate immune, non-specific factors such as type I and 
III Ifns, as well as PaMPs.
similar to that demonstrated for macrophages and nK cells in Chapter 4, 
Il-12-mediated cross-talk has been described between Cd8 t cells and macro-
phages.28 Reports describing effects of type III IFNs on T cells directly have been 
unconvincing,29,30 with our own preliminary screenings performed during previous 
studies also failing to demonstrate T cell responses after exposure to IFN-λ alone 
or in combination with various co-stimuli (data not shown). this again implicates 
only an indirect role for IFN-λ in modulating CD8 T cell responses, that contrasts 
starkly to that of IFN-α, which has been described to directly regulate IFN-γ 
production by cytolytic T cells. These direct type I IFN effects have been shown 
to be both inducing as well as inhibiting in the production of IFN-γ by CD8 T cells 
and to have anti-proliferative effects on T cells.31 If IFN-λ is able to indirectly 
enhance IFN-γ production of CD8 T cells, as we describe for NK cells, without 
the anti-proliferative effects of type I IFNs, this could provide distinct advantages 
in immune response to viral hepatitis infections. Effective IFN-γ production has 
been shown to be a critical factor in the inhibition of HBV and HCV replication 
and in the early response to hepatitis infections.32–34 additionally, the favoring 
of IL-12 production by IFN-λ, that we and others describe, also indicates a role 
for promoting type 1 over type 2 immune response and the induction of strong 
antiviral responses from type 1 helper t (tH1) cells as well as Cd8 t cells.14,30,35 
Collectively, via an alternative indirect route, IFN-λ has the ability to induce an 
anti-viral immune response by NK cells and cytolytic T cells, both required for an 
effective clearance of viral hepatitis infections.36,37
Conclusion and future perspectives
The ubiquitous expression of the IFN-α receptor across leukocyte populations 
(e.g. monocytes, NK cells, and T cells) and the ability of IFN-α to directly act 
on many of these cell types distinguishes it from IFN-λ. These features make 
IFN-α an integral and direct mediator in the induction of the immediate immune 
response to viral infection in the peripheral as well as the tissue compartments. In 
contrast, the restricted expression of the IFN-λ receptor prevents the direct action 
of IFN-λ on a significant proportion of leukocyte populations, with the exception of 
B cells, monocyte-differentiated macrophages, and pDCs. However, other studies 
have described effects of type III IFNs on tissue-resident cells, such as epithelial 
cells, hepatocytes, and synovial fibroblasts (discussed in Chapter 5).38–40 the 
responses to IFN-λ have also been described to be kinetically distinct to those 
of IFN-α, with a more delayed and prolonged effect through activation of specific 
tissue-resident cells, such as hepatocytes.15,41 these observations, in combina-
tion with the delayed indirect activation of NK cells by IFN-λ, mediated through 
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macrophage IL-12 production, could explain differences in biological functions 
described between the type I and type III IFNs in inflammatory responses, with a 
more tissue-specific (e.g intrahepatic) response induced type III IFNs. This local-
ized induction of the immune response by IFN-λ could provide potential benefits 
over the aspecific, systemic effects of IFN-α, especially as an alternative thera-
peutic for viral hepatitis infections or other tissue-localized viral infections where 
ddas are not available and/or patients are immune-compromised (e.g. hepatitis 
e virus (HeV) or hepatitis d virus (HdV)/HBV co-infection). additionally, recent 
literature has shown that DAAs in HCV infection, although very highly efficacious 
and tolerable, may have some limitations in specific subpopulations that have a 
history of HCC, with surprisingly high rates of HCC reoccurrence being reported 
after sVr.42 This has not been described for previous responders to IFN-α-based 
therapies, potentially due to the immunomodulatory properties of Ifns promoting 
not only antiviral, but also antitumor immunity. Therefore, the addition of IFN-λ to 
DAA therapy in specific subpopulations that have high grade fibrosis/cirrhosis, 
a high risk for HCC, and/or a history of HCC may help prevent the (re)occur-
rence of HCC, while providing a more tissue-specific immune response and less 
undesired adverse events than IFN-α.
THE PHENoTyPE aNd FUNcTIoNaL REsPoNsEs oF NK cELLs 
aRE assocIaTEd wITH dIsEasE sTaTE aNd oUTcomE IN VIRaL 
hepatitis infeCtion
NK cells represent one of the first lines of defense of the innate immune response 
to viral hepatitis infections. Both the phenotype and function of nK cells have 
been extensively studied in chronic HBV and HCV infection, with studies report-
ing altered phenotype, cytokine production, and cytolytic capacity of nK cells in 
viral hepatitis patients.37,43,44 However, many of these findings attributing various 
roles for nK cells in the pathogenesis of acute and chronic liver disease caused 
by HCV and HBV are controversial.45 therefore, in Chapters 6 and 7 we chose to 
address this issue by dissecting the heterogeneous chronic HBV and HCV popu-
lations into clinically relevant subgroups or by disease outcome, and analyzing 
specific phenotypic and function parameters of NK cells within these sub-groups.
NK cells in the natural history of chronic HBV infection
Blood transcriptome analysis of HBV patients identified NK cell and cytotoxicity 
related genes as distinctive markers in phases with elevated alt levels, Ia and 
eneG, when compared to the It phase.46 to build on this study, in Chapter 6 
we performed a detailed examination of blood nK cells throughout the course 
of the natural history of chronic HBV infection, specifically in regards to their 
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potential causal role in the fluctuations of liver damage markers and HBV replica-
tion observed during these clinical phases. the overall composition, phenotype, 
and cytolytic activity of the peripheral nK cell compartment remained relatively 
constant across all clinical phases, with the exception of a few specific markers 
(e.g. KIrs, nKp46, and Cd57). However, the Cd56bright nK cell population of 
chronic HBV patients differed in their ability to produce IFN-γ between the clinical 
phases pre- and post-HBeag seroconversion. these results reject our original 
hypothesis that elevated levels of liver damage markers observed in the Ia and 
eneG clinical phases could be attributed to direct cytolytic killing of infected 
hepatocytes by NK cells, as no differences were observed in expression of the 
cytotoxic mediators perforin, granzyme B, and traIl across all clinical phases. 
this, however, does not rule a role for other cytotoxic immune cells, such as 
Cd8+ t cells, in immune-mediated liver damage, although a recent study was 
unable to demonstrate distinct HBV-specific or global T cell activities in any of the 
clinical phases.47 a potential limitation in this area of our study was that in order 
to provide a homogenous basis of comparison between groups, all patients with 
moderate to severe fibrosis or cirrhosis (fibrosis score > F2) were excluded. NK 
cells in patients with more advanced or severe fibrosis/cirrhosis could display dif-
fering phenotypic or functional profiles due to changes in intrahepatic factors (e.g. 
exposure to activated hepatitis stellate cells and altered cytokines micro-milieus).
although the nK cell compartment composition and expression of cytolytic 
mediators did not differ between clinical phases, this does not exclude potential 
effects of other NK cell functions on the clinical manifestations observed in the 
natural history of HBV infection. The differential capacity to produce IFN-γ in 
Cd56bright cells of chronic HBV patients pre- and post-HBeag seroconversion, 
specifically between the IT/IA and IC phases, could be partially responsible for 
the changes in clinical parameters seen during the transition between these 
phases. IFN-γ has been shown to be a trigger for the process of non-cytolytic HBV 
clearance and recruitment of inflammatory immune cells in both the innate and 
adaptive immune response to HBV infection.48,49 The increase in IFN-γ produc-
tion we observe in Cd56bright nK cells of IC patients could therefore be a driving 
factor in inhibiting HBV viral replication and a trigger for the subsequent immune 
responses eventually leading to HBsag seroconversion and the viral control 
characteristic of this phase. The other possibility is that this differential production 
of IFN-γ observed could be the result of enhanced immune pressure due to high 
viral and antigen load present during the HBeag-positive clinical phases, relieved 
after seroconversion and the subsequent viral suppression. However, we cannot 
say if this is a direct result of the high levels of viral particles and antigens present 
on NK cells or an indirect effect due to the coinciding immune activity in these 
phases. This data may also help to understand the impaired IFN-γ production de-
scribed for nK cells of chronic HBV patients when compared to healthy controls, 
and suggests that this may not be a global phenomenon for chronic patients, but 
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only for those in specific phases with high viral pressure. This is corroborated 
by the recovery in IFN-γ production observed after anti-viral treatment and viral 
suppression, or blockade of specific immune cytokines observed in these stud-
ies.50–52 overall, this data shows that nK cell cytolysis is not directly responsible 
for initiating shifts in markers of liver damage observed in the progressing HBV 
clinical phases, but that these cells do play a role in the viral control characteristic 
of specific stages of the natural history of chronic HBV infection.
NK cell differentiation and memory in resolved and chronic HcV infections
Recent studies have demonstrated developmental and functional qualities for 
nK cells that are commonly associated with immunological memory, including 
the continuous differentiation and formation of specific NK cell repertoires in viral 
infection settings.53–57 In Chapter 7, we assessed these phenotypic and functional 
parameters associated with NK cell differentiation and memory in patients three 
years after acute HCV infection and either the subsequent spontaneous clear-
ance of infection or progression to chronicity. although we were able to identify 
the Cd57+nKG2C++ memory-like NK cell population, no significant differences 
were observed in the total percentages of this specific NK cell repertoire between 
uninfected, resolved, and chronic HCV patients, arguing against the hypothesis 
that the Cd57+nKG2C++ nK cells observed are memory nK cells induced by 
HCV infection. additionally, the protective features attributed to expanded ex-
pression of these populations upon re-exposure previously described in other 
viral infections, cannot justify the increased resistance to reinfection described in 
acute-resolved HCV patients. Our findings did, however, depict an altered, more 
extensively differentiated (increased KIR and CD57, as well as reduced NKG2A 
expression) nK cell compartment in patients after resolving an acute infection. the 
presence of a highly differentiated KIR+Cd57+nKG2a- nK cell repertoire in acute 
HCV patients that clear infection is in line with previously described associations 
between the resolution of acute HCV infection and nK cell inhibitory receptors. 
Gene expression of KIRs, specifically KIR2DL3 and its human leukocyte antigen 
C group 1 (Hla-C1) ligand, have previously been linked to increased odd ratios 
of spontaneous HCV resolution and increased prevalence of KIr2dl3+nKG2a- 
nK cells has been associated with protection from HCV infection in people who 
inject drugs.58,59 This further suggests that presence of these differentiated NK 
cells, along with other innate immune system components, contribute to the viral 
containment and clearance in an acute HCV infection.
In contrast to patients that spontaneously resolve acute HCV infection, the nK 
cells of chronic HCV patients display a more naïve and effector phenotype (in-
creased Cd56bright, NKp46, and IFN-γ expression) with elevated cytolytic capaci-
ties (granzyme B and traIl). nKp46 has been shown to be one of the principle 
avenues of nCr-mediated killing, with increased expression of this nCr being 
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correlated to the cytolytic activity of nK cells in HCV patients.60 this supports 
the skewing toward cytotoxicity, with increased frequencies of granzyme B and 
traIl expressing cells, observed in chronic HCV patients. these phenotypic 
and functional traits of NK cells could be reflective of the persistent exposure to 
viral antigens and infected cells in a chronic disease setting. However, due to the 
retrospective nature of our study, and looking at patients three years after acute 
infection, we were unable to determine if these specific differences in NK cell 
compartments are the cause or result of the resolution of the acute infection or 
progression to chronicity. future prospective studies, following individual patients 
with acute HCV infections could provide insight on this and potentially if baseline 
characteristics of or shifts in nK cell compartments are predictive of acute HCV 
infection outcome.
Conclusion and future perspectives
although our initial hypotheses regarding the roles of nK cells in the varying HBV 
clinical phases as well as in the resolution of and protection against acute HCV 
(re)infection were proven incorrect, we were still able to demonstrate distinctive 
features and functions of nK cells that were linked to disease state and outcome. 
By dissecting the heterogeneous chronic HBV patient population into the four 
clinically distinct phases, we were able to assess aspects of nK cells in a more ho-
mogenous setting and investigate associations with specific disease parameters. 
the data presented in this thesis suggests that nK cells are not globally impaired 
both in their ability to produce IFN-γ and other facets, but instead that functional 
differences exist in specific NK cell subsets pre- and post-HBeAg seroconversion. 
The therapeutic response rates to IFN-α and likelihood of HBsAg conversion are 
significantly higher in HBeAg-positive patients, suggesting an underlying differ-
ence of immune mechanisms between HBeag-negative and -positive disease. as 
IFN-α has been shown to be a potent regulator of NK cells, the phenotypic and 
functional shifts we describe could be one of these underlying factors dictating 
the differences in HBV patient treatment outcomes. Lastly, although memory-like 
nK cells have been associated with protection upon re-exposure of other viral 
infections, such as CMV, this does not appear to be the case for HCV. Why this 
differs remains unclear, but differences in viral antigens, tropism, other immune 
responses and cytokine milieus could have an effect on the differentiation and 
development of a memory-like nK cell population.
lastly, the work in this thesis, and in the majority of other published studies, is 
focused on the peripheral compartment and understanding the systemic effects of 
viral hepatitis on nK cells and the immune system. this completely neglects the 
intrahepatic compartment, where nK cells represent one of the most abundant 
lymphocyte populations and highly specialized liver-resident nK cells have been 
described. These observations, in combination with the unique microenvironment 
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of the liver, make it imperative that future studies, although difficult, investigate 
the role of intrahepatic NK cells on specific disease parameters, such as ALT and 
fibrosis, as well as in the resolution of or progression to chronicity of viral hepatitis 
infections.
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Hepatitis B virus (HBV) en hepatitis C virus (HCV) infecties zijn wereldwijd de 
twee voornaamste oorzaken van chronische ontsteking van de lever. ongeveer 
370–390 miljoen mensen lijden eraan. Op dit moment worden de virale en immu-
nologische mechanismen die de basis vormen van zowel de chronische infectie 
van virale hepatitis als de genezing niet volledig begrepen. onderzoek naar en 
identificatie van de integrale componenten in de immuun reacties van de patiënt 
die cumulatief leiden tot de ontwikkeling van een chronische infectie of tot een 
effectieve uitroeiing van het virus zijn van het grootste belang. Het algemene 
doel van deze thesis is daarom het begrijpen van de functie, en dysfunctie, van 
specifieke aspecten van het aangeboren immuunsysteem in de aanhoudendheid 
en/of de genezing van virale hepatitis infectie. de twee voornaamste componen-
ten van de immuunrespons waarop in deze thesis het focus ligt zijn de rollen die 
interferon (Ifns) en natural killer (nK) cellen spelen in het bepalen van de staat 
van de ziekte en het resultaat van infectie.
sysTEmIscHE waaRdEN EN ImmUNoLogIscHE REgULaTIE VaN 
type iii ifns in Virale hepatitis infeCtie
Ifns zijn een van de basis componenten van de aangeboren immuunrespons op 
virale infecties en zijn voor vele jaren een belangrijke hoeksteen in de behande-
ling van chronische HCV en HBV infectie geweest tot aan de recente introductie 
van direct-acting antivirals (daas). deze klasse van cytokines is beschreven als 
hebbende een antivirale, antiproliferatieve, en immunomodulerende uitwerking, 
en is verdeeld in drie grote subklassen; type I, II, en III Ifns, elk met unieke 
complementaire receptor complexen waardoor zij signaleren. echter, in tegen-
stelling tot de hoog prominente type I IFNs (bijv. IFN-α), kregen type III IFNs, 
opgemaakt uit IFN-λ1, IFN-λ2, IFN-λ3, en IFN-λ4, relatief weinig aandacht tot 
de ontdekking van polymorfismen binnen de IFN-λ gen die geassocieerd zijn 
met spontane zowel als met IFN-α/ribavirin therapie geassocieerde genezing van 
HCV infectie. Alle leden van de IFN-λ familie gebruiken een specifiek transmem-
braan receptor heterodimer, het IFN-αR1 en IL-10R2 complex, dat structureel 
verschilt van het IFN-α receptor complex, een heterodimer van de IFN-αR1 en 
IFN-αR2 moleculen. In tegenstelling tot de alomtegenwoordige IFN-α receptor is 
de distributie van de IFN-λ receptor meer gelimiteerd. Type I IFNs blijken sterke 
modulatoren van meerdere immuun cellen populaties te zijn, inclusief antigeen–
presenterende cellen zoals dendritische cellen (dCs), monocyten en macrofagen 
(en hun stimulatie van t-cel responses) zowel als B cellen en nK cellen. echter, 
ten gevolge van de verschillen in IFN-α en IFN-λ receptor prevalentie en hun 
respectievelijke signalering kinetiek, blijven de effecten van IFN-λ op immuun 
cellen nog controversieel met beperkt bewijs voor veel van deze populaties.
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De associatie tussen polymorfismen binnen het IFN-λ gen locus en genezing 
van HCV infectie wordt nog slecht begrepen, maar suggereert dat IFN-λ een 
belangrijke rol speelt in het tot stand komen van een effectieve antivirale respons. 
Daarom was de eerst logische stap in het bepalen van het belang van IFN-λ in 
virale hepatitis het onderzoeken van endogene waarden in het serum van chro-
nisch geïnfecteerde patiënten en hoe die geassocieerd zijn met patiënt IFN-λ 
polymorfisme genotypen zowel als ziekte status/uitkomst in HBV en HCV infectie. 
In Hoofdstuk 2 hebben we de waarden van IFN-λ1 en IFN-λ2/3 gemeten in het 
serum van gezonde controle personen, chronische HCV patiënten, patiënten die 
genezen zijn van HCV infectie, chronisch geïnfecteerde HBV patiënten, acuut ge-
infecteerde HBV patiënten en chronische HBV patiënten die op dit moment DAA 
therapie krijgen. We laten zien dat serum IFN-λ waarden niet worden beïnvloed 
door infectie met zowel HCV of HBV, en dat IFN-λ waarden niet geassocieerd 
zijn met specifieke ziekte stadia, de uitkomst van het ziekteproces of andere 
parameters (bijv. ALT en IFN-λ3 rs12979860 genotype).
Naast de rol van endogeen geproduceerd IFN-λ in de setting van chronische 
virale hepatitis, blijft ook veel van de onderliggende basale biologie van IFN-λ 
onverklaard. de antivirale aspecten van deze klasse cytokines zijn welomschre-
ven, met vele overeenkomsten met die toegeschreven aan type I Ifns. dit brengt 
dan echter de vraag op wat het evolutionaire voordeel van het hebben van twee 
klassen Ifns als hun immunologische rol inderdaad hetzelfde is? daarom is er 
meer onderzoek nodig t.a.v. de weinige onderscheidingen beschreven voor type 
III IFNs, met name de IFN-λ receptor en diens expressie op immuun cellen zowel 
als op de geassocieerde responsen na stimulatie. omdat er studies waren die 
de expressie van de IFN-λ receptor op B cellen rapporteren, maar met beperkt 
beschikbare informatie over de werkelijke effecten van IFN-λ, besloten we om de 
rol van IFN-λ in de regulatie en modulatie van menselijke B cell functie in detail 
te bestuderen, en die te vergelijken met die van IFN-α.
In Hoofdstuk 3 laten we zien dat zowel type I en III Ifns in staat zijn om 
zowel toll-like receptors (tlr)-gemedieerde B cellen activatie als cytokine (Il-6 
en Il10) en immunoglobuline productie (lgG en lgM) te verbeteren. dit was ten 
dele toegeschreven aan een verhoging in tlr7 respons en proliferatie. Hoewel 
IFN-λ alleen in staat is om IFN-stimulated genes (ISGs; MX1 en OAS1) zowel 
als tlr7 expressie teweeg te brengen, zijn er aanvullende tlr en helper t cel 
signalen, Cd40 en BCr ligatie nodig voor B cel activatie en het opwekken van 
functionele responsen.
nK cellen vertegenwoordigen een andere groep van lymfocyten met slecht be-
schreven respons op type III Ifns; er zijn tegenstrijdige resultaten gerapporteerd 
voor zowel de expressie van de IFN-λ receptor als de directe effecten van IFN-λ 
op menselijke nK cellen. studies hebben aangetoond dat monocyt-afgeleide 
macrofagen de Ifn receptor expressen en tevens deze cellen de productie van 
Il-12p40 verhogen als deze receptor geactiveerd wordt, met name in combinatie 
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met activatie via tlrs. dit is vooral van belang in hepatitis infectie omdat tlr-
geactiveerde macrofagen van de lever een effector functie blijken uit te oefenen 
in nK cellen, door tussenkomst van cytokine-geïnduceerde activatie en productie 
van IFN-λ.
Om de biologische rol van IFN-λ daarom beter te kunnen begrijpen hebben 
we de effecten van IFN-λ op NK cellen in zowel een directe en indirect capaciteit 
door zijn modulatie van tlr-geactiveerde macrofagen onderzocht (Hoofdstuk 
4). In dit hoofdstuk laten we zien dat in tegenstelling tot IFN-α, IFN-λ niet in 
staat is om de effector functie in NK cellen (IFN-γ, CD107a, en GZMB expres-
sie) direct te activeren en stimuleren, waarschijnlijk door het gebrek aan cel-
lulaire expressie van de IFN-λR1 molecuul van het type III IFN receptor complex. 
Echter, IFN-λ priming, in combinatie met TLR activatie, is in staat om expressie 
van selecte leden van de Il-12 familie van cytokines (Il12B, Il23a, Il27a, en 
eB13) te induceren in monocyt-afgeleide macrofagen. overeenkomstig hebben 
andere studies de effecten van IFN-λ op het moduleren van de functie van TLR-
geactiveerde fibroblasten onderzocht, met name IL-6 en IL-8 productie, in het 
kader van reumatoïde artritis synoviale ontsteking. onze commentaren op deze 
studies en het belang van IFN-λ in het kader van chronische ontstekings ziekten 
zoals reumatoïde artritis worden besproken in Hoofdstuk 5.
Conclusies ifns
De alomtegenwoordige expressie van de IFN-α receptor over leukocyten popula-
ties (bijv. monocyten, NK cellen en T cellen) en het vermogen van IFN-α om direct 
op deze cel typen te werken onderscheidt het van IFN-λ. Deze kenmerken maken 
IFN-α een integrale en directe mediator in de inductie van de onmiddellijke im-
muun respons op virale infectie zowel in de perifere als de weefsel compartimen-
ten. In tegenstelling hiertoe belet de beperkte expressie van de IFN-λ receptor de 
directe actie van IFN-λ op een aanzienlijk deel van de leukocyten populaties, met 
uitzondering van B cellen, monocyt-afgeleide macrofagen, en plasmacytoid dCs.
type III Ifns echter zijn in staat om te werken op weefsel-resident cellen, 
zoals epitheel cellen, hepatocyten, en synoviale fibroblasten. Deze lokale 
inductie van de immuun respons door IFN-λ zou mogelijke voordelen kunnen 
bieden ten opzichte van de aspecifieke, systemische effecten van IFN-α, vooral 
als een alternatieve therapie voor virale hepatische infecties of andere weefsel-
gelokaliseerde virale infecties waar DAAs niet beschikbaar zijn en/of bij patiënten 
met een verzwakt immuun system (bijv. hepatitis e virus) of hepatitis delta virus/
HBV co-infectie). Verder heeft recente literatuur laten zien dat daas in HCV 
infectie, hoewel zeer effectief en goed te verdragen, mogelijk enige beperkingen 
zou kunnen hebben in specifieke subpopulaties zoals patiënten met de ziekte-
geschiedenis hepatocellular carcinoma (HCC), waarbij een verrassend hoog 
recidief HCC gerapporteerd wordt na sustained virological response (sVr). dit 
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is niet beschreven voor eerdere responderen op IFN-α-gebaseerde therapieën, 
mogelijk door de immunomodulerende eigenschappen van Ifns die niet alleen 
antivirale, maar ook antitumor immuniteit bevorderen. daarom kan de toevoeging 
van IFN-λ aan DAA therapie in specifieke subpopulaties die een hoge graad van 
fibrose/cirrose, een hoog risico voor HCC, en/of bekend zijn met HCC mogelijk 
een recidief van HCC helpen voorkomen, terwijl het een meer weefselspecifieke 
respons en minder ongewenste schadelijke effecten geeft dan IFN-α.
dE FENoTyPE EN FUNcTIoNELE REsPoNsE VaN NK cELLEN zIJN 
gEassocIEERd mET sTaaT VaN dE zIEKTE EN aFLooP VaN dE 
Virale hepatitis infeCtie
nK cellen vertegenwoordigen een van de eerste verdediging linies van de na-
tuurlijke immuun respons op virale infecties. Geactiveerde nK cellen reageren op 
stress signalen van met virus geïnfecteerde cellen door middel van twee typen 
mechanismen; directe mechanismen, zoals vrijgave en expressie van cytotoxi-
sche mediators als granzymes, perforins, en tumor necrosis factor (tnf)-related 
apoptosis-inducing ligand (traIl), dat resulteert in lysis van de geïnfecteerde 
cellen, en indirecte mechanismen die de afgifte van cytokines zoals IFN-λ en TNF 
omvatten, en antivirale responsen oproepen die virale replicatie remmen. deze 
door stress op gang gebrachte signalen bestaan uit oppervlakte markers, zoals 
gemodificeerde major histocompatibility complex (MHC) expressie en liganden 
op regulerende receptoren zowel als ongebonden factoren. nK cel activiteit wordt 
alleen geregeld door een evenwicht van activerende en remmende receptoren op 
het cel oppervlak (bijv. C-type lectin-like receptoren; natural cytotoxicity receptors 
[NCRs] en killer Ig-like receptors [KIRs]). Tijdens een virale infectie verschuift het 
evenwicht van remming naar activering nadat de kritieke drempel van activatie 
signalen het wint van de drempel van remming signalen. Zowel het fenotype en 
de functie van nK cellen zijn grondig bestudeerd in chronische HBV en HCV 
infectie, met studies die gewijzigd fenotype, cytokine productie, en cytologische 
capaciteit van NK cellen in patiënten met virale hepatitis rapporteren. Echter, 
veel van deze resultaten, die nK cellen verschillende rollen in de pathogenese 
van acute en chronische leverziekte veroorzaakt door HCV en HBV toeschrijven, 
zijn controversieel. daarom hebben we ervoor gekozen om in de Hoofdstukken 
6 en 7 dit onderwerp te bespreken door de heterogene chronische HBV en HCV 
populaties te ontleden in klinisch relevante subgroepen of door ziekte uitkomst, 
en specifieke fenotypische en functie parameters van NK cellen binnen deze 
subgroepen te analyseren.
Chronische HBV infectie wordt gekarakteriseerd door ziekte episodes met 
verschillende virale titers en/of tekenen van lever beschadiging (bijv. alt). een 
eerdere systems-biologie studie van de perifere bloed transcriptomes in de ver-
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scheidene chronische HBV klinische fasen rapporteerde een upregulatie van cy-
totoxiciteit/nK cel activiteit-gerelateerde genen geclusterd in de HBeag-positive 
immune active (Ia) en HBeag-negative hepatitis (eneG) fasen, mogelijk duidend 
op een link tussen nK cel activiteit en de verhoging in alt die gezien wordt 
in deze fasen. We hebben er daarom voor gekozen om de rol van differentiaal 
nK cel functionaliteiten in het bijdragen aan de onderscheidende kenmerken die 
gezien worden tijdens de HBV klinische fasen, met inbegrip van de fluctuaties in 
lever toxiciteit en HBV replicatie te bestuderen. daarom hebben we in Hoofdstuk 
6 een gedetailleerd onderzoek van bloed nK cellen gedurende het natuurlijke 
verloop van chronische HBV infectie gedaan, in het bijzonder met betrekking tot 
hun mogelijke causale rol in de fluctuaties van lever toxiciteit en HBV replicatie 
die gezien wordt tijdens deze klinische fasen. de algemene samenstelling, 
fenotype, en cytolytische activiteit van het perifere nK cel compartiment bleef 
relatief constant gedurende alle klinische fasen, met uitzondering van een paar 
specifieke markers (bijv. KIRs, NKp46, en CD57). Echter, de CD56bright nK cel 
populatie van chronische HBV patiënten verschilde in hun vermogen om IFN-λ te 
produceren tussen de klinische fasen pre- en post-HBeag seroconversie. deze 
resultaten verwerpen onze oorspronkelijke hypothese dat verhoogde waarden 
van lever enzymen gezien in de Ia en eneG klinische fasen toegeschreven zou-
den kunnen worden aan direct cytolytische doden van geïnfecteerde hepatocyten 
door nK cellen, omdat er geen verschillen werden gezien in expressie van de 
cytotoxische mediators perforin, granzyme B en traIl over alle klinische fasen.
De hoge graad van spontane genezing gezien in patiënten waarbij eerder een 
acute HCV infectie is verdwenen wijzen er in sterke mate op dat immunologisch 
geheugen, en daarna immuniteit verkregen tijdens de primaire infectie een rol 
zou kunnen spelen in de bescherming tegen HCV re-infectie. recente studies 
hebben ontwikkelende en functionele kwaliteiten voor nK cellen beschreven die 
veelal geassocieerd worden met immunologisch geheugen, met inbegrip van 
de voortdurende differentiatie en formatie van specifieke NK cellen repertoires 
tijdens virale infectie. Met beperkt beschikbare informatie over de ontwikkeling en 
persistentie van memory-like nK cellen gedurende en na HCV infectie, hebben 
we ervoor gekozen om in Hoofdstuk 7 de nK cel compartimenten van individu-
ele personen die een HCV infectie hebben overwonnen te karakteriseren en te 
vergelijken met die van individuele personen die een chronische infectie hebben 
ontwikkeld. In dit hoofdstuk hebben we de fenotypische en functionele parame-
ters die geassocieerd zijn met NK cel differentiatie en geheugen onderzocht in 
patiënten drie jaar na acute HCV infectie en ofwel de daaropvolgende spontane 
genezing of de ontwikkeling tot chronische infectie. Hoewel we in staat waren 
om de Cd57+nKG2C++ memory-like cellen populaties te identificeren, werden er 
geen significante verschillen gezien in de totale percentages van dit specifieke 
nK cel repertoire tussen de niet-geïnfecteerde, genezen, en chronische HCV 
patiënten; dit verwerpt de hypothese dat de geobserveerde CD57+nKG2C++ nK 
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cellen memory nK cellen zijn die geïnduceerd zijn door HCV infectie . Verder kun-
nen de beschermende kenmerken die toegeschreven werden aan de uitgebreide 
expressie van deze populaties bij hernieuwde blootstelling eerder beschreven in 
andere virale infecties niet de verhoogde resistentie tegen re-infectie beschreven 
in acuut-genezen HCV patiënten verklaren. Onze bevindingen geven echter wel 
een veranderd, meer uitgebreid gedifferentieerd (verhoogd KIR en CD57, zowel 
als verminderd NKG2A expressie) NK cel compartiment te zien in patiënten na 
een acuut genezen infectie. In tegenstelling tot de acute-genezen patiënten, 
hebben de NK cellen van chronische HCV patiënten een meer naïef en effector 
fenotype, met verhoogd Cd56bright, NKp46, en IFN-γ expressie, zo wel als ver-
hoogde cytolytische capaciteiten (granzyme B en traIl).
conclusies NK cellen
alhoewel onze aanvankelijke hypotheses met betrekking tot de rol van nK cel-
len in de verschillende HBV klinische fasen zowel als in de genezing van en 
bescherming tegen acute HCV (re)infectie onjuist bleken te zijn, zijn we er wel toe 
in staat gebleken om de kenmerkende eigenschappen en functies van nK cellen 
die gekoppeld waren aan de staat van de ziekte en eventuele afloop te definiëren. 
Door het ontleden van de heterogene chronische HBV patiënten populatie in vier 
klinisch kenmerkende fasen zijn we in staat geweest om aspecten van nK cellen 
in een meer homogene setting te benaderen en om associaties met specifieke 
ziekte parameters te onderzoeken. de in deze thesis gepresenteerde data sug-
gereren dat NK cellen in HBV patiënten over het algemeen niet aangetast zijn in 
zowel hun vermogen om IFN-γ en andere factoren te produceren, maar in plaats 
daarvan dat er functionele verschillen bestaan in specifieke NK cellen subsets 
pre- en post-HBeag seroconversie. de therapeutische responsen met betrekking 
tot IFN-α en de waarschijnlijkheid van HBsAg seroconversie zijn beduidend in 
HBeAg positieve patiënten, duidend op een onderliggend verschil in immuun 
mechanismen tussen HBeag-negatieve en-positieve ziekte. omdat het is aange-
toond dat IFN-α een sterke regulator van NK cellen is, zouden de fenotypische 
en functionele veranderingen die wij beschrijven een van deze onderliggende 
factoren kunnen zijn die de verschillen in behandeling uitkomst in HBV sturen. 
ten laatste, hoewel memory-like nK cellen geassocieerd zijn met bescherming 
bij re-exposure in andere virale infecties zoals cytomegalovirus (CMV), lijkt dit 
niet het geval te zijn voor HCV. Waarom dit anders is blijft onduidelijk, maar 
verschillen in virale antigenen, tropisme, andere immuun responses en cytokine 
milieus zouden een effect kunnen hebben op de differentiatie en ontwikkeling van 
een memory-like nK cel populatie. Verder inzicht in de rol die nK cellen spelen in 
de progressie van de ziekte en de uiteindelijke afloop van virale hepatitis is van 
belang, met name om deze en andere natuurlijke immuun cellen te manipuleren 
met als doel om hun activiteit tegen virale infecties te vergroten.
Chapter 10
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and natural magnetism always seems to draw people toward you and for good 
reason. You’ve become a great friend over the past years, and I couldn’t imagine 
my Phd time without you and Wesley in the “Man Cave”. the occasional wiener 
melange, put-put, blind beer-tastings (preferably alcohol-free), and whisky on the 
beach to name just a few of the memories we’ve made over the years. Best of 
luck with finishing your MDL specialization, although I know you don’t need it, and 
hopefully this year we can celebrate “3 oktober” on the 10th of october instead!
evelyn, I’ve said it before but I’ll say it again, I can’t think of anyone more deserv-
ing of their dr. title than you. Your relentless determination as well as genuine 
thoughtfulness and kindness made you both a great colleague and an even better 
friend. thank you for bringing some female perspective and balance to the male 
dominated “Man Cave” shenanigans, I’m sure it wasn’t easy to tolerate at times. I 
wish you all the best with your new career at J&J, and I’m sure you’ll be success-
ful wherever life takes you (you’ve always got a promising career as a clown to 
fall back on ;P).see you around dr. van der aa.
michelle, we started in the viral hepatitis group together and I can’t say how 
thankful I am for that. It was always great to have someone, that was also 
relatively new, to bounce ideas off and work together in the lab. You’ve been in 
London the past couple years, and are finally moving back to Rotterdam (which 
Team BOTM is very excited about!), so I hope we can finally all grab a drink 
together soon. Best of luck with starting your journey into Mdl specialization, and 
don’t be a stranger!
Vincent, how am I supposed to summarize someone as unique as Vincent 
Janmaat in just a few sentences? Maybe I’ll write a book about you someday. 
Until then, thank you for the many, many fantastic memories over the past years. 
You’re a great friend and gym/running-buddy, and I was beyond ecstatic to hear 
you are staying in rotterdam for you Mdl specialization. When is pole-camping 
expedition #2? I want to catch a real loch ness monster next time.
Lauke, if it would take me an entire book to thoroughly address Vincent Janmaat, 
it would take an entire encyclopedia collection to comprehensively cover lauke 
Boeijin. I swear you two are two peas in a pod, or should I say two goldfish in a 
bowl (who’s Rik and who’s Elmer???)? From Le Lac De Zombies and Oktoberfest 
in Dolce Bad Nauheim, to BBQ and beer pong belts in Egmond aan Zee, the 
past two years have been a riot. Unfortunately you’ve moved to Utrecht now, but 
you’ve always got a couch to crash on at the oude Binnenweg.
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martijn, chef BBQ maestro! You’ve introduced us to so many great craft beers 
over the years, and I’m therefore very happy we could repay the favor by intro-
ducing you to Jupiler ;) Best of luck in Utrecht with your new job, and of course 
with your upcoming thesis defense!
Jasmijn, even despite your frequent absence due to scheduling conflicts (week-
ends in Paris, every festival known to man, thursday night Ikea trips, etc.) we 
were still able to hang out every blue moon ;) You’re directness and sense of 
humor are refreshing, and try to keep some weekends open this year, so we can 
all hang out with the Roffa crew.
xiaolei, my mentor in all things Chinese. Your eastern wisdom (and general 
absentmindedness) made for an very diverse and entertaining “Man Cave”. I’m 
very glad you decided to come back to the netherlands, and it’s great to have a 
surf and Simonis fish buddy in Den Haag. Surfs up, see you soon, and best of 
luck with your journey into patent law ;)
guoying and yingying, the other 2 ambassadors from China! It’s been a plea-
sure to work and learn about Chinese culture from you both, and I have incredible 
respect for your interest and curiosity in dutch (and even american!) culture. 
thanks to you both, hot pot has become a staple dish for me at home, and I hope 
to continue to improve my Chinese cooking skills the coming years! We’ll stay in 
touch, and best of luck to you both with the last stretch of your Phd time.
michiel and floris, I believe the lab “party committee” has been left in capable 
hands. It’s up to you two to keep the oktoberfest and camping traditions alive, 
and I have nothing but the utmost confidence you will do so (no pressure) ;)!
Jasper and werner, it’s been a few years since you’ve left the lab, but thank you 
both for being so welcoming and inviting when I first moved to the Netherlands to 
work in the lab. Hopefully we’ll see each other again soon!
Reneé, Eelke, Emmeloes, the first female residents of the “Man Cave”. Thank 
for the great times and many laughs, I wish you all the best in your diverse paths 
in the future.
leonie and gwenny, the Bert and ernie of the lab ;) (don’t get too mad, it’s 
meant to be endearing)! We’ve shared many a beer and glass of wine, and it 
usually only ended when the last bottle was empty. always a tragedy! thank you 
both for the friendship and support with my Phd over the years, and especially for 
the extra effort you’ve put in with helping me complete the last items for my thesis 











arjan “I could Eat” Rauwers, stay hungry! What can I say roomie, we’ve had 
some great times and there are many more ahead. road tripping through america 
(even in a red ford Mustang…) was amazing, and I have high expectations for 
lowlands 2018. thanks for helping me tap into my dutch side, and I hope I’ve 
been able to pass on some of my american wisdom to you… trump 2016!
dak duifjes, thank you for the great memories during the friday borrels, rotjong 
games, and of course the legendary department ski trips ;P. I wish you all the 
best in the future!
to Raymond, Jan, Buddy, Frances, Ester, martine, Hanneke, auke, greta, 
Jaap, alexander, Rogier, Patrick, shanta, Kostas, Jesse, Pieter, Luc, Henk, 
Petra, monique, suomi, Elvira, wendy, susanne, waqar, sohrab, Ron, 
marcel, Huga, Pauline, abdullah, wenshi, yuebang, Lei, Xingying, Juan, 
changbo, wanlu, wen, wenhui, Kan, Hakim, Rajesh, and countless lab-mates 
I’m probably forgetting, thank all you so very much for making it an enjoyable 5 
years, both in and out of the lab, with endless banter in the coffee/lunchroom and 
unforgettable lab/department events and parties.
Team Futsal and whisky thanks for the many great times and adopting me for 
the yearly excursions throughout europe. I’m looking forward to another epic 
weekend in Glasgow in november! I would also like to thank all the healthy 
controls and patients, that so generously donated blood and tissue to make this 
research possible. Without them, this thesis would not exist.
Nick, Brad, Eric, dean, John, and mark, I’ve known most of you longer than I 
can remember, and never really understood how lucky I was to have you all as 
friends until after I left the Usa. I look back fondly on the many memories we’ve 
made over the past ≈ 30 years, and look forward to the ones yet to come. See 
you boys on the other side of the pond!
Bhrunil, Bryce, Lukas, zac, clay, mohammed, and my other university 
friends, thanks for the great memories and the time we spent together during our 
first years of adulthood. You’ve all had a profound impact on me, I miss you all, 
and we need another reunion soon!
lieve familie de groen en Janssen, I could write second entire dissertation on 
the things I need to be thankful for when it comes to my family. I’d prefer to do it in 
person, and hopefully one day repay the favor. I would like to say a special thank 
you to Harry, godelieve, and Lodewijk, who helped really make rotterdam my 
new home. I can never thank you three enough for this.
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opa, I’ve saved a spot for you front and center. It took a few generations, but 
someone will finally defend their thesis. I hope I’ve made you as proud as I am to 
have you here today.
max, Ryah, madeleine, and anton crazy Uncle rik is beyond ecstatic to have 
all 4 of your sitting here today. I look forward to watching Madeleine and anton 
grow up, and giving them both the noisiest of toys every birthday (what are your 
thoughts on a drum set?).
rob, I can’t tell you how much I’ve missed you over the past 6 years. It means 
the world to me that you are hear today, and that you can share in celebrating this 
occasion with me. talk soon little brother.
mom and dad, this book is as much a product of you both as it is of me. thank 
you for the years of unwavering support, although sometimes overbearing, I 
always knew it came from the right place. I hope I’ve made you proud today.
Timshel.
